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This thesis describes the development of a synthetic strategy to obtain all the 
sulfation pattern isomers possible in the repeating unit of chondroitin sulfate (CS). 
The strategy incorporates orthogonal protecting groups in four glycosyl donor and 
four glycosyl acceptor building blocks which are synthesized in a divergent mode 
using 2 common intermediates. Through the judicious choice of donor and 
acceptor building blocks, any sulfation pattern required in the final CS 
disaccharide can be obtained by modular glycosylation and selective 
transformations. Specifically, any sulfation pattern required in the final product is 
obtained by regioselective sulfation of either the benzyl ether protected hydroxyl 
groups or the ester protected hydroxyl groups to furnish all 16 theoretically 
plausible CS disaccharides; these include analogues currently available as well as 
novel sulfation motifs. 
 
To determine if the sulfate groups present in CS encode important functional 
information for the regulation of physiological processes such as cancer 
progression, biological evaluation of all 16 CS disaccharides was next conducted 
on breast cancer cells. Cell viability assay results indicated that CS sulfation 
patterns had differing effects for different breast cancer cell types. The greatest 
inhibitory effect was observed for the most aggressive, triple negative breast 
cancer cell line MDA-MB-231, while low grade breast cancer cells (MCF-7 and 
T47D) were not affected. Apoptosis assays further indicated that some of these 
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CHAPTER 1: INTRODUCTION 
 
1.1 Introduction to Glycosaminoglycans  
Glycosaminoglycans (GAGs) are a distinct class of carbohydrates widely 
distributed in the human body; these complex polysaccharides consist of long, 
unbranched and heterogeneous polysaccharide chains which play diverse roles in 
many key physiological processes.
[1-3]
 GAGs are ubiquitous in the extracellular 
matrix, and can be covalently attached to core proteins to form proteoglycan side 
chains, or are located within intracellular secretory granules.
[4-6]
 GAG chains have 
a common feature: they are constituted by core disaccharide repeat units which 
consist of both the uronic acid and the amino sugar; these are hexose derivatives 
of common monosaccharides.
[7]
 The uronic acid has the C-6 alcohol group 
oxidized to form a carboxylic acid, while amino sugar has the C-2 hydroxyl group 
substituted with an amino group. 
 
 
Hyaluronic acid (HA) 
 
Keratan sulfate (KS) 
 
Heparan sulfate (HS) 
 
Chondroitin sulfate (CS) 
Figure 1-1. Classes of glycosaminoglycans 
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Four main classes of GAGs have been identified, and they can be classified based 
on the structures of their repeat units
[8]
 (Figure 1-1). These include hyaluronic 
acid (HA), keratan sulfate (KS), heparan sulfate (HS) and chondroitin sulfate (CS). 
In each GAG polysaccharide, the monosaccharide units are connected together by 
glycosidic bonds, which may either be of α- or β- stereochemical configuration. 
This linkage occurs between the C-1 (anomeric) hydroxyl group of the first unit 
and the C-3 or C-4 position of the adjacent sugar unit. GAGs are highly polar and 





Hyaluronic acid (HA) is only class of GAG polysaccharides which have no sites 
of sulfation. It is one of the principle components of the extracellular matrix, 
where it functions as a shock absorber and also a lubricant.
[9]
 The repeating unit 
of HA consists of D-glucuronic acid and D-N-acetyl glucosamine. In addition, 
HA is a major component of the skin epidermis, and play crucial roles during the 
wound healing process.
[10]
 Similarly, keratan sulfate (KS) can be found in the 
extracellular matrix, although it is concentrated mainly in the cornea, cartilage 
and the central nervous system.
[11, 12]
 KS GAGs consists of N-acetyl glucosamine 
and D-galactose repeating units, and play key roles in several degenerative 
disorders such as macular corneal dystrophy and osteoarticular diseases.
[13]
 Unlike 
other GAGs, KS contains D-galactose sugars in the repeat unit, these are non-
uronic acid moieties. 
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Much emphasis has been placed on the study of heparan sulfate (HS) GAGs with 
the discovery of heparin as an injectable anticoagulant drug.
[14, 15]
 Known as the 
biomolecule with the highest negative charge density, heparin is structurally 
similar to HS and produced exclusively in mast cell secretory granules.
[16-18]
 As 
compared to heparin, HS GAGs are generally longer in length and have fewer 
sulfation sites. The major sequences of heparan sulfate consist of D-glucuronic 
acid and D-N-acetyl glucosamine repeat units, and HS GAGs play critical roles in 
the regulation of signaling processes important for growth development, immune 




1.2 Chondroitin Sulfate Glycosaminoglycans 
Although relatively less studied than heparan sulfate, chondroitin sulfate (CS) 
polysaccharides are the most prevalent GAGs in the body, consisting of D-
glucuronic acid and D-N-acetyl galactosamine repeat units. CS GAGs form 
important structural components of the human connective tissues in cartilage and 
bone joints.
[22]
 In addition, CS GAGs can be covalently bonded to cell membrane 
core proteins to form chondroitin sulfate proteoglycans (CSPG); these CS side 
chains are attached to the protein scaffold via a serine residue, through a 
tetrasaccharide linkage.
[23]
 CS GAGs have been demonstrated to play major 
supportive roles in developmental signaling in neural stem cells,
[24]
 and are 






During the biosynthesis of the CS GAGs, modifications such as epimerization and 
sulfation can occur, which give rise to structural diversity of GAG compounds. 
For instance, CS may be converted to dermatan sulfate (DS) GAGs by DS 
epimerases (Figure 1-2).
[26]
 In this case, the orientation of the C-6 carboxylate 
group in CS is switched from equatorial to axial, and the glucuronic acid moiety 
becomes modified into an epimer, the L-iduronic acid. The L-iduronic acid and N-
acetyl galactosamine pair constitutes the repeat unit found in DS GAGs. 
 
 
Figure 1-2. Epimerization of chondroitin sulfate 
 
In addition, sulfate groups may be attached to specific sites in the CS sequence by 
various sulfotransferase enzymes,
[27]
 such as chondroitin 4-sulfotransferase and 
chondroitin 6-sulfotransferase, which attach sulfate groups to the C-4’ and C-6’ 
position of N-acetylgalactosamine respectively. These modifications create 
structural diversity of CS GAGs which enable specific binding interactions with 
different ligands.
[28-31]
 The myriad of signaling effects generated thus allows for 
the modulation of many different cellular events and physiological processes, 
which include morphogenesis, viral invasion, cancer metastasis, spinal cord injury 
and stem cell proliferation.
[32-41]
 For example, it has been demonstrated that CS 
GAGs can interact with key bioactive growth factors and neurotrophic factors 
implicated in various neuro-generative functions, via distinct sulfated sequences 
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embedded within the CS GAGs
[42-44]
. Specifically, it was shown that the CS-E 
sulfation motif can act as molecular recognition elements for growth factors 
which promote neuronal growth.
[45, 46]
 This indicates that the sulfation patterns on 
CS chains do not occur randomly, but a “sulfation code” exists to mediate the 
physiological functions of these sequences.
[47, 48]
 Important functional information 
can thus be encoded in CS GAGs via the attachment of position-specific sulfate 
groups.   
 
There are 4 possible sites of sulfation in the CS repeat unit. Sulfate groups may be 
attached on the C-2, C-3 positions of glucuronic acid or the C-4’, C-6’ positions 
of N-acetyl galactosamine (Figure 1-3). A total of 16 sulfation patterns are thus 
theoretically possible; some of these CS sulfation patterns have already been 





Figure 1-3. Sulfation sites in CS 
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The commonly occurring forms include a single sulfation on C-4’ and C-6’ of the 
N-acetyl galactosamine unit, known as CS-A and CS-C respectively. Over 
sulfation occurs when both C-4’ and C-6’ are sulfated on the N-acetyl 
galactosamine moiety to form CS-E, or when sulfation occurs on D-glucuronic 
acid. Slight changes in the sulfation pattern can have a major impact on biological 
processes. Most commonly occurring forms CS-A and CS-C have been well 




 and inhibition 
of complement factor Clq
[56]
, while over-sulfated CS-D and CS-E have been 
proven to promote neurite outgrowth toward embryonic rat mesencephalic and 
hippocampal neurons.
[57]
 Although sulfation on the C-2 and C-3 positions of 
glucuronic acid is relatively less common, some of these CS isomers such as CS-




1.3 Sulfation Code in Chondroitin Sulfate   
To investigate the molecular level interactions of CS, techniques have to be 
employed to obtain pure and well-defined sulfated motifs to determine how CS 
sulfation patterns affect biological activity. However, procurement of pure, 
homogenous CS motifs which are not commonly expressed is a challenging task 
due to isolation difficulty and structural complexity. Current approaches to probe 
the “sulfation code” include genetic modifications which involve knocking out 
sulfotransferase genes to probe phenotypic development[60-62] or knocking down 
sulfotransferase genes to observe the effects on tumor cell proliferation and 
adhesiveness.[63] These methods are confined by the scope of the sulfotransferase 
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gene sequences available, which can result in the generation of a limited range of 
CS isomers. Moreover, the genetically modified CS sequences have diverse and 
heterogeneous sulfation profiles, thus it becomes difficult to ascertain the 
biological effects of any particular sulfation motif.[64, 65]  
 
Biochemical methods of acquiring CS from natural sources also face challenges 
in purification and separation, and often result in mixtures of differently sulfated 
polysaccharides with poor linear definition due to the structural complexity and 
heterogeneity of GAGs.[66, 67] Since unique CS sulfation patterns have differing 
therapeutic potentials for different disease states[68], the possible confounding and 
contradictory effects exerted by different CS isomers could hamper systematic 
study.[69]  
 
To circumvent limitations faced by current methods, chemical synthesis emerges 
as a viable alternative to prepare CS sequences via control of the site(s) of 
sulfation required in the final product. Through this approach, pure CS sequences 
with homogenous sulfation profiles can be obtained, to systematically probe the 
effect of CS sulfation patterns on various physiological processes. To achieve this, 
the organic chemist must first devise a synthetic strategy to obtain CS GAGs via 
chemical transformation of monosaccharides to form derivatized glycosides. 
Commonly known as carbohydrate chemistry, this sub-field of organic chemistry 
deals with the synthesis and chemical reactions for the preparation of natural and 
unnatural carbohydrate compounds. 
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1.4 Chemical Synthesis of Carbohydrates 
Carbohydrates are the most abundant class of biomolecules found in nature, and 
can be broadly defined as polyhydroxy aldehydes and ketones with the general 
formula Cn(H2O)n.  Research in carbohydrate chemistry began in the nineteenth 
century, pioneered by Nobel laureate Emil Fischer who first elucidated the basic 
structure and stereochemistry of monosaccharides. He created the Fischer 
projection system to depict the spatial orientation of the various hydroxyl groups 
present in monosaccharides, through a two-dimensional representation.[70] 
General interest in synthetic carbohydrate chemistry however developed only 
later in the 1960s, primarily motivated by the identification of biologically active 
carbohydrate compounds isolated from natural products and micro-organisms, 
such as unusual sugar fragments in antibiotics. The initial discovery of 
streptomycin as an effective antibiotic for the treatment of mycobacterium 
tuberculosis infections[71] sparked the interest in aminoglycoside drugs; these 
compounds consisted of an aminocyclitol fragment connected to one or two 
carbohydrate units.  
 
By the 1990s, the boom in modern reagent methodology and asymmetric 
synthesis further encouraged the use of monosaccharides as chiral building blocks 
for the synthesis of complex glycosides.[72] However, despite the advancements in 
synthetic carbohydrate chemistry, this area of research remains a challenging field 
for organic chemists, due to the structural complexity of carbohydrates. The 
chemical synthesis of saccharides has been known to be a tedious and arduous 
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process, involving more than 40 steps of linear synthesis to obtain a single 
oligosaccharide.[73] Hans Paulson succinctly summarized this in 1982, which 
largely still holds true till date: “Each oligosaccharide synthesis remains an 
independent problem which resolution requires considerable systematic research 
and a good deal of know-how. There are no universal reaction conditions for 
oligosaccharide synthesis”.[74]  
 
1.5 Protecting Group Chemistry 
In carbohydrate sugars, the presence of multiple hydroxyl groups with similar 
chemical reactivities and other reactive functional groups such as carboxyl and 
amino groups have posed many challenges to the synthesis. Protecting group 
chemistry thus became a cornerstone in carbohydrate research, and the concept of 
orthogonal protecting groups was developed, to protect neighbouring functional 
groups from undesired side reactions during the course of synthesis. This involved 
selective cleavage of individual protecting groups under different reaction 
conditions to release specific groups for reaction and modification. Protection was 
essential as neighbouring functional groups would otherwise undergo similar 
reactions to form unwanted side products.  
 
In any synthetic strategy, the type of protecting group used must be carefully 
chosen to ensure reaction compatibility. The protecting groups used must be 
robust to the reaction conditions to keep the functionalities sufficiently protected, 
but be labile to removal when reaching specific points during synthesis, 
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preferably under facile conditions. In addition, regioselectivity is required during 
protection to discern between different hydroxyl groups present in the 
carbohydrate backbone to enable functionalization of specific positions in the 
monosaccharide to obtain the target compound.  When glycosidic bond formation 
is needed, only the anomeric C-1 hydroxyl group should be exposed for 
attachment to the neighbouring fragment, with the other functionalities suitably 
protected. Numerous hydroxyl protecting groups have been developed in the past 
few decades, and are now commonly used by organic chemists.
[75-78]
 These 
orthogonal protecting groups can be cleaved under different reaction conditions, 




1.5.1 Hydroxyl protecting groups: esters 
 
 
Figure 1-4. Protection of hydroxyl groups as esters 
 
Esters are the most conventional modes of protection utilised for hydroxyl groups 
(Figure 1-4), and can be cleanly cleaved via basic hydrolysis, using catalytic 
sodium methoxide in methanol. Acetates (Ac) are generally more labile than 
benzoates (Bz), while pivaloyl esters (Piv) are the most stable to hydrolysis. Some 
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esters can also be cleaved via other orthogonal methods. These include the 
chloroacetates (ClAc), which can be selectively cleaved using DABCO as the 
dechloroacetylation reagent
[83]
, and the levulinoyl ester (Lev), which can be 




1.5.2 Hydroxyl protecting groups: ethers 
 
 
Figure 1-5. Protection of hydroxyl groups as ethers  
 
Ethers are also a popular choice of protection for hydroxyl groups (Figure 1-5), as 
these groups are cleaved under reaction conditions orthogonal to that of esters. 
For the benzyl ether (Bn), cleavage occurs via catalytic hydrogenation, in the 
presence of palladium on charcoal (10% Pd/C) as the catalyst. On the other hand, 
the naphthyl ether (Nap), p-methoxybenzyl ether (PMB) and p-methoxylphenyl 
ethers (PMP) can all be cleaved via oxidative conditions, using either ceric 
ammonium nitrate (CAN) or 2,3-dichloro-5,6-dicyano-1,4-benzoquinone (DDQ) 
as the oxidant
[76]
; these do not affect the benzyl ethers.  
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For regioselective protection of the primary C-6 alcohol, the sterically bulky trityl 
group can be employed; this trityl group can be cleaved via acidic hydrolysis or 
hydrogenolysis when required. 
 
1.5.3 Hydroxyl protecting groups: silyl ethers  
 
 
Figure 1-6. Protection of hydroxyl groups as silyl ethers  
 
Silyl ether protecting groups are introduced under mild conditions by reacting the 
hydroxyl functionally with silyl chlorides in the presence of bases such as 
imidazole or pyridine (Figure 1-6). These protecting groups can be cleaved with 
acid, or with fluoride ions such tetrabutylammonium fluoride. The order of acid 
stability is proportional to the steric size of the silyl ether, and increases in the 
following order: TMS < TBDMS < TIPS < TBDPS. Regioselective silylation of 
the primary C-6 hydroxyl group is similarly possible by reacting pyranoses with 







1.5.4 Hydroxyl protecting groups: cyclic acetals  
 
 
Figure 1-7. Protection of hydroxyl groups as cyclic acetals  
 
Acetal protecting groups are also commonly used in carbohydrate chemistry, and 
can be removed via acidic hydrolysis to regenerate the hydroxyl group. To direct 
regioselective protection of a pair of hydroxyl groups in monosaccharides, cyclic 
acetals are commonly employed, which are more stable than acyclic variants 
(Figure 1-7). Isopropylidene acetals enable simultaneous protection of cis-
positioned 1,2-diols groups in the sugar unit to obtain the furanose derivative. 
Selective cleavage of the C-5,C-6 isopropylidene acetal is possible using a weaker 
acid, as both isopropylidene acetals have different stabilities.  
 
Alternatively, benzylidene acetals can be used for protection of both the C-4 and 
C-6 hydroxyl groups (1,3-diols) to form the stable bicylic ring system in 
pyranoses. This benzylidene acetal can be regioselectively opened up to generate 











Figure 1-8. Glycosylation between a glycosyl donor and acceptor 
 
To synthesize oligosaccharides, glycosylation is required: this involves 
connecting 2 suitably protected saccharide units to form a longer fragment, 
generating the glycosidic linkage at anomeric C-1 carbon of the glycosyl donor 
(Figure 1-8). For glycosylation to proceed smoothly, a suitably protected glycosyl 
donor with a leaving group (LG) attached to the anomeric positon is required, 
which is replaced by the hydroxyl group of the acceptor during glycosylation. The 
glycosidic linkage formed can either be 1,2-cis or 1,2-trans (alternatively 
classified as α- or β-configuration). Depending on the target molecule, synthetic 
methods have to be devised to obtain the required stereochemistry so as to probe 
the biological effects conferred by the carbohydrate motif in chiral living 
organisms.  
 
Many types of glycosyl donors have been devised and optimized for the synthesis 
of different oligosaccharides (Figure 1-9).
[89]
 To activate the glycosyl donor, 
various glycosyl auxiliaries can be attached to the anomeric C-1 carbon. 
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Examples include substituents like halides, thioglycosides, sulfoxides, 
selenoglycosides, and the trichloroacetimidate auxiliary, which is most commonly 
used. These substituents are activated by Lewis acids such as trimethylsilyl 
trifluoromethanesulfonate (TMSOTf), boron trifluoride diethyl etherate 
(BF3.OEt2), silver triflate and triflic acid/N- iodosuccinimide. 
 
 
Figure 1-9. Examples of different glycosyl donors 
 
1.6.1 Stereoselectivity of Glycosylation 
 
Figure 1-10. Glycosylation reaction mechanism 
 
During glycosylation, nucleophilic displacement occurs at the anomeric carbon, 
involving the attack of a weak nucleophile (the glycosyl acceptor) on the 
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secondary carbon center via a unimolecular SN1 mechanism.
[90]
 When promoted 
by an activator, the glycosyl auxiliary departs as a stable leaving group which 
generates the reactive oxocarbenium ion, facilitating attack by the hydroxyl group 
of the glycosyl acceptor (Figure 1-10). The acceptor can either attack from the top 
or bottom of the plane, to form a mixture of 1,2-cis and 1,2-trans glycosides. 
Although the 1,2-cis product is thermodynamically favoured due to stabilization 
by the anomeric effect, 1,2-trans product is also kinetically formed due to 
irreversible glycosidic bond formation. Both the α and β anomers are difficult to 
separate by chromatographic techniques as they have very similar physical 
characteristics; formation of the undesired anomer not only contaminates the 
product, but also reduces yield of the glycosylation step. Hence there is a need for 
stereochemical control during glycosylation to maximize yield of the required 
anomer. Different methods have been developed to direct the stereoselectivity of 









To direct 1,2-trans stereoselective glycosylation, neighbouring group 
participation can be employed by using protecting groups such as esters and 
amides on the C-2 position of the glycosyl donor
[90]
 (Figure 1-11). This 
anchimeric effect occurs when the electrons from the C-2 participating group 
delocalizes into the oxocarbenium ion ring to stabilize the positive charge. The C-
2 O-acyl group forms a stable 1,2-cis fused ring system with the sugar unit via 
axial attack from the bottom face to generate the acyloxonium ion. This exposes 
the top plane to attack by the glycosyl acceptor which generates 1,2-trans 




Figure 1-12. Solvent participation for stereoselective glycosylation 
 
In the absence of C-2 participating group, solvent effects may also be utilised to 
direct stereoselectivity at the anomeric position
[91]











solvents such as acetonitrile and diethyl ether can be used to direct the formation 
of β-glucosides and α-glucosides respectively. When glycosylations are carried 
out in acetonitrile, an acetronitrilium ion intermediate is formed in situ, which 
adopts the axial configuration.
[92-94]
 Subsequent displacement of the acetonitrile 
group via SN2 attack by the acceptor generates the glycosidic linkage at the 
equatorial position to obtain the 1,2-trans glycoside, even in the absence of the C-
2 participating group. Conversely, diethyl ether forms the oxonium ion at the 
equatorial position due to electronic stabilization via anomeric effects, thus the 
acceptor attacks from the axial position to form the 1,2-cis glycoside.
[95]
 
Alternatively, pre-activation of thioglycosyl donors with DMF prior to the 





In naturally occurring CS polysaccharides, the glycosidic bonds have β 
stereoselectivity. Hence, the protection strategy designed should enable 
stereoselective formation of the desired 1,2-trans glycosidic linkage, preferably 
through the use of neighbouring group participation on C-2 of the donor unit.  
 
1.7 Chemoenzymatic Synthesis of Heparin Sulfate Construct 
Due to the structural complexity of glycosaminoglycans, commercially available 
heparin drugs such as Arixtra are highly costly, requiring more than 50 steps to 
obtain via chemical synthesis.[97] The importance of anti-coagulant drugs has 
prompted the development of new methods to complement existing methods. To 
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improve overall yields, chemoenzymatic approaches were devised, these methods 
mimic biosynthesis, by utilizing heparan sulfate biosynthetic enzymes such as HS 
polymerases, epimerases and sulfotransferases. 
 
Recently, Xu et al. demonstrated the chemoenzymatic synthesis of ultralow 
molecular weight heparin construct 1-4 (Figure 1-13).[98] Core disaccharide unit 
1-1 was utilised as the starting material, which was readily available from 
heparosan, obtainable via fermentation. Through the use of two bacterial glycosyl 
transferases (N-acetyl glucosaminyl transferase of Escherichia coli K5 (KfiA) and 
heparosan synthase-2 (pmHS2) from Pasteurella multocida), tetrasaccharide 1-2 
was prepared by attaching the GlcNTFA and GlcUA units to disaccharide 1-1. 
Similarly, 1-2 was further extended by attaching 3 additional monosaccharides to 
obtain heptasaccharide 1-3. 
 
Subsequent epimerization of gluA to IdoA (residue D, 1-4) was accompanied by 
2-O-sulfation, 6-O-sulfation and 3-O-sulfation (residue C, 1-4) to obtain heparin 
construct 1-3, ultilizing 3'-phosphoadenosine-5'-phosphosulfate (PAPS) as the 
sulfo group donor.  It was noted that selective epimerization/2-O-sulfation of 
residue D (instead of residue B) and 3-O-sulfaton of residue C (instead of residue 
A and E) required careful structural control of the substrate, which was dependent 
on the polysaccharide sequence. To obtain N-sulfo groups in 1-4, trifluoroacetyl 





Figure 1-13. Chemoenzymatic synthesis of heparin sulfate construct 
 
Unlike conventional chemical synthesis[99], the need to introduce and remove 
protecting groups could be averted through the use of chemoenzymatic methods. 
In addition, stereoselectivity of the glycosylation step could be readily controlled 
by using appropriate enzymes, without the need for glycosyl mediators to effect 
stereochemical outcome. This reduces the number of synthetic steps required, 
which improves overall reaction yields. However, a major limitation in 
chemoenzymatic methods is high substrate specificity; the constructs have to be 
carefully selected to ensure compatibility with enzymes used, and also to prevent 
the formation of other side products. In fact, to ensure compatibility with this 
chemoenzymatic approach, the heparin constructs synthesized via this method 
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were not the actual structure of Arixtra, but modified variants. Chemoenzymatic 
methods may thus not be viable for synthesis of a library of analogues. 
 
1.8 Chemical Synthesis of Chondroitin Sulfate 
 
 
Figure 1-14. CS sulfate motifs obtained via chemical synthesis 
 
Although relatively less studied than heparan sulfate GAGs, notable work has 
been achieved by various groups to synthesize CS GAGs of varying chain 
length[45, 46, 51, 52, 100-108], with a primary focus on commonly occurring CS 
sulfation patterns such as CS-A, CS-C and CS-E (Figure 1-14). Much effort has 
been expended on the synthesis of longer CS sequences, including tetra-, hexa- 
and octa- saccharides, and some of these analogues have been studied for their 
biological effects.[45, 109, 110] The synthetic precursors used usually involve 
derivatized glucose and galactose monosaccharides, furnished with appropriate 
protecting groups to allow for chain elongation and site specific sulfation required 
in the final compounds. Typically, these protecting groups are manipulated after 
glycosylation, which involve regioselective deprotection and sulfation to obtain 
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the required CS analogue. Recently, some rare CS isomers have also been 
obtained through an alternative approach; these include CS-K, CS-L and CS-
M.[52, 111] This method employs a different synthetic precursor: non-sulfated CS 
disaccharides derived from the acidic hydrolysis of commercially available CS 
polymers,[112, 113] which are further modified and protected to enable preparation 
of additional CS sulfation motifs.  
 
However, based on the current synthetic strategies reported, not all the sulfation 
patterns possible in the CS repeating unit can be obtained, particularly CS 
sequences where the sulfate groups occur on the C-2 or C-3 position of the 
glucuronic acid moiety. We opined that these CS sulfate motifs that are not 
commonly expressed could encode important regulatory information for various 
physiological processes, but glycobiological research has been impeded due to the 
difficulty in acquiring these CS sequences. To address this, there is therefore a 
need to design new methods to facilitate access to all 16 unique CS sulfation 










1.9 Objective of Research Work  
Thus, the aim of this project is to devise a synthetic strategy which would allow 
for the chemical synthesis of all 16 possible sulfation patterns present in the CS 
repeating unit. Ideally, the synthetic route should utilize common intermediates to 
obtain all 16 isomers via a divergent approach, providing access to novel CS 
sulfation motifs not hitherto reported. The library of synthesized compounds 
empowers us to systematically evaluate the effect of CS sulfation patterns on 
important biological events. In this project, some preliminary biological 
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CHAPTER 2: CHEMICAL SYNTHESIS OF  





Figure 2-1. Retrosynthetic analysis for CS disaccharide synthesis 
 
A retrosynthetic analysis of chondroitin sulfate (CS) is depicted in Figure 2-1. To 
obtain the sulfation patterns theoretically possible in the CS repeating unit, the 
required monomeric building blocks include the glucuronic acid and N-acetyl 
galactosamine precursors which could be obtained from D-glucose and D-
galactose respectively; these monosaccharides are readily available and of low 
cost.  We first embarked on the synthesis of sulfation patterns CS-A, CS-C, CS-E, 
CS-O, CS-K and CS-M which were more well studied
[1-12]
 to familiarize with the 
chemical synthesis of CS before devising the synthetic strategy to obtain other 
novel sulfation patterns. These six analogues mainly involve sulfation at the C-4’ 
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and/or C-6’ positions on the N-acetyl galactosamine moiety, or have sulfate 
groups on C-3 of the glucuronic acid moiety. For the efficient synthesis of the CS 
disaccharide library, a divergent approach was adopted, through the use of 
common reaction intermediates. 
 
In naturally occurring CS polysaccharides, the glycosidic bonds have β-
stereoselectivity. Hence, stereoselective formation of the 1,2-trans glycosidic 
linkage is required, which can be obtained by attaching participating groups on 
the C-2 position of the donor unit, such as ester protecting groups. In the accepter 
unit, the N-acetyl group is required on the C-2’ position. However, N-acetyl 
groups reduce solubility and reactivity of the precursor
[6]
 hence temporary 
protecting groups such as trichloroacetyl, trichloroethoxycarbonyl and phthaloyl 
groups may be used
[13-15]
, these can be converted into N-acetyl groups during later 
steps of synthesis.  
 
For the synthesis of each CS analogue, different protection strategies have to be 
utilised to direct regioselective sulfation of the required sites in the presence of 
other chemically equivalent hydroxyl groups. Upon attachment of the O-sulfate 
groups in the CS disaccharide, the increase in negative charges decrease solubility 
of the compound in common organic solvents, making isolation and 
characterization difficult.
[16]
 These acidic groups are also reactive and labile to 
various pH conditions, making them incompatible with many of the modification 
steps. Thus, the sulfate groups should only introduced during the final steps of 
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synthesis upon selective cleavage of orthogonal protecting groups. To introduce 
the sulfate groups, selectively deprotected hydroxyl groups are first reacted with 
the sulfating agent, prior to cleavage of the remaining protecting groups. 
 
By adapting some of the currently available methods
[3]
, we improved on the 
strategy to prepare CS-A, CS-C, CS-E, CS-O, CS-K and CS-M by reducing 
reaction time and increasing reaction yield through a divergent synthetic approach. 
Two protected glucuronic acid donors and one protected N-acetyl galactosamine 
acceptor were prepared after careful retrosynthetic analysis (Figure 2-2). The 
protecting groups utilised were carefully chosen to allow for stereoselective 
glycosylation and sulfation of appropriate sites to obtain the required CS 
analogues.   
 
 
Figure 2-2. Glycosyl donor and acceptor for the synthesis of CS disaccharides 
 
D-glucose was derivatized to obtain protected glucuronic acids D1
[17]
 and 2-17, 
which were used as the glycosyl donors. To form the glycosidic linkage, the 
trichloroacetimidate auxiliary
[18]
 was required at C-1 to function as the leaving 
group and facilitate attachment of the neighboring sugar unit. The C-2 and C-3 
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positions were possible sites of sulfation and hence depending on the target 
sulfation sites, appropriate protecting groups which could be selectively cleaved 
were required to enable regioselective sulfation. Since a C-2 ester protecting 
group can also act as a participating group during glycosylation to direct the 
formation of the desired β-glycosidic bond[1], the benzoyl ester protecting group 
was chosen for C-2. In CS polysaccharides, the C-4 position is the site of 
elongation. Hence another orthogonal protecting group was required, to enable 
selective cleavage and synthesis of longer CS sequences when required. To obtain 
the C-6 carboxyl functional group, selective oxidation of the C-6 primary alcohol 
in D-glucose was required, followed by protection of the C-6 carboxylate as a 
methyl ester. 
 
Similarly, D-galactose was derivatized by the introduction of appropriate 
protecting groups to obtain protected N-acetyl galactosamine 2-30, which was 
used as the glycosyl acceptor during synthesis. The terminal C-1’ position was 
protected as methyl ether, this served as a bioisosteric group and also kept the 
anomeric proton in the axial conformation to aid in compound characterization.
[19]
 
In N-acetylgalactosamine, a nitrogen was required in C-2’ position and thus the 
C-2’ oxygen atom in D-galactose was replaced. The trichloroacetyl (TCAHN) 
group was chosen as the temporary C-2’ amide protecting group[15]; this acted as 
the precursor to form the C-2’ N-acetyl functionality. This TCAHN group could 
also direct β-stereoselective glycosylation, and promote substrate solubility. In CS, 
the possible sites of sulfation on N-acetyl galactosamine include C-4’ and C-6’, 
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hence both positions were simultaneously protected as a benzylidene acetal, 
which acts as an orthogonal protecting group that could be cleaved when required 
for selective attachment of sulfate groups. A free hydroxyl group was also 
required on the C-3’ position for reaction with the glycosyl donor during 
glycosylation.  
 
2.1.1 Protection Strategy to Obtain CS-A, CS-C, CS-E and CS-O  
Glucuronic acid donor D1 and N-acetyl galactosamine acceptor 2-30 were utilised 
for the synthesis of CS-A, CS-C, CS-E and CS-O disaccharides (Figure 2-1).
[1]
 In 
these four CS sulfation patterns, there are no sulfate groups on the glucuronic acid 
moiety, hence the C-2 and C-3 hydroxyl groups can be protected orthogonally as 
benzoyl esters to protect against sulfation, and cleaved only in the final step. The 
benzylidene acetal protecting group can first be cleaved by acidic hydrolysis to 
regenerate the C-4’ and C-6’ hydroxyl groups, to enable sulfation on the N-acetyl 
galactosamine moiety. To obtain regioselective sulfation of the C-6’ primary 
alcohol, milder reaction conditions and shorter reaction times can be used (to 
obtain CS-C). Similarly when sulfation on C-4’ site is required, the more reactive 
C-6’ primary alcohol can first be preferentially protected[20], before subjecting the 
free C-4’ alcohol to the sulfating agent (to obtain CS-A). If both C-4’ and C-6’ 
sites require sulfation, a prolonged sulfation step would proceed upon removal of 
the benzylidene acetal (to obtain CS-E). For non-sulfated CS disaccharide, global 
deprotection of all remaining ester protecting groups would proceed after 
glycosylation without any sulfation step (to obtain CS-O). In this way, all 4 
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possible sulfation combinations on the N-acetyl galactosamine moiety can be 
obtained.  
 
2.1.2 Protection Strategy to Obtain CS-K and CS-M 
Glucuronic acid donor 2-17 and N-acetyl galactosamine acceptor 2-30 were used 
to prepare CS-K and CS-M analogues.
[4]
 These analogues are sulfated at the C-3 
position of the glucuronic acid moiety, in addition to sulfation on N-acetyl 
galactosamine. Hence, an additional orthogonal protecting group was required at 
C-3 to allow for selective deprotection and sulfation in later steps of synthesis. To 
achieve this, the naphthyl ether protecting group was introduced at the C-3 
position. This protecting group could be selectively removed via oxidative 
cleavage with DDQ to release the C-3 hydroxyl group for reaction with the 
sulfating agent prior to the global deprotection step.  
 
2.2 Synthesis of Glucuronic Acid Donors D1 and 2-17 
D-glucose was used as the starting material to prepare common intermediate 2-5, 
which was required for the synthesis of glycosyl donors D1 and 2-17 (Scheme 2-
1). The five hydroxyl groups in D-glucose were first protected using acetic 
anhydride and pyridine to form penta-acetylated glucose 2-2. This provided 
solubility of the substrate in organic solvents, and intermediate 2-2 was next 
reacted with thiophenol and boron trifluoride as the Lewis acid. This step 
introduced the thiophenol protecting group exclusively at the anomeric C-1 
carbon to form thioglycoside 2-3. 
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Reagents and conditions: (a) Ac2O, DMAP, pyridine, 1 h, 85%; (b) PhSH, 
BF3.OEt2, 35
o
C, 14 h, 70%; (c) NaOMe, MeOH, 1 h, 90%, (d) PhCH(OMe)2, 
CSA, CH3CN/DMF, 16 h, 60
o
C, 72%;  (e) Bu2SnO, toluene, 4 h, 110
o
C, then 
NapBr, CsF, DMF, 12 h, 47%; (f) Bz2O, TEA, DMAP, CH2Cl2, 1 h, 2-6: 80%,   
2-9: 86%; (g) TFA, CH2Cl2/H2O, 4 h, 2-7:85%, 2-10: 88%; (h) TEMPO, BAIB, 
CH2Cl2/H2O,  4 h, then MeI, NaHCO3, TBAI, DMF, 1 h, 50
o
C, 2-11: 51%, 2-12: 
48%; (i) Cl2Ac2O, pyridine, 1 h, CH2Cl2, 2-13: 89%, 2-14: 82%; (j) NIS, TFA, 14 
h, CH2Cl2/H2O, 2-15: 72%, 2-16: 70%; (k) Cl3CCN, DBU, CH2Cl2, 6 h, D1: 74%, 




With the anomeric carbon protected, the remaining acetyl groups could then be 
cleaved by basic hydrolysis to form 2-4, followed by regioselective protection of 
the C-4 and C-6 hydroxyl group as a benzylidene acetal via the formation of a 
stable double chair conformation to obtain common intermediate 2-5.
[21]
 By 
varying some of the synthetic steps to establish different protecting groups on the 
C-2 and C-3 positions, both glucuronic acid donors D1 and 2-17 could be 
prepared by using 2-5 as the common precursor. 
 
To obtain glycosyl donor D1, the hydroxyl groups on C-2 and C-3 were first 
benzoylated by reacting intermediate 2-5 with benzoic anhydride and DMAP as 
the nucleophilic catalyst to form intermediate 2-6. For donor 2-17, regioselective 
naphthylation at the C-3 position was required. This was achieved by refluxing 2-
5 with dibutyltin oxide in toluene to first generate the dibutyl tin complex in situ, 
before reacting the intermediate with naphthyl bromide and caesium fluoride to 
direct naphthylation at the C-3 position to form intermediate 2-8.
[22]
 The free 
hydroxyl group on C-2 was next protected with benzoic anhydride to form 2-9. 
With the key protecting groups established on C-2 and C-3 positions, 
intermediates 2-6 and 2-9 were next subjected to acidic hydrolysis using 
trifluoracetic acid in the presence of water to cleave the benzylidene acetal and 
release the C-4 and C-6 hydroxyl groups.
[23]
 This formed intermediates 2-7 and 2-




The C-6 primary alcohols in intermediates 2-7 and 2-10 were then selectively 
oxidized using TEMPO as the radical initiator and BAIB co-oxidant to form the 
C-6 carboxylate group
[24]
, which was subsequently protected as a methyl ester to 
form intermediates 2-11 and 2-12. The C-4 hydroxyl groups were next protected 
as chloroacetyl esters to form intermediates 2-13 and 2-14. This chloroacetate 
could serve as an orthogonal protecting group which can be selectively cleaved to 
release the C-4 hydroxyl group for further elongation when required.
[25]
 
Thioglycoside 2-13 was initially used as the glycosyl donor as the anomeric 
thiophenol protecting group could be activated by a promoter to function as the 
leaving group during glycosylation. 
 
To further increase the reactivity of 2-13 and 2-14, two additional steps were 
introduced to obtain glucuronic acid donors D1 and 2-17. This involved cleavage 
of the thiophenol protecting group by N-iodosuccinimide (NIS) and trifluoroacetic 
acid (TFA) to regenerate the anomeric hydroxyl group in intermediates 2-15 and 
2-16
[26]
, prior to attachment of the trichloroacetimidate auxiliary to form D1 and 
2-17.  
 
2.3 Synthesis of N-acetyl galactosamine Acceptor 2-30 
To obtain N-acetyl galactosamine acceptor 2-30, D-galactose was used as the 
starting material (Scheme 2-2). D-galactose was first protected with acetic 
anhydride and pyridine to form penta-acetylated galactose 2-19. Intermediate 2-19 
was next reacted with HBr in acetic acid to replace the anomeric group with a 
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bromine atom followed by reductive elimination using zinc and sodium acetate to 
form the double bond in D-galactal 2-21.
[27, 28]
 Azidonitration via a radical 
mediated approach enabled attachment of the azide group onto the C-2’ position 
in intermediate 2-22, by reacting intermediate 2-21 with excess cerium 
ammonium nitrate and sodium azide.
[29]
 This introduced the nitrogen atom on the 
C-2’ position of galactose as an azide group; however only moderate yields of 45% 
could be obtained.  
 






Reagents and conditions: (a) Ac2O, DMAP, pyridine, 1 h, 85%; (b) HBr, AcOH, 
EtOAc, 1 h, 76%; (c) Zn, CuSO4, NaOAc, EtOAc, AcOH/H2O, 4 h, 85%; (d) 
NaN3, CAN, MeCN, -15
o
C, 14 h, 45%; (e) NaOAc, AcOH, 100
o
C, 1 h, 82%; (f) 
H2, Pd/C, TsOH.H2O, THF, 14 h, 90%; (g) Cl3CCOCl, TEA, THF, 30 mins, 71%; 
(h) 33% MeNH2 in EtOH, THF, 4 h, 71%; (i) Cl3CCN, DBU, CH2Cl2, 6 h, 72%; 
(j) MeOH, TMSOTf, CH2Cl2, 3Å MS, 1 h, -10
o
C, 84% (k) NaOMe, MeOH, 1 h, 





The anomeric group was next substituted with a stable acetate group, and the C-2’ 
azide in 2-23 was hydrogenated to obtain amine 2-24. To obtain the C-2’ N-acetyl 
group, direct acetylation of the amine group by reaction with acetyl chloride and 
pyridine was initially attempted, but solubility of the product was very poor and 
isolation was difficult. Thus, the amine group was protected as an N-
trichloroacetyl group (TCANH) to form 2-25
[30, 31]
; this group could be reduced to 
an N-acetyl group when required.  
 
With the amine functionality suitably protected, the anomeric acetate group was 
next selectively deprotected using methylamine to release the hydroxyl group, 
before attachment of the trichloroacetimidate auxiliary to form 2-27. 
Glycosylating intermediate 2-27 with methanol using TMSOTf catalyst formed 
the methyl ether with β-stereoselectivity due to the C-2’ TCANH directing group. 
Deacetylation followed by regioselective protection of the C-4’ and C-6’ hydroxyl 
groups with benzylidene acetal formed protected N-acetyl galactosamine acceptor 
2-30. 
 
Glycosyl acceptor 2-30 was next reacted with glycosyl donors D1 and 2-17 to 
obtain protected disaccharides 2-31 and 2-32, which was utilised for the synthesis 






2.4 Synthesis of Protected Disaccharides 2-31 and 2-32 via Glycosylation 
 
Table 2-1. Synthesis of protected disaccharides 2-31 and 2-32 
 
 
Entry  Glycosyl  
donor 




1 2-13 NIS, TfOH 2-31 52 80 
2 D1 TMSOTf 2-31 78 >99  
3 D1 CuOTf 2-31 68 >99 
4 D1 AgOTf 2-31 60 >99 
5 2-17 TMSOTf 2-32 74 >99 
 
During the initial glycosylation attempts, thioglycoside 2-13 was used as the 
donor, by utilising the anomeric thiophenol group as the glycosyl auxiliary, 
activated by NIS and triflic acid. The presence of the C-2 participating group in 
donor 2-13 directed β-stereoselective glycosylation with acceptor 2-30 to form 
mainly the β-product 2-31; but a fraction of the desired product was lost due to 
formation of the α-anomer (Table 2-1, entry 1). In addition, it was difficult to 
separate the anomers via chromatographic techniques as both anomers were 
structurally very similar, and some desired product had to be sacrificed for purity. 
To avert this, thioglycoside 2-13 was modified to donor D1, which employed the 
more reactive trichloroacetimidate auxiliary. In the presence of the C-2 
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participating group, donor D1 formed almost exclusively the β-product (table 2-1, 
entry 2)
[1]
; thus the trichloroacetimidate auxiliary was utilised for subsequent 
glycosylation reactions. To further improve glycosylation yield, several Lewis 
acids such as TMSOTf, CuOTf and AgOTf were attempted, but it was noted that 
TMSOTf gave the highest reaction yields (Table 2-1, entries 2 – 4). 
 
Due to the high reactivity of donor D1, a low temperature of -40
o
C was used 
initially. However, glycosylation of D1 with acceptor 2-30 using TMSOTf could 
not proceed at -40
o
C after 24 hours, while raising the temperature to -10
o
C 
allowed completion of the reaction within 1 hour. A further increase to room 
temperature however caused the formation of side products due hydrolysis of the 
glycosyl donor, and a drop in β-stereoselectivity. Thus, we decided to add the 
TMSOTf Lewis acid at -20
o
C and allow the reaction to proceed at -10
o
C for 1 
hour. The optimized reaction conditions were applied for the synthesis of 
protected disaccharides 2-31 and 2-32, using glycosyl donors D1 and 2-17 
respectively (Table 2-1, entries 2 and 5). 
 
2.5 Synthesis of CS-A, CS-C, CS-E, CS-O, CS-K, CS-M 
After the glycosylation step, protected dimers 2-31 and 2-32 were subjected to 
reduction with tributyl tin hydride to convert the N-trichloroacetyl group to N-
acetyl group required in the N-acetylgalactosamine moiety
[15]
 (Scheme 2-3). The 
benzylidene acetal was next cleaved via acidic hydrolysis, by refluxing in aqueous 
acetic acid to liberate the C-4’ and C-6’ hydroxyl groups in disaccharides 2-31b 
52 
 
and 2-32b. It was noted that prolonged heating in acid caused an unwanted side 
reaction: acid catalyzed ring opening of the anomeric methyl ether linkage, and a 
mixture of α- and β- anomers (via subsequent ring closure) were isolated at the 
end of the reaction. Hence, this reaction had to be monitored carefully and 
quenched immediately upon completion to reduce side product formation.  
 





Reagents and conditions: (a) Bu3SnH, ABCN, toluene, 4 h, 2-31a: 68%; 2-32a: 
73%; (b) 80% AcOH, 1 h, 80
o
C, 2-31b: 85%; 2-32b: 88% 
 
With disaccharides 2-31b and 2-32b on hand, the free hydroxyl groups on the N-
acetyl galactosamine moiety were next subjected to regioselective sulfation with 
the other functionalities suitably protected. 2-31b was utilised for the synthesis of 
CS-A, CS-C, CS-E and CS-O, while 2-32b was used for the synthesis of CS-K 
and CS-M. 
 
For the sulfation of both C-4’ and C-6’ hydroxyl groups, 2-31b was reacted with a 
large excess of sulfating agent SO3.TMA (30 equiv), and the reaction was heated 
for a prolonged period (48 hours), to obtain disulfated product 2-31c (Scheme 2-
4)
[1]
. Mono-sulfation of the more reactive C-6’ primary hydroxyl group required 
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milder conditions, employing a smaller amount of sulfating agent (3 equiv.), and a 
shorter reaction period of 4 hours to obtain C-6’ monosulfated disaccharide 2-31d. 
For the mono-sulfation of the C-4’ hydroxyl group, the more reactive C-6’ 
hydroxyl group was first protected as a benzoyl ester by reacting 2-31b with 
benzoyl cyanide in pyridine to form 2-31e.
[11]
 Sulfation of intermediate 2-31e 
furnished C-4’ monosulfated analogue 2-31f.  
 





Reagents and conditions: (a) BzCN, pyridine, 16 h, 75%; (b) 2-31c: SO3.TMA 
(30 equiv.), DMF, 50
o
C, 48 h, 60%; 2-31d: SO3.TMA(3 equiv.), DMF, 50
o
C, 4 h, 
67%; 2-31f: SO3.TMA (10 equiv.), DMF, 50
o
C, 48 h, 64%  
 
In the structure of CS-M, both the C-4’ and C-6’ hydroxyl groups in the N-
acetylgalactosamine moiety are sulfated, in addition to the C-3 hydroxyl group on 
the glucuronic acid moiety. Hence, the C-3 protecting group in 2-32b was first 
cleaved by DDQ oxidation to form 2-32c
[32]
 before sulfation step of all three 
hydroxyl groups to form tri-sulfated analogue 2-32d (Scheme 2-5). To obtain the 
sulfation pattern on CS-K, where the C-3 and C-4’ positions are sulfated, the 
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more reactive hydroxyl group on the C-6’ position of 2-32b was first selectively 
protected as a benzoyl ester to form 2-32e. The C-3 naphthyl ether on the 
glucuronic acid moiety was next removed by oxidative cleavage with DDQ to 
release the hydroxyl group to form 2-32f. The two unprotected hydroxyl groups 
were then subjected to sulfation to obtain 2-32g.
[4]
 It was noted that a stronger 
sulfating agent SO3.TEA was required for the sulfation of the C-3 hydroxyl group 
on glucuronic acid to obtain 2-32d and 2-32g, as SO3.TMA was not sufficiently 
strong to ensure reaction completion. 
 





Reagents and conditions: (a) BzCN, pyridine, 16 h, 42%; (b) DDQ, 
CH2Cl2/MeOH, 12 h, 2-32c: 64%, 2-32f: 33%; (c) SO3.TEA (20 equiv.), DMF, 48 
h, 50
o
C, 2-32d: 57%, 2-32g: 80% 
 
With the sulfate groups attached at the desired positions, global deprotection of 
the ester protecting groups proceeded in the final step to release all the masked 
hydroxyl groups to form the target molecules (Scheme 2-6). In this basic 
hydrolysis step, the intermediates were first subjected to LiOH/H2O2 before 
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saponification with NaOH; this sequential LiOOH-NaOH treatment was to 
minimize β-elimination at the C-4 position.[33] Through this approach, CS-A, CS-
C, CS-E, CS-O, CS-K and CS-M were successfully synthesized. 
 




2.6 Protection Strategy to Obtain CS-R 
Upon successful synthesis of the 6 CS disaccharides, we proceeded to prepare 
CS-R, which has sulfation on both C-2 and C-3 of glucuronic acid, but no sulfate 
groups on N-acetyl galactosamine.
[1]
 An orthogonal protecting group was thus 
required on both C-2 and C-3 positions of the glucuronic acid monomer for 
selective deprotection and sulfation. Several orthogonal protecting groups were 
attempted, which included the chloroacetate ester and levulinate ester. Ester 
protecting groups were favored on C-2 as they can also serve as participating 






2.6.1 Synthesis of Glucuronic Acid Donors 2-35 and 2-38 
The proposed glycosyl donors were prepared using similar synthetic steps 
employed for the synthesis of donors D1 and 2-17, by replacing the C-2 benzoyl 
ester with other ester groups which can be cleaved in an orthogonal fashion.  
Scheme 2-7. Synthesis of glycosyl donors 2-35 and 2-38 
 
 
Reagents and conditions: (a) Cl2Ac2O, pyridine, CH2Cl2, 1 h, 85%; (b) MeI, 
NaHCO3, DMF, 1 h, 55
o
C; (c) levulinic acid, DCC, DMAP, CH2Cl2, 4 h, 73% 
 
Common intermediate 2-5 was first protected at the C-2 and C-3 position using 
chloroacetic anhydride to obtain intermediate 2-33 (Scheme 2-7). Following 
similar modification steps of acid hydrolysis and selective primary oxidation, 
intermediate 2-34 was obtained, and was next subjected to methylation for the 
protection of the C-6 carboxyl group. However, the chloroacetyl protecting group 
was not stable under the methylation reaction conditions and many side products 
were formed. This was partly attributed to the acidic nature of the chloroacetate 
protons, which reacted with the methylating agent in the presence of weak bases 
such as carbonates. Thus, we decided to modify the C-2 and C-3 protecting 
groups to levulinate esters by coupling 2-5 with levulinic acid, in the presence of 
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DCC and DMAP catalyst to form 2-36. 2-36 was modified by similar methods 
which included benzylidene acetal cleavage, selective C-6 oxidation and 
methylation of the C-6 acid to obtain intermediate 2-37. The C-4 hydroxyl group 
was next protected as the orthogonal chloroacetate ester before anomeric 
deprotection and attachment of the trichloroacetimidate auxiliary to form 
protected glucuronic acid donor 2-38. 
 
2.6.2 Synthesis of Disaccharide 2-39d  
Using the previously optimized glycosylation conditions, 2-38 was used as the 
glycosyl donor to react with acceptor 2-30 to obtain disaccharide 2-39 (Scheme 2-
8). A relatively low glycosylation yield was obtained when the C-2 levulinate 
ester was used (donor 2-38), this could be attributed to long length of the C-2 
protecting group, which could interfere with glycosylation at the anomeric 
position. 2-39 was next subjected to tributyltin hydride reduction to obtain the C-2’ 
N-acetyl group, before acidic hydrolysis to cleave the benzylidene acetal. Both the 
C-4’ and C-6’ hydroxyl groups in 2-39b were then protected as benzoyl esters; 
these serve as temporary protecting groups during the sulfation step, which can be 
cleaved via basic hydrolysis in the global deprotection step. 
 
The levulinate esters on C-2 and C-3 in intermediate 2-39c were finally subjected 
to selective cleavage by hydrazine acetate in acetic acid to release the hydroxyl 
groups for reaction with the sulfating agent, but this step had very poor yields of 
30%. There was insufficient product (intermediate 2-39d) to proceed to sulfation 
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and global deprotection step to obtain CS-R, even after several repeated attempts. 
Extensive modification of the disaccharide was not very feasible as the losses 
were compounded from the already low yields obtained during glycosylation. We 
realized that it was extremely important to reduce the number of modification 
steps after glycosylation to cut losses, and a new protection strategy was required 
to obtain CS-R. 
 






Reagents and conditions: (a) TMSOTf, CH2Cl2, 4Å MS, 1 h, 41%; (b) Bu3SnH, 
AIBN, toluene, 80
o
C, 4 h, 70%; (c) 80% AcOH, 80
o
C, 1 h, 65%; (d) Bz2O, 
DMAP, pyridine, 1 h, 30%; (e) H2NNH2.CH3COOH, EtOH/toluene, 6 h, 30% 
 
In our exploratory attempts, C-2 ester protecting groups were favoured as these 
groups could direct β-stereoselectivity during glycosylation. However, both the 
levulinate and chloroacetate esters were unsuccessful, and there were no other 
viable ester protecting groups which could be cleaved orthogonally in the 
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presence of other esters, for regioselective deprotection and sulfation of C-2 and 
C-3 hydroxyl groups for the synthesis of CS-R. Thus, other non-ester protecting 
groups had to be employed for the C-2 hydroxyl group. The loss of the C-2 ester 
to direct β-stereoselective glycosylation meant that other reaction conditions 
would have to be modified to control stereoselectivity. The failed synthesis of CS-
R prompted us to re-evaluate our synthetic approach: it was too time consuming 
to explore and develop a new protection strategy for each subsequent analogue, 
and we needed to devise a common method for the synthesis of all 16 sulfation 
patterns possible in CS.  
 
2.7 Sulfation Specific Protection Strategy 
To devise a general method to obtain all 16 isomers possible in the CS repeating 
unit, it would be ideal if we had a pair of orthogonal protecting groups 
specifically introduced for the 4 sulfation sites, to either release the hydroxyl 
groups for sulfation to occur, or protect the hydroxyl groups against sulfation. In 
addition, the required protecting groups should be introduced onto the monomeric 
units to reduce the number of modification steps required in the disaccharide stage 
so as to improve reaction yields. 
 
To achieve this, we decided to utilize the ester and ether protecting groups, which 
can be cleaved via different reaction conditions; this enables regioselective 
deprotection and sulfation of the required sites. Ether groups were first designated 
for the protection of hydroxyl sites which require sulfation, since the C-6 carboxyl 
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group (non-sulfation site) was protected as a methyl ester. In this approach, ether 
protected hydroxyl groups would first be liberated upon glycosylation to allow for 
sulfation to occur, while the ester protecting groups remain attached. After the 
sulfation step, the remaining protecting groups can then be cleaved in a global 
deprotection step to obtain the desired product.  
 
 
Scheme 2-9. Retrosynthetic analysis for synthesis of CS-R 
 
The retrosynthetic analysis of CS-R is depicted in scheme 2-9. In this strategy, 
CS-R would require ether protecting groups on C-2 and C-3 positions of the 
glucuronic acid moiety; these are selectively cleaved after glycosylation to enable 
sulfation on C-2 and C-3. The C-4’ and C-6’ hydroxyl groups (on N-acetyl 
galactosamine) which do not require sulfation would be orthogonally protected as 




Table 2-2. Sulfation specific strategy to obtain all 16 CS disaccharides 
 























































































To extend this approach, all 16 CS sulfation patterns can be obtained by 
manipulating the protecting groups present in the donor and acceptor building 
blocks. 4 possible protecting group combinations are possible for the glycosyl 
donor and acceptor, which give rise to a total of 16 possible CS disaccharides 
(Table 2-2). Preferably, a common intermediate should be used for the synthesis 








To obtain the sulfation pattern required in CS-R which has sulfate groups on C-2 
and C-3 of glucuronic acid, the monomeric precursors required are glycosyl donor 
A (C-2 and C-3 ether protection) and acceptor 4 (C-4’ and C-6’ ester protection).  
Unlike glycosyl donors B and D which have C-2 ester protecting groups to direct 
β-stereoselective glycosylation, glycosyl donors A and C utilize ether protecting 
groups on C-2 which are non-participating groups. Thus, other factors such as 
solvent effects would be required to direct β-stereoselectivity.  
 
2.7.1 Synthesis of Glycosyl Donors 2-42, 2-45 
 
Scheme 2-10. Synthesis of glycosyl donors 2-42 and 2-45 
Reagents and conditions: (a) BnBr, NaH, DMF, 3 h, 85%; (b) NapBr, NaH, DMF, 
3 h, 80%  
 
To prepare the glycosyl donors for the synthesis of CS-R, both the C-2 and C-3 
hydroxyl groups were either protected as benzyl ethers (2-42) or naphthyl ethers 
(2-45) (Scheme 2-10). Protecting both the C-2 and C-3 of the glucuronic acid 
donor with benzyl ether or naphthyl ether functionality enables regioselective 
deprotection by catalytic hydrogenation or DDQ oxidation respectively to free the 
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hydroxyl groups to direct site specific sulfation at C-2 and C-3 during later steps 
of synthesis.  
 
Intermediate 2-5 was first reacted with benzyl bromide and sodium hydride to 
introduce the benzyl ether at the C-2 and C-3 position in intermediate 2-40. 
Similarly, both the C-2 and C-3 hydroxyl groups on 2-5 could be protected as 
naphthyl ethers by reaction with naphthyl bromide and sodium hydride to obtain 
intermediate 2-43. Both 2-40 and 2-43 were next subjected to acetal hydrolysis, 
primary alcohol oxidation, methylation and C-4 choloroacetylation to obtain 
thioglycosides 2-41 and 2-44. An ester protecting group was utilised for the C-4 
hydroxyl group as C-4 is a non-sulfation site which required orthogonal 
protection. Deprotection of the anomeric thiophenol group and attachment of the 
trichloroacetimidate auxiliary furnished glycosyl donors 2-42 and 2-45. The loss 
of C-2 ester participating groups in these donors required a change in the 
glycosylation solvent to direct β-stereoselectivity through the use of participating 
solvents such as acetonitrile (MeCN). 
 
2.7.2 Synthesis of Glycosyl Acceptor A1 
In order to minimize the number of modification steps required after 
glycosylation, the required ester protecting groups on C-4’ and C-6’ were now 
introduced into glycosyl acceptor 2-30 (Scheme 2-11). The C-3’ hydroxyl group 
was first protected as a chloroacetyl ester in 2-46, prior to cleavage of the 
benzylidene acetal via acidic hydrolysis to release the C-4’ and C-6’ hydroxyl 
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groups; these were both acetylated to obtain 2-48. The acidic cleavage of the 
benzylidene acetal however, was not very favorable due to the acid catalyzed ring 
opening at the anomeric methyl ether linkage, which converted some β-product 
into the α form and the reaction had to be carefully monitored (discussed later). 
To obtain glycosyl acceptor A1, the C-3’ chloroacetyl ester in 2-48 was 
selectively deprotected by reaction with thiourea in ethanol/pyridine to regenerate 










Reagents and conditions: (a) Cl2Ac2O, pyridine, CH2Cl2, 1 h, 85%; (b) 80% 
AcOH, 80
o
C, 1 h, 60%; (c) Ac2O, DMAP, pyridine, 1 h, 82%; (d) thiourea, 




2.7.3 Synthesis of Protected Disaccharides 2-49 and 2-50 via Glycosylation 
Glycosyl donors 2-41 and 2-42 were first utilised for glycosylation to obtain 
disaccharide 2-49 (Table 2-3) as benzyl ether protecting groups could be cleanly 
cleaved via catalytic hydrogenation when required. This was preferred to naphthyl 
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ether protecting groups (in donors 2-44 and 2-45) which require oxidative 
cleavage, resulting in the formation of water soluble salts that are difficult to 
remove. 
 
Table 2-3. Glycosylation reaction to obtain protected disaccharides 2-49 and 2-50 
 
 
Entry Donor  Lewis acid 
(equiv.) 
Solvent Temp. Product (%) 
1 2-41 NIS,TfOH 
(1.68,0.63) 
DCM -20 to 0
o
C 2-49 (43%) 
(α:β) =1:1 
2 2-41 NIS,TfOH 
(1.68,0.63) 
MeCN -20 to 0
o
C - 
3 2-41 NIS,TMSOTf  
(1.68,0.24) 
DCM/MeCN/
EtCN (1:2:1)  
-78 to -40 to  
-20
 o
C to r.t. 
- 
4 2-42 TMSOTf 
(1.1) 
EtCN -78 to -40 to  
-20
 o
C to r.t. 
- 









6 2-44 NIS,TfOH 
(1.68,0.63) 
DCM -20 to 0
 o
C - 
7 2-45 TMSOTf 
(0.2) 
DCM -20 to -10
 o





Since the C-2 benzyl ether was not a participating group, solvent effects were 
required to direct β-stereoselectivity of the glycosylation step. To ascertain 
reactivity of the donor and acceptor, we first reacted thioglycoside 2-41 and 
acceptor A1 using the previously optimized solvent system dichloromethane 
(DCM), and disaccharide 2-49 was obtained in 43% yield after 1 hour (Table 2-3, 
entry 1). As expected, there was no stereoselectivity in the glycosylation step due 
to the loss of the C-2 ester group and both the α- and β- product were obtained in 
approximately equal amounts. Both anomers were structurally very similar and it 
was difficult to separate them by chromatography without compromising on the 
yield. Moreover, too much product was lost from the formation of the undesired 
anomer. To overcome this, we proceeded to direct β-stereoselectivity by 
modifying the reaction conditions, through the use of participating solvents. 
 
Glycosylation was re-attempted with acetonitrile (MeCN), this solvent was 
postulated to participate by first displacing the auxiliary group on the donor to 
form a stable leaving group at the anomeric carbon of the glycosyl donor, in the 
axial position. Acceptor A1 thus attacks the nitrilium intermediate from the 
equatorial position to displace the nitrile solvent, to form the β-glycosidic linkage 
through the solvent effect.
[34-37]
 However, when donor 2-41 was reacted with 
acceptor A1 using MeCN, no product was observed (Table 2-3, entry 2). 
Monitoring of the reaction by mass spectrometry did indicate formation of the 
nitrilium intermediate, but the nitrilium intermediate formed was too stable and 
the acceptor A1 could not displace the nitrile group to form the glycosidic linkage. 
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Upon reaction workup, only the hydrolyzed donor with anomeric hydroxyl group 
could be identified, together with the unreacted acceptor A1, and no disaccharide 
was obtained. 
 
To facilitate attack of the glycosyl acceptor to the nitrilium intermediate to form 
the glycosidic linkage, a stronger Lewis acid TMSOTf was used, to coordinate to 
the nitrile group and generate a stable leaving group. The reaction was re-
attempted at -78
o
C and a solvent mixture of DCM/MeCN/EtCN (1:2:1) was used; 
DCM and propionitrile (EtCN) were required as co-solvents as MeCN freezes at -
45
o
C. The reaction unfortunately again, did not proceed. The reaction temperature 




C to room temperature, but no 
disaccharide could be detected after 24 hours (Table 2-3, entry 3).  
 
We next modified the glycosyl donor to 2-42 to increase the donor reactivity for 
glycosylation to proceed, by replacement of the anomeric thiophenol group with 
the trichloroacetimidate auxiliary. More Lewis acid (1.1 equivalent TMSOTf) was 
also added to promote completion of the reaction; EtCN was used as the solvent 
since MeCN was not a suitable at -78
o
C. Unfortunately, no disaccharide was 





room temperature (Table 2-3, entry 4). Upon prolonged stirring, the nitrilum 
intermediate hydrolysed to form the hydroxyl group at the anomeric carbon. To 
push the acceptor to react and displace the nitrilium intermediate, the 
concentration of the nitrile solvent was subsequently reduced by changing the 
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solvent system to DCM/MeCN (1:3). However, no disaccharide was observed 






C (Table 2-3, entry 
5). 
 
Since C-2 benzyl ether protecting groups were not suitable, we re-attempted using 
the C-2 naphthyl ether by utilising glycosyl donors 2-44 and 2-45. Similarly, we 
first reacted glycosyl donors 2-44 and 2-45 with acceptor A1 using previously 
optimized conditions in dichloromethane solvent to ascertain the donor reactivity 
(Table 2-3, entries 6 and 7). Unfortunately, the glycosylation steps gave very low 
reaction yields, and only trace amount of the dimer could be obtained when donor 
2-45 was used. The low reaction yield was further compounded by the lack of β-
stereoselectivity during glycosylation due to the loss of C-2 participating group. 
Poor reactivity of the donors 2-44 and 2-45 could be attributed to the bulky 
naphthyl ether at the C-2 position, which caused steric hindrance, blocking the 
attack of the glycosyl acceptor at the anomeric position. Thus naphthyl ether 
protecting group was also not suitable for C-2 hydroxyl group protection. 
 
The use of nitrile solvents to direct β-stereoselectivity have been reported to be 
highly substrate dependent, and different reaction yields and stereoselectivities 
have been reported for different donors, depending on the structure of the 
protected glycosyl donors.
[34, 37]
 Unfortunately, this method could not be applied 
to the protection strategy utilised for our monomeric building blocks. The 
nitrilium intermediate generated was too stable for glycosylation to proceed; no 
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disaccharide product could be obtained when glycosyl donors 2-41 and 2-42 were 
reacted with acceptor A1 using nitrile solvents. The sulfation specific protection 
strategy thus had to be further fine-tuned to account for β-stereoselective 
glycosylation, which is the required stereochemistry in CS GAGs. 
 
2.8 Modifying the Sulfation Specific Protection Strategy 
To obtain all the 16 sulfation patterns possible in CS through a more general 
approach, a sulfation specific protection strategy was devised, which incorporated 
the use of ether and ester protecting groups as orthogonal handles to direct 
sulfation. One of these protecting groups was denoted as sulfation sites, and 
cleaved first to release the free hydroxyl groups for sulfation, prior to global 
deprotection of the remaining protecting groups.  
 
From our failed glycosylation attempts, it was noted that ether protecting groups 
were not suitable for the C-2 position of the glycosyl donor as we were not able to 
direct β-stereoselective glycosylation though the use of nitrilium solvents. Due to 
the lack of options to direct β-stereoselectivity, we had to revisit the use of C-2 
participating groups for the glucuronic acid donor. Since our attempts at 
identifying orthogonal ester protecting groups (such as chloroacetyl and levulinyl) 
were also not successful, we decided to return to the use of benzoyl ester for C-2 
protection as this group was able to direct β-stereoselective glycosylation and also 
make the donor sufficiently reactive for glycosylation to proceed in good yields, 
as shown from the synthesis of CS-A, CS-C, CS-E, CS-O, CS-K and CS-M. 
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However in CS, the C-2 position of glucuronic acid might require attachment of 
sulfate groups.  Thus when we fixed the C-2 protecting group as the benzoyl ester 
to direct β-stereoselective glycosylation, esters now need to serve as both 
sulfation and non-sulfation protection handles, depending on which CS isomer is 
synthesized. In the case when C-2 sulfation is required, esters will be designated 
as sites of sulfation (since C-2 benzoyl ester is mandatory).  On the other hand, 
when C-2 sulfation is not required, ethers now become the designated as sites of 
sulfation.  
 
2.8.1 Protection Strategy for Glycosyl Donors 
 
 




Four different glycosyl donors were thus proposed, which can be synthesized 
from common intermediate 2-5 (Figure 2-3). In all four glycosyl donors, C-2 is 
always protected as a benzoyl ester, this serves to direct β-stereoselective 
glycosylation. On the other hand, the C-3 hydroxyl group can either be protected 
as a benzyl ether or benzoyl ester. 
 
The C-1 position retains the trichloroacetimidate auxiliary which functions as the 
leaving group during glycosylation, and the C-6 carboxyl group will still require 
protection as a methyl ester.  
 
The C-4 position of the glucuronic acid donor is the site of elongation and is 
never sulfated, thus the protecting group chosen for C-4 must be orthogonal to 
protecting groups utilised for sulfation sites. If ethers are used to mask the 
sulfation sites, ester protecting group would be required on C-4, but if ester 
groups denote sulfation sites, ether protection would be needed on C-4.  
 
For donors D1 and D2, benzyl ether protected hydroxyl groups are marked as 
sulfation sites, hence C-4 was protected with the orthogonal chloroacetyl ester.  





For donors D3 and D4, ester protected hydroxyl groups are denoted as sulfation 
sites, hence C-4 was protected with the orthogonal benzyl ether. Donors D3 and 
D4 form CS analogues which have sulfate groups attached at C-2.  
 
2.8.2 Protection Strategy for Glycosyl Acceptors 
Four different glycosyl acceptors were also proposed, these can be prepared from 
intermediate 2-30 which was previously synthesized. We decided to retain the C-1’ 
methyl ether and the C-2’ N-trichloroacetyl group (which assisted in solubility 
and reactivity of the acceptor during glycosylation), but modify the benzylidene 
acetal since the C-4’ and C-6’ positions were possible sites of sulfation. Through 
regio-reductive ring opening of the benzylidene acetal, we could direct formation 
of the benzyl ether on either C-4’ or C-6’. This introduces sulfation specific 
protecting groups on the glycosyl acceptor at the C-4’ and C-6’ positions: either 
as esters, benzyl ethers or a combination of both (Figure 2-4).  
 
The C-3’ hydroxyl group should first be protected prior to modification of the C-4’ 
and C-6’ groups. Since C-3’ is the site of elongation, this temporary protecting 
group must be cleaved in the final step to generate the free C-3’ hydroxyl group in 






Figure 2-4. Glycosyl acceptors for CS disaccharide library synthesis 
 
 
2.8.3 Synthetic Strategy to Obtain CS Disaccharide Library 
In this strategy, sulfation specific protecting groups are first incorporated into the 
monomeric units; these precursors were synthesized in a divergent manner using 
common intermediates. With glycosyl donors D1–D4 and glycosyl acceptors A1–
A4 on hand, any sulfation pattern required in the final CS disaccharide can be 
obtained by appropriate combination of donor and acceptor building blocks, 
through modular glycosylation and selective final transformations. Due to the 
need for the C-2 ester group to direct β-stereoselective glycosylation, both the 
ester and benzyl ether protecting groups may be required as sulfation sites. The 




As shown in Table 2-4, eight plausible CS disaccharides (P1 – P8) can be 
obtained when benzyl ether protecting groups are designated the sulfation sites, 
by employing D1 and D2 as the glycosyl donors and selectively coupling with the 
required acceptors A1 – A4. In addition, another 8 unique CS disaccharides (P9 – 
P16) can be prepared when ester protecting groups are designated as the sulfation 
sites, through the use of glycosyl donors D3 and D4 and acceptors A1 – A4 (Table 
2-5). Both approaches enable the preparation of all 16 theoretically plausible CS 
disaccharides; these include previously synthesized CS sulfation patterns CS-A, 
CS-C, CS-E, CS-O, CS-K and CS-M, and novel sulfation patterns which were not 
isolated or synthesized earlier. Our synthetic strategy thus expands the scope of 
CS motifs obtainable via chemical synthesis, allowing access to rare sulfate 

























































A1      P1             P5 
A2      P2                          P6 
A3        P3               P7 
A4        P4               P8 
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A1      P9                P13 
A2      P10               P14 
A3        P11                P15 
A4        P12                P16 
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2.9 Synthesis of Glycosyl Donors D1, D2, D3, D4 
 






Reagents and conditions: (a) Bu2SnO, toluene, 3 h, 90
o
C, then BnBr, CsF, DMF, 
14 h, 65%; (b) Bz2O (1.2 equiv. per –OH), DMAP, CH2Cl2, 1 h, 2-6: 88%, 2-52: 
85%; (c) BH3.THF, CoCl2, 2 h, 2-53: 72%, 2-54: 75%; (d) TFA, CH2Cl2/H2O, 12 
h, 2-7: 84%, 2-55: 88%; (e) TEMPO, BAIB, CH2Cl2/H2O, 4 h, then MeI, 
NaHCO3, TBAI, DMF, 1 h, 50
o
C, 2-11: 48%, 2-56: 55%, 2-59: 50%, 2-60: 52%; 
(f) Cl2Ac2O, pyridine, CH2Cl2, 1 h, 2-13: 89%, 2-57: 92% (g) NIS, TFA, 
CH2Cl2/H2O, 14 h, 2-15: 74%, 2-58: 70%, 2-61: 77%, 2-62: 75%; (h) Cl3CCN, 
DBU, CH2Cl2, 8 h, D1: 68%, D2: 75%, D3: 70%, D4: 78% 
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To obtain glycosyl donors D1 – D4, common intermediate 2-5 was used as the 
synthetic precursor (Scheme 2-12). Through a divergent approach, the protecting 
groups present on C-2, C-3 and C-4 sites could be varied by modifying some of 
the key synthetic steps. C-2 ester protection was required for all 4 donors to direct 
β-stereoselective glycosylation, and the C-3 hydroxyl group could either be 
protected as a benzoyl ester (to obtain 2-6) or selectively protected as a benzyl 
ether via the dibutyl tin oxide mediated approach
[22]
 (to obtain 2-52). The 
benzylidene acetal protecting group in intermediates 2-6 and 2-52 were next 
subjected to different cleavage methods, either by regio-reductive ring opening 
using to obtain the C-4 benzyl ether in 2-53 and 2-54, or completely removed via 
acidic hydrolysis to liberate both C-4 and C-6 hydroxyl groups in 2-7 and 2-55. 
 
For D3 and D4, ester protected hydroxyl groups were denoted as sulfation sites; 
hence an orthogonal benzyl ether protecting group was required on C-4, which 
was achieved by regio-reductive ring opening of the benzylidene acetal protecting 
group using CoCl2 and BH3.THF as the reductant
[38, 39]
  to form 2-53 and 2-54. 
Complete regioselective ring opening was achieved to obtain the benzyl ether on 
the C-4 position; retaining the benzylidene group on C-4 reduced the number of 
steps required which improved overall synthetic yield. Conversely, D1 and D2 
mark benzyl ether protected hydroxyl groups as sulfation sites and hence require 
the orthogonal ester protection at C-4; chloroacetyl ester was attached to form 2-
13 and 2-57, this protection can be selectively cleaved to allow for the synthesis 
of longer CS fragments when required
[12, 25]
. Using synthetic methods highlighted 
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previously, intermediates 2-7, 2-53, 2-54, 2-55 were subjected to C-6 oxidation 
and carboxylate methylation, followed by C-4 chloroacetylation (for 
intermediates 2-11, 2-56) prior to anomeric thiophenol deprotection and 
attachment of the trichloroacetimidate glycosyl auxiliary to furnish donors D1–D4. 
 
2.10 Synthesis of Glycosyl Acceptors A1, A2, A3, A4 
To obtain the four glycosyl acceptors, previously synthesized intermediate 2-46 
was used as the common intermediate. Modification of the benzylidene acetal 
protecting group enabled attachment of sulfation specific protecting groups on C-
4’ and C-6’ positions. The C-3’ chloroacetyl ester could be selectively cleaved in 
the final step to regenerate the acceptor.  
 
Table 2-6. Hydrolysis of benzylidene acetal in 2-46 
 
Entry Reaction conditions Yield (β:α) Time Temp. (oC) 
1 80% AcOH 70:30 1 h 80 





- 24 h r.t. 
4 H2, Pd/C, THF - 12 h r.t. 




For acceptors A1 and A4, the benzylidene acetal was first removed by acidic 
hydrolysis (Table 2-6, entry 1) to release the free hydroxyl groups on C-4’ and C-
6’ positions. Both hydroxyl groups can next be protected as esters (to obtain A1) 
or benzyl ether groups (to obtain A4). However, acidic hydrolysis of the 
benzylidene acetal by refluxing 2-46 in 80% acetic acid led to the unwanted side 
reaction: acid catalyzed ring opening of the cyclic sugar 2-46 at anomeric carbon 
to form the open chain (as mentioned previously). Upon ring cyclization, both the 
α- and β- anomers were obtained, and some β- anomer was converted into the α- 
form (2-47a). Although this side reaction could be minimized by reducing the 
reaction time, some α- anomer was still formed as the side reaction proceeded 
concurrently with the deprotection step. Milder reaction conditions were next 
attempted, by reacting 2-46 with trifluoroacetic acid in CH2Cl2/H2O at room 
temperature, and by using by H
+
 resins, but deprotection did not proceed (Table 
2-6, entries 2 and 3). In addition, hydrogenation of the benzylidene acetal via 
palladium catalyst was unsuccessful (Table 2-6, entry 4). Hence, the reaction was 
repeated by reducing the reaction time to 15 minutes, by refluxing 2-46 in 60% 
acetic acid at 110
o
C through the use of microwave irradiation (Table 2-6 entry 5). 
This reduced α- anomer formation to smaller amounts which improved reaction 
yield. 
 
We next proceeded to modify 2-46 for the synthesis of acceptors A2 and A3, 
which required the benzyl ether protecting group on either the C-4’ or C-6’ 
positions. To achieve this, the benzylidene acetal protecting group was modified 
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via regio-reductive ring opening to retain the benzyl ether on either the C-4’ or C-
6’ position, before protecting the other hydroxyl group with an ester group.  
 









Regio-reductive ring opening of the benzylidene acetal protecting group was first 
attempted using sodium cyanoborohydride and molecular iodine (Table 2-7, entry 
1), which was reported to yield  C-6 benzyl ether in hexopyranosides
[40]
. However 
when the conditions were applied to intermediate 2-46, no regioselectivity was 
observed, and both C-4 and C-6 benzyl ethers were formed in equal amounts. 
Other stronger reducing agents such as NaBH4 and LiAlH4 were not suitable as 
they were not compatible with the ester and amide protecting groups present in 
intermediate 2-46.  
 
Hence, we varied the reducing agent to triethylsilane to determine if 
regioselective reduction can be obtained, through the similar activation by iodine. 
 
Entry Reaction conditions Product 
1 sodium cyanoborohydride, iodine 2-63 and 2-63a 
2 triethylsilane, iodine 2-47 
3 triethylsilane, TfOH - 
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Unfortunately, complete cleavage of the benzylidene ring proceeded to form the 
diol 2-47 (table 2-7, entry 2), and no benzyl ether could be obtained. This reaction 
was also attempted using triethylsilane/triflic acid system but was unsuccessful 
(table 2-7, entry 3); side products were formed as a result of the incomplete 
reduction of the chloro groups on C-2’ and C-3’ positions. It was noted that the 
chloroacetyl groups present were incompatible with the triethylsilane reducing 
agent. Since intermediate 2-46 was not versatile as a synthetic precursor, we had 








Several factors were identified from the failed attempts and these had to be 
addressed in the new route. Firstly, the C-1’ methyl ether group was not stable to 
acidic reflux which was required for benzylidene acetal hydrolysis (to obtain 
acceptor A1 and A4). Secondly, the C-2’ trichloroacetyl group and C-3’ 
chloroacetyl ester groups were not compatible with the reducing agents required 
for regio-reductive ring opening (to obtain acceptor A2 and A3).  
 
Thus, a new intermediate was proposed to obtain acceptors A1 – A4 (Figure 2-5). 
The required protecting groups on the C-4’ and C-6’ positons was first introduced 
via modification of the benzylidene acetal (acidic hydrolysis/regio-reductive ring 
opening), prior to the attachment of the C-1’ methyl ether group and the C-2’ 
trichloroacetyl group. In addition, the chloroacetyl protecting group on C-3’ was 
also replaced with a naphthyl ether to ensure reaction compatibility. In the revised 
strategy, the inert protecting groups chosen for the C-1’, C-2’ and C-3’ positions 
were the thiophenol, azide and naphthyl ether protecting groups respectively; 
these were used as temporary protecting groups to prepare glycosyl acceptors A1 
– A4. To achieve this, 2-23 was used as the synthetic precursor, which was 
obtained from D-galactose over 5 steps as previously described. 2-23 was first 
subjected to anomeric thiophenol protection to form 2-65 (Scheme 2-13), prior to 
removal of the acetyl protecting groups and attachment of the benzylidene acetal 
on C-4’ and C-6’ to form 2-66. With C-1’ protected as a thiophenol group and C-
2’ protected as an azide group, the benzylidene acetal was further modified to 
obtain the protecting groups required in acceptors A1 – A4. 
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Reagents and conditions: (a) PhSH, BF3.OEt2, CH2Cl2, 14 h, 78%; (b) NaOMe, 
MeOH, 30 mins, then PhCH(OMe)2, CSA, MeCN, 60
o
C, 14 h, 74%; (c) NapBr, 
NaH, DMF, 3 h, 81%; (d) TES, TfOH, CH2Cl2, -78
o
C, 3 h, 78%; (e) TES, PhBCl2, 
CH2Cl2, -78
o
C, 3 h, 68%; (f) Ac2O, DMAP, CH2Cl2, 1 h, 2-69: 88%, 2-71: 89%, 
2-74: 85%; (g) 80% AcOH, 80
o
C, 1 h, 90%; (h) BnBr, NaH, DMF, 75%; (i)  Zn, 
NH4Cl, EtOH/H2O, 80
o
C, 1 h then Cl3COCl, TEA, THF, 30 mins, 2-75: 54%, 2-
76: 58%, 2-77: 55%, 2-78: 60%; (j) NIS/TMSOTf, MeOH, CH2Cl2, -10
o
C, 1 h, 2-
79: 75%, 2-80: 70%, 2-81: 74%, 2-82: 68%; (k) DDQ, H2O, CH2Cl2, 12 h, A1: 
70%, A2: 69%, A3: 72%, A4: 68% 
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The naphthyl ether was first attached on the C-3’ hydroxyl group by reacting 2-66 
with naphthyl bromide and sodium hydride to obtain common intermediate 2-67. 
This bulky protecting group was chosen to assist in the regio-reductive ring 
opening of benzylidene acetal protecting group. The phenyl ring from the 
benzylidene acetal and naphthyl groups provided a steric block at C-4’ site during 
ring opening of the benzylidene acetal. Coordination to the C-4’ oxygen is not 
thus favorable if a bulky Lewis acid is used, enabling regioselective benzylidene 
ring opening by steric control. 
 
To obtain the C-4’ benzyl ether, we first attempted the regio-reductive ring 
opening method utilised for synthesis of glycosyl donors D3 and D4. However, 
using the BH3.THF/CoCl2 system
[39]
 gave very low yields of product 2-70 (about 
30%) and thus we had to modify our approach. Through the use of triethylsilane 
reducing agent, we proceeded to direct regio-selectivity of the benzylidene ring 
opening by varying the Lewis acids used.   
 
To obtain the C-4’ benzyl ether 2-70, common intermediate 2-67 was first reacted 
with a sterically demanding electrophile PhBCl2 in the presence of triethylsilane 
reductant.
[41]
 Coordination of PhBCl2 occurred at the less hindered C-6’ oxygen 
and the triethylsilane hydride was regioselectively added at C-6’ to form the C-6’ 





To obtain the C-6’ benzyl ether in 2-68, common intermediate 2-67 was next 
reacted with triflic acid and triethylsilane.
[41]
 Coordination of the sterically less 
hindered electrophile occurred at the C-4’ oxygen and the triethylsilane reductant 
was regioselectively added at C-4’ to form the C-4’ hydroxyl group; this 
generated the benzyl ether on C-6’ in intermediate 2-68. Selectivity was favored 
by placing the bulky benzyl substituent on the equatorial position at C-6’ as 
opposed to the axial position at C-4’; this reduced ring strain arising from the 1,3-
diaxial interactions.  
 
Through this approach, we managed to direct regio-reductive ring opening of the 
benzylidene acetal in common intermediate 2-67 to obtain the benzyl ether on 
either the C-4’ or C-6’ position. The remaining hydroxyl groups were then 
protected as esters, to obtain the C-4’ and C-6’ protection required in acceptors 
A2 and A3. Alternatively, the benzylidene acetal in common intermediate 2-67 
could also be cleaved by acidic hydrolysis to form diol 2-72. Both resulting 
hydroxyl groups are then protected as esters or ethers to obtain the C-4' and C-6' 
protection required in acceptors A1 and A4. 
 
With the key protecting groups established on C-4’ and C-6’, the C-2’ azide group 
in intermediates 2-69, 2-71, 2-73 and 2-74 were next reduced to a primary amine 
and the N-trichloroacetyl group (TCAHN) introduced onto the C-2’ position by 
reacting with trichloroacetyl chloride in the presence of TEA. This C-2’ TCAHN 
participating group next directed stereoselective glycosylation of methanol at the 
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anomeric position to form the β-methyl ether linkage. In the final step, cleavage 
of the C-3’ naphthyl ether in 2-79, 2-80, 2-81 and 2-82 via DDQ oxidation 
furnished acceptors A1–A4. 
 
2.11 Glycosylation of Monomeric Building Blocks  
 
Figure 2-6. Glycosyl donors and acceptors designed for CS disaccharide library 
synthesis 
 
With glycosyl donors D1–D4 and glycosyl acceptors A1–A4 on hand (Figure 2-6), 
any sulfation pattern required in the final CS disaccharide can be obtained by the 
judicious choice of donor and acceptor building blocks. This strategy can be 
classified into 2 main categories depending on the sulfation pattern required in the 
final CS disaccharide, which is illustrated in the synthesis of CS-R and CS-L.  
 
For the synthesis of CS-R, sulfate groups are attached on the C-2 and C-3 
positions of glucuronic acid moiety (Figure 2-7). Since glucuronic acid C-2 
sulfation is required, ester protecting groups are denoted as sulfation sites (C-2 
benzoyl ester mandatory to direct β-stereoselectivity). Hence only the C-2 and C-
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3 hydroxyl groups of glucuronic acid require ester protection, with the other sites 
protected as benzyl ethers. Based on this analysis, donor D3 and acceptor A4 





Figure 2-7. Retrosynthetic analysis for CS-R disaccharide 
 
In CS-L, sulfation occurs on C-3 of the glucuronic acid and C-6’ of the N-acetyl 
galactosamine (Figure 2-8). Since glucuronic acid C-2 sulfation is not required, 
benzyl ethers are now denoted as sulfation sites. Hence only C-3 glucuronic acid 
and C-6’ N-acetyl galactosamine require benzyl ether protection, while the other 
sites are protected as esters. Donor D2 and acceptor A2 are the required 









2.12 Synthesis of CS Disaccharide Analogues P1 to P8 
In eight of the CS disaccharide analogues, C-2 sulfation is not required. To 
synthesize these eight compounds, glycosyl donors D1 and D2 were utilized, with 
benzyl ether protected hydroxyl groups denoted as sulfation sites. D1 and D2 
employ the orthogonal chloroacetyl ester protecting group on the C-4 position.  
 
Glycosyl donors D1 and D2 were first glycosylated with acceptors A1–A4 using 
TMSOTf catalyst to form the protected disaccharides (Scheme 2-14).  The C-2 
directing group present in donors D1 and D2 enabled exclusive formation of the 
β-product[1]. After glycosylation was completed, the N-trichloroacetyl group was 
reduced to an N-acetyl group by radical mediated tributylstannane reduction to 
obtain 2-83a to 2-83h. Direct basic hydrolysis of 2-83a formed non-sulfated CS 
disaccharide P1. 
 
For the seven remaining intermediates 2-83b to 2-83h, hydrogenation of the 
benzyl ether groups liberated the free hydroxyl groups to form 2-84b to 2-84h, 
which were next reacted with sulfating agent SO3.TEA to sulfate at the required 
sites to form 2-85b to 2-85h. Following this, global deprotection by basic 
hydrolysis liberated all the remaining ester protecting groups to form P2 to P8. 




aReagents and conditions: (a) TMSOTf, 4Å MS, CH2Cl2, -10
oC, 1 h; (b) Bu3SnH, 
ABCN, toluene, 100oC, 4 h; (c) H2 gas, Pd/C, CH2Cl2/MeOH 14 h; (d) SO3.TEA, 
DMF, 50oC 40 h; (e) LiOH, H2O2, THF/H2O, -5
oC to r.t., 14 h, then NaOH, 
MeOH, 0oC to r.t, 6 h. 










2.13 Synthesis of CS Disaccharide Analogues P9 to P16 
In the other eight CS disaccharide analogues, C-2 sulfation is required. To obtain 
these eight analogues, glycosyl donors D3 and D4 were utilised, with ester 
protected hydroxyl groups denoted as sulfation sites. D3 and D4 employ the 
orthogonal benzyl ether protecting group on the C-4 position.  
 
Glycosylation of D3 and D4 with the glycosyl acceptors A1–A4 via TMSOTf 
catalyst formed another eight distinct protected disaccharides (Scheme 2-15). 
Presence of the C-2 directing group on D3 and D4 again enabled stereoselective 
formation of the β-glycosidic linkage. The N-trichloroacetyl groups present in the 
protected disaccharides were similarly reduced to the N-acetyl group in 2-86a to 
2-86h. This was next followed by basic hydrolysis of the ester protecting group to 
release the hydroxyls groups[11] in 2-87a to 2-87h.  
 
With the benzyl ether protecting groups intact, the free hydroxyl groups in 2-87b 
to 2-87h were then reacted with sulfating agent SO3.TEA to sulfate at the desired 
sites to form intermediates 2-88b to 2-88h. Fortunately, the C-6 carboxylate group 
generated from the ester deprotection step did not affect the sulfation reaction. 
With the sulfate groups attached at the required positions, global deprotection by 
hydrogenation of the remaining benzyl ether groups proceeded in the final step to 





aReagents and conditions: (a) TMSOTf, 4Å MS, CH2Cl2, -10
oC, 1 h; (b) Bu3SnH, 
ABCN, toluene, 100oC, 4 h; (c) LiOH, H2O2, THF, -5
oC to r.t., 14 h, then NaOH, 
MeOH, 0oC to r.t., 6 h; (d) SO3.TEA, DMF, 50
oC, 40 h; (e) H2 gas, Pd/C, 
MeOH/H2O, 14 h. 
 







For intermediate 2-87a, sulfation of all four free hydroxyl groups made the 
tetrasulfated product very polar and difficult to isolate. Hence, an extra step was 
included where the carboxylate group was first protected as benzyl ester 2-87a’ 
(Scheme 2-16). This protecting group facilitated purification of the highly 
negatively charged tetrasulfated product. Sulfation of the free hydroxyl groups in 
2-87a’ formed 2-88a, and the benzyl groups were similarly cleaved by 
hydrogenation in the final step to form P9. A total of eight CS disaccharide 
analogues P9 to P16 were thus synthesized via this approach.  
 
Scheme 2-16. Synthesis of CS disaccharide P9 
 
aReagents and conditions: (a) BnBr, NaHCO3, DMF, 50
oC, 89%, 1 h; (b) 
SO3.TEA, DMF, 50
oC, 68%, 48 h; (c) H2 gas, Pd/C, MeOH/H2O, 90%, 14 h. 
 
The combination of both methods enabled the synthesis of all the 16 CS 
disaccharides which can be categorized based on the number sulfate groups 
present (Table 2-8). These included disaccharides which have already been 
reported and given nomenclature, in addition to novel sulfation motifs. The 
synthesized CS disaccharide library empowered us to systematically probe the 
























P5 C-3  
P3 C-4’  CS-A 











P14 C-2, C-4’  
P15 C-2, C-6’ CS-D 
P7 C-3, C-4’ CS-K 
P6 C-3, C-6’ CS-L 







C-2, C-3, C-4’ 
 
P10 C-2, C-3, C-6’  
P13 C-2, C-4’, C-6’ CS-T 











2.14 Conclusion  
A versatile synthetic strategy has been devised for the chemical synthesis of all 
the sulfation patterns possible in the CS repeating unit. A total of 16 different CS 
disaccharides have been synthesized; these include analogues currently available 
as well as novel sulfation motifs. This strategy incorporated orthogonal protecting 
groups in four glycosyl donor and four glycosyl acceptor building blocks which 
were synthesized in a divergent mode using common intermediates. Through the 
glycosylation of appropriate donor and acceptor building blocks, any sulfation 
pattern required in the final CS disaccharide can be obtained by regioselective 
sulfation of either the benzyl ether protected hydroxyl groups or the ester 















2.15 Experimental  
 
General 
All commercially available reagents purchased from Sigma Aldrich and Alfa 
Aesar were used without further purification. Solvents such as hexane, ethyl 
acetate, dichloromethane, and methanol were pre-distilled prior to usage. 
Moisture-sensitive reactions were conducted under N2 environment using 
commercially obtained anhydrous solvents and activated molecular sieves. Thin 
layer chromatography (TLC) was performed using Merck silica gel 60 F254 pre-
coated glass plates and visualised under UV light prior to charring with 10% 
concentrated sulphuric acid in ethanol. Flash column chromatography was carried 
out with silica gel (Merck, 230 – 400 mesh); gel filtration chromatography was 





spectrums were recorded on Bruker Avance 500 (DRX500) and Bruker Avance 
500 (AV500) at 298K. All J-values are reported in Hz and chemical shift (δ) 
reported in parts per million (ppm) relative to tetramethylsilane (TMS). Mass 
spectra were determined by high resolution mass spectrometry (HRMS) 









Compound 2-3: D-(+)-glucose (Compound 2-1) (6 g, 33.3 mmol) and DMAP 
(101.8 mg, 0.83 mmol) were added to pyridine (16.1 mL, 200 mmol) and Ac2O 
(18.9 mL, 200 mmol) and stirred at room temperature for 2 h. When TLC analysis 
(hexane/EtOAc, 1:1 v/v) showed completion of reaction, the reaction mixture was 
diluted with EtOAc and washed with 5M HCl (3x), followed by saturated 
NaHCO3 (3x) and brine (1x). The organic layer was dried over Na2SO4, filtered 
and concentrated to a white solid (crude compound 2-2), which was redissolved in 
CH2Cl2 (80 mL), followed by the addition of BF3
.
OEt2 (12.3 mL, 100 mmol) and 
PhSH (10.3 mL, 100 mmol). The reaction mixture was stirred for 16 h at 35°C. 
When TLC analysis (hexane/EtOAc, 2:1 v/v) showed completion of the reaction, 
the reaction mixture was diluted with CH2Cl2, washed with NaHCO3 (3x) and 
brine (1x), dried over Na2SO4, filtered, and concentrated. The product was 
purified by flash column chromatography (hexane/EtOAc, 4:1 towards 3:1 
towards 2:1) to afford compound 2-3 as a white solid (11.88 g, 81%, 2 steps). 
1
H 
NMR (500 MHz, CDCl3) δ 7.52 – 7.46 (m, 2H), 7.35 – 7.27 (m, 3H), 5.22 (t, J = 
9.4 Hz, 1H), 5.03 (t, J = 9.8 Hz, 1H), 4.97 (t, J = 9.7 Hz, 1H), 4.70 (d, J = 10.1 Hz, 
1H), 4.19 (qd, J = 12.2, 3.8 Hz, 2H), 3.72 (ddd, J = 10.0, 5.1, 2.5 Hz, 1H), 2.07 (d, 
J = 3.8 Hz, 6H), 1.99 (d, J = 14.4 Hz, 6H). 
13
C NMR (500 MHz, CDCl3) δ 170.5, 
170.1, 169.3, 169.2, 133.1, 131.6, 128.9, 128.4, 85.7, 75.8, 73.9, 69.9, 68.2, 62.1, 
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20.7, 20.7, 20.5, 20.5. HRMS (ESI): m/z: calcd for C20H24NaO9S [M + Na]: 
463.1033; found: 463.1041. 
 
 
Compound 2-5: To a solution of compound 2-3 (10.77 g, 24.48 mmol) in 
methanol (100 mL) and CH2Cl2 (10 mL) was added NaOMe (529.4 mg, 9.8 mmol) 
and the mixture was stirred at room temperature for 1 h. When TLC analysis 
(hexane/EtOAc, 2:1 v/v) showed completion of reaction, the reaction mixture was 
quenched with Amberlyst-15 and stirred for another 15 min. When the pH was 
about 3 – 4, the mixture was filtered and concentrated to form a yellow oil (crude 
compound 2-4), which was redissolved in MeCN (87.4 mL) and DMF (8.7 mL), 
followed by the addition of PhCH(OMe)2 (7.4 mL, 48.96 mmol) and 
camphorsulfonic acid (1.86 g, 9.80 mmol). The reaction mixture was stirred for 
16 h at 55°C. When TLC analysis (hexane/EtOAc, 1:1 v/v) showed completion of 
reaction, the reaction mixture was quenched with TEA (2.8 mL), followed by 
evaporation of solvent. The product was purified by flash column 
chromatography (hexane/EtOAc, 1.5:1 towards 1:1 towards 1:2) to afford 
compound 2-5 as a white solid (7.1 g, 80%, 2 steps). 
1
H NMR (500 MHz, CDCl3) 
δ 7.58 – 7.51 (m, 2H), 7.52 – 7.45 (m, 2H), 7.41 – 7.31 (m, 6H), 5.52 (s, 1H), 4.62 
(dd, J = 10.0, 0.8 Hz, 1H), 4.37 (dd, J = 10.4, 3.1 Hz, 1H), 3.88 – 3.72 (m, 2H), 
3.48 (dq, J = 22.0, 9.1 Hz, 3H), 2.99 (s, 1H), 2.81 (s, 1H). 
13
C NMR (500 MHz, 
99 
 
CDCl3) δ 136.8, 133.0, 131.3, 129.3, 129.1, 128.4, 128.3, 126.3, 101.9, 88.6, 80.2, 
74.6, 72.6, 70.5, 68.5. HRMS (ESI): m/z: calcd for C19H20NaO5S [M + Na]: 
383.0924; found: 383.0923. 
 
 
Compound 2-6: To a solution of compound 2-5 (6.52 g, 18.1 mmol) in CH2Cl2 
(70 mL) was added Bz2O (10.2 g, 45.3 mmol), DMAP (5.53 g, 45.3 mmol) and 
the reaction mixture was stirred for 2 h at room temperature. When TLC analysis 
(hexane/EtOAc, 6:1 v/v) showed completion of reaction, the reaction mixture was 
diluted with CH2Cl2 and washed with 5M HCl (3x), followed by saturated 
NaHCO3 (3x) and brine (1x). The organic layer was dried over Na2SO4, filtered 
and concentrated to give crude compound 2-6 as a white solid which was 
immediately used for the next reaction to obtain compound 2-7. 
 
 
Compound 2-7: Crude compound 2-6 was redissolved in CH2Cl2 (100 mL) and 
TFA (2.75 mL) and water (5 mL) was added. The reaction mixture was stirred for 
4 h at room temperature. When TLC analysis (hexane/EtOAc, 1:1 v/v) showed 
completion of reaction, the reaction mixture was diluted with CH2Cl2, washed 
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saturated NaHCO3 (3x) and brine (1x). The organic layer was dried over Na2SO4, 
filtered, and concentrated. The product was purified by flash column 
chromatography (hexane/EtOAc, 3:1 towards 1:1) to afford compound 2-7 as a 
white solid (6.4 g, 74%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.95 (dd, J = 13.0, 
7.9 Hz, 4H), 7.55 – 7.42 (m, 4H), 7.37 (dt, J = 12.6, 7.7 Hz, 4H), 7.33 – 7.28 (m, 
3H), 5.43 (dd, J = 7.4, 4.0 Hz, 2H), 5.01 – 4.91 (m, 1H), 4.02 (dd, J = 12.0, 3.1 
Hz, 1H), 3.91 (ddd, J = 16.9, 13.7, 7.0 Hz, 2H), 3.67 – 3.55 (m, 1H). 13C NMR 
(500 MHz, CDCl3) δ 167.5, 165.2, 133.6, 133.3, 132.7, 132.0, 130.0, 129.8, 129.2, 
129.0, 128.8, 128.4, 128.4, 128.3, 86.1, 80.0, 78.3, 70.2, 69.8, 62.4. HRMS (ESI): 
m/z: calcd for C26H24NaO7S [M + Na]: 503.1135; found: 503.1130. 
 
 
Compound 2-11: Compound 2-7 (5.06 g, 10.54 mmol)  was dissolved in CH2Cl2 
(70 mL) followed by the addition of TEMPO (201 mg, 1.29 mmol), BAIB (5.18 g, 
16.1 mmol) and H2O (35 mL), and the reaction mixture was stirred at room 
temperature for 4 h. When TLC analysis (hexane/EtOAc, 1:1, v/v) showed 
completion of reaction, the reaction mixture was quenched with saturated 
Na2S2O3, diluted with CH2Cl2 and washed with saturated Na2S2O3 (3x), brine (1x). 
The organic layer was dried over Na2SO4, filtered and concentrated to form a 
brown oil, which was redissolved in DMF (40 mL), followed by the addition of 
MeI (0.6 mL, 9.64 mmol), NaHCO3 (2.7 g, 32.2 mmol) and TBAI (59.4 mg, 0.16 
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mmol), and stirred at 50°C for 1 h. When TLC analysis (hexane/EtOAc, 3:1 v/v) 
showed completion of reaction, the reaction mixture was diluted with diethyl 
ether, washed with water (3x), brine (1x), dried over Na2SO4, filtered, and 
concentrated. The product was purified by flash column chromatography 
(hexane/EtOAc, 5:1 towards 3:1) to afford compound 2-11 as a white solid (2.68 
g, 50%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 8.00 – 7.88 (m, 4H), 7.58 – 7.45 
(m, 4H), 7.42 – 7.33 (m, 4H), 7.33 – 7.28 (m, 3H), 5.55 (t, J = 9.2 Hz, 1H), 5.42 (t, 
J = 9.7 Hz, 1H), 4.97 (d, J = 10.0 Hz, 1H), 4.18 (td, J = 9.4, 2.1 Hz, 1H), 4.11 (d, 
J = 9.6 Hz, 1H), 3.89 (s, 3H), 3.32 (s, 1H). 
13
C NMR (500 MHz, CDCl3) δ 168.8, 
166.6, 165.1, 133.4, 133.3, 133.0, 131.9, 129.9, 129.8, 129.1, 129.0, 128.9, 128.4, 
128.4, 87.0, 78.1, 76.2, 70.4, 69.7, 53.0. HRMS (ESI): m/z: calcd for 
C27H24NaO8S [M + Na]: 531.1084; found: 531.1092. 
 
 
Compound 2-13: Compound 2-11 (2.80 g, 5.27 mmol) was dissolved in CH2Cl2 
(30 mL) followed by the addition of chloroacetic anhydride (1.8 g, 10.54 mmol) 
and pyridine (4.25 mL, 52.7 mmol) and the reaction mixture was stirred at room 
temperature for 1 h. When TLC analysis (hexane/EtOAc, 2:1, v/v) showed 
completion of reaction, the reaction mixture was diluted with CH2Cl2 and washed 
with 5M HCl (3x), followed by saturated NaHCO3 (3x) and brine (1x). The 
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organic layer was dried over Na2SO4, filtered and concentrated to crude 
compound 2-13 as a white solid which was immediately used for the next reaction.  
 
 
Compound 2-15: Crude compound 2-13 was redissolved in CH2Cl2 (50 mL) 
followed by the addition of NIS (1.77 g, 7.91 mmol) and TFA (807 μL, 8.99 
mmol) and H2O (8 mL). The reaction was stirred at room temperature for 16 h. 
When TLC analysis (hexane/EtOAc, 2:1, v/v) showed completion of reaction, the 
reaction mixture was diluted with CH2Cl2 and washed with saturated Na2S2O3 (3x) 
and brine (1x). The organic layer was dried over anhydrous Na2SO4, filtered and 
concentrated. The product was purified by flash column chromatography 
(hexane/EtOAc, 4:1 towards 2:1) to afford compound 2-15 as a white solid (1.72 
g, 68%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.95 (dt, J = 16.5, 8.1 Hz, 4H), 
7.56 – 7.48 (m, 2H), 7.42 – 7.34 (m, 4H), 6.08 (t, J = 9.7 Hz, 1H), 5.80 (t, J = 4.5 
Hz, 1H), 5.57 – 5.46 (m, 1H), 5.30 – 5.20 (m, 1H), 4.78 (d, J = 10.0 Hz, 1H), 3.97 
(t, J = 6.7 Hz, 2H), 3.80 – 3.75 (m, 3H). 13C NMR (500 MHz, CDCl3) δ 168.0, 
166.2, 165.6, 133.6, 133.5, 129.9, 129.8, 129.8, 128.8, 128.7, 128.5, 128.5, 90.5, 
71.4, 70.8, 69.2, 68.0, 53.1, 40.3. HRMS (ESI): m/z: calcd for C23H21ClNaO10 [M 






Donor D1: Compound 2-15 (250 mg, 0.49 mmol) was dissolved in CH2Cl2 (5 
mL) followed by the addition of DBU (30.5 μL, 0.2 mmol) and 
trichloroacetonitrile (511.4 μL, 5.1 mmol) and the reaction mixture was stirred for 
4 hours at room temperature. When TLC analysis (hexane/EtOAc, 4:1, v/v) 
showed completion of reaction, the solvent was evaporated and the compound 
was purified by flash column chromatography (hexane/EtOAc, 4:1) to afford 
donor D1 as a white foam (220.9 mg, 68%). 
1
H NMR (500 MHz, CDCl3) δ 8.69 
(s, 1H), 7.96 – 7.89 (m, 4H), 7.55 – 7.48 (m, 2H), 7.37 (dt, J = 15.8, 7.7 Hz, 4H), 
6.85 (d, J = 3.5 Hz, 1H), 6.13 (t, J = 10.0 Hz, 1H), 5.64 – 5.49 (m, 2H), 4.68 (d, J 
= 10.2 Hz, 1H), 3.99 (q, J = 14.9 Hz, 2H), 3.80 (s, 3H). 
13
C NMR (500 MHz, 
CDCl3) δ 166.9, 166.2, 165.5, 165.2, 160.2, 133.7, 129.9, 129.8, 128.5, 128.5, 
128.4, 128.3, 92.7, 90.4, 70.4, 70.3, 70.0, 69.2, 53.2, 40.2. HRMS (ESI): m/z: 
calcd for C25H21Cl4NNaO10 [M + Na]: 657.9812; found: 657.9817. 
 
 
Compound 2-21: D-(+)-galactose (Compound 2-18) (6.00 g, 33.33 mmol) and 
DMAP (101.80 mg, 0.83 mmol) were added to pyridine (16.1 mL, 200 mmol) and 
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Ac2O (18.9 mL, 200 mmol) and stirred at room temperature for 2 h. When TLC 
analysis (hexane/EtOAc, 1:1 v/v) showed completion of reaction, the reaction 
mixture was diluted with EtOAc and washed with 5M HCl (3x), followed by 
saturated NaHCO3 (3x) and brine (1x). The organic layer was dried over Na2SO4, 
filtered and concentrated to a white solid (crude compound 2-19), which was 
redissolved in EtOAc (80 mL), cooled to 0 °C and treated with HBr (41.1 mL). 
The reaction mixture was allowed to warm to room temperature and stirred for 1 h. 
When TLC analysis (hexane/EtOAc, 2:1 v/v) showed completion of reaction, the 
mixture was quenched with saturated NaHCO3, diluted with EtOAc and washed 
with saturated NaHCO3 (3x) and brine (1x). The organic layer was dried over 
anhydrous Na2SO4, filtered and concentrated. The crude product 2-20 was 
redissolved in EtOAc (44 mL), followed by the addition of Zn (11.96 g, 183 
mmol), NaOAc (13.04 g, 150 mmol), CuSO4 (259.0 mg, 1.04 mmol), AcOH (31 
mL) and H2O (12.2 mL). The mixture was stirred for 2 h at room temperature. 
When TLC analysis (hexane/EtOAc, 2:1 v/v) showed completion of reaction, the 
mixture was filtered, diluted with EtOAc, washed with saturated NaHCO3 (3x) 
and brine (1x).  The organic layer was dried over Na2SO4, filtered and 
concentrated. The product was purified by flash column chromatography 
(hexane/EtOAc, 3:1 towards 2.5:1) to afford compound 2-21 as a pale yellow oil 
(4.99 g, 55%, 3 steps). 
1
H NMR (500 MHz, CDCl3) δ 6.40 (dd, J = 6.3, 1.7 Hz, 
1H), 5.54 – 5.45 (m, 1H), 5.36 (dd, J = 4.4, 1.7 Hz, 1H), 4.66 (ddd, J = 6.3, 2.4, 
1.3 Hz, 1H), 4.26 (d, J = 6.2 Hz, 1H), 4.18 (ddd, J = 17.0, 11.6, 6.3 Hz, 2H), 2.06 
(s, 3H), 2.02 (s, 3H), 1.96 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.3, 170.1, 
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169.9, 145.2, 98.7, 72.6, 63.7, 63.6, 61.7, 20.6, 20.5, 20.4. HRMS (ESI): m/z: 
calcd for C12H16NaO7 [M + Na]: 295.0788; found: 295.0781. 
 
 
Compound 2-22: A solution of compound 2-21 (5.60 g, 20.59 mmol) in MeCN 
(50 mL) was added dropwise to a solution of NaN3 (2.01 g, 65.05 mmol) and 
CAN (33.87 g, 61.77 mmol) in MeCN (50 mL) at -25°C. The reaction mixture 
was allowed to warm to -15°C and stirred for 18 h. When TLC analysis 
(hexane/EtOAc, 2:1 v/v) showed completion of reaction, the mixture was diluted 
with diethyl ether, washed with water (2x) and brine (1x). The organic layer was 
dried over Na2SO4, filtered and concentrated. The product was purified by flash 
column chromatography (hexane/EtOAc, 4:1 towards 3:1) to afford 2-22 as a 
yellow solid (3.49 g, 45%). 
1
H NMR (500 MHz, CDCl3) δ 6.28 (d, J = 4.1 Hz, 
1H), 5.57 (d, J = 8.8 Hz, 1H), 5.41 (d, J = 2.4 Hz, 1H), 5.30 (d, J = 3.2 Hz, 1H), 
5.15 (dd, J = 11.3, 3.2 Hz, 1H), 4.93 (dd, J = 10.6, 3.3 Hz, 1H), 4.30 (t, J = 6.5 Hz, 
1H), 4.10 – 3.99 (m, 6H), 3.75 (dd, J = 10.5, 8.9 Hz, 1H), 2.08 (s, 6H), 1.97 (d, J 
= 1.2 Hz, 6H), 1.94 (d, J = 5.0 Hz, 6H).
 13
C NMR (500 MHz, CDCl3) δ 170.0, 
170.0, 169.7, 169.5, 169.3, 169.2, 97.8, 96.8, 71.6, 71.4, 69.2, 68.3, 66.4, 65.7, 
60.7, 60.7, 57.3, 55.7, 20.2, 20.2. HRMS (ESI): m/z: calcd for C12H16N4NaO10 [M 





Compound 2-23: Compound 2-22 (2.76 g, 7.34 mmol) was dissolved in AcOH 
(20 mL), followed by addition of NaOAc (1.2 g, 1.47 mmol). The mixture was 
stirred for 1 h at 100°C. When TLC analysis (hexane/EtOAc, 2:1 v/v) showed 
completion of reaction, the mixture was diluted with EtOAc, washed with 
saturated NaHCO3 (3x) and brine (1x). The organic layer was dried over Na2SO4, 
filtered and concentrated to form a yellow oil, which was used immediately for 
the next step to obtain 2-65.  
 
 
Compound 2-51: To a solution of compound 2-5 (9.50 g, 26.4 mmol) in toluene 
(92.4 mL) was added dibutyltin oxide (7.23 g, 29 mmol) and the reaction mixture 
was stirred for 3 h at 110°C. The solvent was next evaporated off to form a yellow 
oil which was redissolved in DMF (100 mL), followed by the addition of benzyl 
bromide (3.77 mL, 31.7 mmol) and cesium fluoride (5.21 g, 34.31 mmol). The 
reaction mixture was stirred for 16 h at room temperature. After TLC analysis 
(hexane/EtOAc, 4:1 v/v) indicated completion of the reaction, the mixture was 
diluted with CH2Cl2 and washed with water (3x) and brine (1x), dried over 
Na2SO4, filtered, and concentrated. The product was purified by flash column 
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chromatography (hexane/CH2Cl2, 6:1 towards 100% CH2Cl2) to afford compound 
2-51 as a white solid (7.72 g, 65%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.52 
(ddd, J = 27.8, 6.9, 2.5 Hz, 4H), 7.42 – 7.27 (m, 11H), 5.58 (s, 1H), 4.88 (dd, J = 
80.6, 11.5 Hz, 2H), 4.64 (d, J = 9.7 Hz, 1H), 4.40 (dd, J = 10.5, 5.0 Hz, 1H), 3.80 
(t, J = 10.3 Hz, 1H), 3.73 – 3.62  (m, 2H), 3.60 – 3.46 (m, 2H). 13C NMR (500 
MHz, CDCl3) δ 138.1, 137.1, 133.4, 131.3, 129.0, 128.4, 128.3, 128.2, 128.1, 
127.9, 126.0, 101.2, 88.4, 81.6, 81.1, 74.8, 72.2, 70.7, 68.6. HRMS (ESI): m/z: 
calcd for C26H26NaO5S [M + Na]: 473.1393; found: 473.1388. 
 
 
Compound 2-52: Compound 2-51 (7.72 g, 17.1 mmol) was treated as described 
for the preparation of compound 2-6 except that 1.2 equivalents of Bz2O and 
DMAP were used. Compound 2-52 was obtained as a white solid which was 




Compound 2-53: Crude compound 2-6 was dissolved in 1M BH3
.
THF (54.3mL) 
and CoCl2 (7.05g, 54.3mmol) was added in 3 portions. The reaction was stirred 
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for 2 h at room temperature. When TLC analysis (hexane/EtOAc, 3:1 v/v) showed 
completion of reaction, the reaction was diluted with EtOAc and quenched with 
saturated NaHCO3. The solid precipitates were filtered off, and the organic layer 
washed with saturated NaHCO3 (3x) and brine (1x). The organic layer was dried 
over anhydrous Na2SO4, filtered and concentrated. The product was purified by 
flash column chromatography (hexane/EtOAc, 5:1 towards 3:1) to afford 
compound 2-53 as a white solid (6.51 g, 63%, 2 steps). 
1
H NMR (500 MHz, 
CDCl3) δ 8.04 (dd, J = 29.4, 7.4 Hz, 4H), 7.59 – 7.55 (m, 2H), 7.48 (dd, J = 14.2, 
7.2 Hz, 2H), 7.33 (ddd, J = 14.9, 10.9, 5.1 Hz, 7H), 7.23 – 7.16 (m, 5H), 6.01 – 
5.92 (m, 1H), 5.58 (t, J = 9.7 Hz, 1H), 5.19 (d, J = 10.0 Hz, 1H), 4.71 (dd, J = 
27.9, 11.1 Hz, 2H), 4.10 – 4.01 (m, 2H), 3.93 (dd, J = 12.1, 3.4 Hz, 1H), 3.81 – 
3.74 (m, 1H), 3.04 (s, 1H). 
13
C NMR (500 MHz, CDCl3) δ 165.4, 165.0, 136.9, 
132.9, 132.8, 132.3, 131.9, 129.4, 129.3, 129.0, 128.8, 128.7, 128.0, 128.0, 127.8, 
127.6, 127.5, 85.8, 79.4, 76.0, 75.1, 74.4, 70.7, 61.0. HRMS (ESI): m/z: calcd for 
C33H30NaO7S [M + Na]: 593.1604; found: 593.1609. 
 
 
Compound 2-54: Crude compound 2-52 was treated as described for the 
preparation of compound 2-53 to afford compound 2-54 as a white solid (6.1 g, 
64%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 8.11 – 8.07 (m, 2H), 7.62 (t, J = 7.5 
Hz, 1H), 7.53 – 7.43 (m, 4H), 7.40 – 7.28 (m, 8H), 7.20 – 7.10 (m, 5H), 5.38 – 
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5.27 (m, 1H), 4.93 – 4.85 (m, 2H), 4.79 (s, 1H), 4.72 (d, J = 11.0 Hz, 2H), 3.99 – 
3.82 (m, 2H), 3.82 – 3.70 (m, 2H), 3.57 (ddd, J = 9.6, 4.7, 2.5 Hz, 1H), 2.17 (s, 
1H). 
13
C NMR (500 MHz, CDCl3) δ 165.1, 137.7, 137.5, 133.1, 132.6, 132.3, 
129.7, 129.7, 128.9, 128.4, 128.3, 128.2, 128.0, 127.9, 127.9, 127.9, 127.6, 86.1, 
83.9, 79.6, 77.4, 75.2, 75.0, 72.4, 61.9. HRMS (ESI): m/z: calcd for C33H32NaO6S 
[M + Na]: 579.1812; found: 579.1814. 
 
 
Compound 2-55 Crude compound 2-52 was treated as described for the 
preparation of compound 2-7 to afford compound 2-55 as a white solid (5.98 g, 
75%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 8.08 (d, J = 8.0 Hz, 2H), 7.61 (dd, J 
= 10.9, 4.2 Hz, 1H), 7.52 – 7.36 (m, 4H), 7.31 – 7.24 (m, 3H), 7.22 – 7.11 (m, 
5H), 5.35 – 5.20 (m, 1H), 4.85 (d, J = 10.1 Hz, 1H), 4.67 (dd, J = 57.9, 11.4 Hz, 
2H), 3.94 (d, J = 11.9 Hz, 1H), 3.85 – 3.76 (m, 1H), 3.76 – 3.67 (m, 2H), 3.48 (dt, 
J = 8.4, 4.4 Hz, 1H). 
13
C NMR (500 MHz, CDCl3) δ 165.2, 137.6, 133.3, 132.7, 
132.3, 129.8, 128.9, 128.5, 128.0, 128.0, 86.4, 83.8, 79.4, 74.8, 72.3, 70.3, 62.5. 






Compound 2-56: Compound 2-55 (3.22 g, 6.9 mmol) was treated as described 
for the preparation of compound 2-11 to afford compound 2-56 as a white solid 
(1.77 g, 52%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 8.05 (d, J = 7.2 Hz, 2H), 
7.63 (t, J = 7.5 Hz, 1H), 7.49 (dd, J = 9.2, 5.9 Hz, 4H), 7.33 – 7.24 (m, 3H), 7.21 
– 7.12 (m, 5H), 5.33 – 5.23 (m, 1H), 4.85 (d, J = 10.1 Hz, 1H), 4.76 (q, J = 11.6 
Hz, 2H), 4.05 (d, J = 9.2 Hz, 1H), 3.97 (d, J = 9.7 Hz, 1H), 3.88 (s, 3H), 3.76 (t, J 
= 8.9 Hz, 1H).
 13
C NMR (500 MHz, CDCl3) δ 169.3, 165.0, 137.6, 133.3, 132.7, 
132.4, 129.8, 129.6, 128.9, 128.4, 128.3, 128.1, 128.0, 127.7, 87.2, 82.2, 77.6, 
74.7, 71.9, 71.3, 52.9. HRMS (ESI): m/z: calcd for C27H26NaO7S [M + Na]: 
517.1291; found: 517.1298. 
 
 
Compound 2-58: Compound 2-56 (1.77 g, 3.58 mmol) was treated as described 
for the preparation of compound 2-15 to afford compound 2-58 as a white solid 
(1.22 g, 69%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 8.12 – 7.95 (m, 2H), 7.59 
(dd, J = 12.5, 4.3 Hz, 1H), 7.45 (q, J = 7.5 Hz, 2H), 7.28 – 7.17 (m, 5H), 5.67 (d, 
J = 3.4 Hz, 1H), 5.25 (d, J = 9.2 Hz, 1H), 5.14 (dd, J = 9.4, 3.3 Hz, 1H), 4.77 (d, J 
= 11.8 Hz, 1H), 4.65 – 4.56 (m, 2H), 4.27 (q, J = 9.0 Hz, 1H), 4.13 – 4.04 (m, 1H), 
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3.90 – 3.86 (m, 1H), 3.71 (s, 3H). 13C NMR (500 MHz, CDCl3) δ 168.6, 166.2, 
165.7, 137.6, 133.7, 133.5, 129.8, 129.8, 128.5, 128.4, 127.9, 127.9, 127.8, 90.2, 
75.9, 75.0, 72.9, 72.0, 68.3, 52.9, 40.3. HRMS (ESI): m/z: calcd for 
C23H23ClNaO9 [M + Na]: 501.0923; found: 501.0922. 
 
 
Compound 2-59: Compound 2-53 (3.67 g, 6.43 mmol) was treated as described 
for the preparation of compound 2-11 to afford compound 2-59 as a white solid 
(1.85 g, 48%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.99 (dd, J = 21.7, 7.9 Hz, 
4H), 7.56 – 7.48 (m, 4H), 7.41 – 7.30 (m, 7H), 7.17 (dt, J = 7.1, 3.9 Hz, 5H), 5.86 
(t, J = 8.9 Hz, 1H), 5.50 (t, J = 9.6 Hz, 1H), 5.09 (d, J = 9.8 Hz, 1H), 4.62 (dd, J = 
31.8, 11.1 Hz, 2H), 4.27 (dd, J = 14.3, 9.1 Hz, 2H), 3.80 (s, 3H).
 13
C NMR (500 
MHz, CDCl3) δ 167.9, 165.3, 164.9, 136.8, 133.1, 132.6, 131.7, 129.6, 129.5, 
128.9, 128.8, 128.2, 128.1, 128.1, 127.8, 127.7, 86.6, 77.8, 77.0, 75.3, 74.5, 70.2, 








Compound 2-60: Compound 2-54 (3.54 g, 6.36 mmol) was treated as described 
for the preparation of compound 2-11  to afford compound 2-54  as a white solid 
(2.04 g, 55%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 8.06 (dd, J = 8.1, 1.0 Hz, 
2H), 7.65 – 7.57 (m, 1H), 7.48 (ddd, J = 6.2, 5.0, 3.0 Hz, 4H), 7.41 – 7.22 (m, 
8H), 7.20 – 7.08 (m, 5H), 5.44 – 5.27 (m, 1H), 4.90 – 4.72 (m, 3H), 4.68 (dd, J = 
11.0, 4.6 Hz, 2H), 4.08 (d, J = 9.5 Hz, 1H), 4.01 (t, J = 9.2 Hz, 1H), 3.90 (t, J = 
8.9 Hz, 1H), 3.78 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 168.2, 164.9, 137.5, 
137.3, 133.2, 132.6, 132.2, 129.7, 129.6, 128.8, 128.3, 128.3, 128.1, 128.0, 127.9, 
127.9, 127.8, 127.6, 86.9, 83.1, 79.0, 78.0, 75.1, 75.0, 71.7, 52.5. HRMS (ESI): 
m/z: calcd for C34H32NaO7S [M + Na]: 607.1761; found: 607.1767. 
 
 
Compound 2-61: Compound 2-59 (1.85 g, 3.09 mmol) was treated as described 
for the preparation of compound 2-15 as a white solid to afford compound 2-61 as 
a white solid (1.16 g, 74%). 
1
H NMR (500 MHz, CDCl3) δ 7.97 (ddd, J = 14.0, 
10.1, 5.4 Hz, 4H), 7.58 – 7.42 (m, 2H), 7.43 – 7.27 (m, 4H), 7.21 – 7.07 (m, 5H), 
6.13 (t, J = 9.6 Hz, 1H), 5.74 (d, J = 3.5 Hz, 1H), 5.24 (dd, J = 10.0, 3.6 Hz, 1H), 





C NMR (500 MHz, CDCl3) δ 169.7, 168. 8, 166.3, 165.7, 165.5, 137.0, 
136.8, 133.3, 133.2, 133.1, 129.7, 129.6, 129.6, 128.3, 128.2, 128.1, 127.9, 95.8, 
90.5, 74.6, 74.4, 74.3, 73.7, 73.6, 71.8, 71.5, 69.8, 52.5. HRMS (ESI): m/z: calcd 
for C28H26NaO9 [M + Na]: 529.1469; found: 529.1473. 
 
 
Compound 2-62: Compound 2-60 (2.04 g, 3.49 mmol) was treated as described 
for the preparation of compound 2-15 to afford compound 2-62 as a white solid 
(1.2 g, 70%). 
1
H NMR (500 MHz, CDCl3) δ 8.08 – 8.02 (m, 2H), 7.57 (t, J = 7.4 
Hz, 1H), 7.43 (t, J = 7.7 Hz, 2H), 7.37 – 7.15 (m, 10H), 5.59 (d, J = 3.6 Hz, 1H), 
5.15 (dd, J = 9.7, 3.5 Hz, 1H), 4.87 – 4.76 (m, 3H), 4.62 (dd, J = 32.8, 10.2 Hz, 
2H), 4.25 (t, J = 9.2 Hz, 1H), 3.96 – 3.87 (m, 1H), 3.73 (s, 4H). 13C NMR (500 
MHz, CDCl3) δ 169.8, 165.8, 137.8, 137.7, 133.3, 129.8, 128.4, 128.3, 128.3, 
127.9, 127.8, 127.8, 127.7, 90.7, 79.2, 78.7, 75.4, 75.0, 73.4, 70.3, 52.5. HRMS 
(ESI): m/z: calcd for C28H28NaO8 [M + Na]: 515.1676; found: 515.1681. 
 
 
Donor D2: Compound 2-58 (250 mg, 0.522 mmol) was treated as described for 




H NMR (500 MHz, CDCl3) δ 8.61 (s, 1H), 7.95 (dd, J = 8.1, 1.0 Hz, 2H), 7.56 (d, 
J = 7.3 Hz, 1H), 7.41 (t, J = 7.8 Hz, 2H), 7.25 – 7.21 (m, 3H), 7.18 – 7.14 (m, 2H), 
6.71 (d, J = 3.6 Hz, 1H), 5.42 (dd, J = 9.9, 3.6 Hz, 1H), 5.38 – 5.31 (m, 1H), 4.69 
(dd, J = 45.7, 11.7 Hz, 2H), 4.46 (d, J = 10.2 Hz, 1H), 4.29 (t, J = 9.6 Hz, 1H), 
3.94 (s, 1H), 3.81 (d, J = 14.7 Hz, 1H), 3.72 (s, 3H). 
13
C NMR (500 MHz, CDCl3) 
δ 167.2, 166.0, 165.1, 160.0, 137.2, 133.6, 129.8, 128.8, 128.5, 128.4, 128.1, 
128.0, 93.0, 90.6, 75.6, 75.1, 71.9, 71.6, 70.6, 53.1, 40.3. HRMS (ESI): m/z: calcd 
for C25H23Cl4NNaO9 [M + Na]: 644.0019; found: 644.0021. 
 
 
Donor D3: Compound 2-61 (250 mg, 0.494 mmol) was treated as described for 
the preparation of donor D1 to afford donor D3 as a white foam (241.1 mg, 75%). 
1
H NMR (500 MHz, CDCl3) δ 8.63 (s, 1H), 8.00 – 7.89 (m, 4H), 7.57 – 7.47 (m, 
2H), 7.40 (t, J = 7.8 Hz, 2H), 7.34 (d, J = 7.8 Hz, 2H), 7.17 (dd, J = 6.5, 3.5 Hz, 
3H), 7.12 (dd, J = 6.5, 3.0 Hz, 2H), 6.78 (d, J = 3.5 Hz, 1H), 6.15 (t, J = 9.8 Hz, 
1H), 5.49 (dd, J = 10.2, 3.7 Hz, 1H), 4.68 – 4.54 (m, 3H), 4.25 (t, J = 9.7 Hz, 1H), 
3.78 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 168.5, 165.4, 165.0, 160.4, 136.7, 
133.5, 133.3, 129.8, 129.7, 129.2, 128.4, 128.4, 128.3, 128.2, 128.0, 93.1, 90.5, 
77.1, 75.0, 72.4, 71.4, 70.4, 52.8. HRMS (ESI): m/z: calcd for C30H26Cl3NNaO9 





Donor D4: Compound 2-62 was treated as described for the preparation of donor 
D1 to afford donor D4 as a white foam (220.9 mg, 68%). 
1
H NMR (500 MHz, 
CDCl3) δ 8.62 (s, 1H), 8.00 (d, J = 7.6 Hz, 2H), 7.59 (t, J = 7.5 Hz, 1H), 7.44 (t, J 
= 7.8 Hz, 2H), 7.40 – 7.29 (m, 5H), 7.29 – 7.17 (m, 5H), 6.71 (d, J = 3.6 Hz, 1H), 
5.46 (dd, J = 9.9, 3.5 Hz, 1H), 4.88 (dt, J = 20.0, 8.5 Hz, 3H), 4.70 (d, J = 10.7 Hz, 
1H), 4.55 (d, J = 10.1 Hz, 1H), 4.34 (t, J = 9.5 Hz, 1H), 4.07 (t, J = 9.7 Hz, 1H), 
3.77 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 168.5, 165.2, 160.1, 137.4, 137.2, 
133.3, 129.6, 128.9, 128.4, 128.3, 128.2, 128.1, 128.0, 127.7, 93.4, 90.6, 78.9, 
78.5, 75.4, 75.4, 72.6, 71.9, 52.5. HRMS (ESI): m/z: calcd for C30H28Cl3NNaO8 
[M + Na]: 658.0773; found: 658.0775. 
 
 
Compound 2-65: Crude compound 2-23 was redissolved in CH2Cl2 (30 mL), 
followed by the addition of BF3
.
OEt2 (2.72 mL, 22 mmol) and PhSH (2.56 mL, 25 
mmol). The reaction mixture was stirred for 16 h at 35°C. When TLC analysis 
(hexane/EtOAc, 3:1 v/v) showed completion of reaction, the mixture was diluted 
with CH2Cl2, washed with NaHCO3 (3x) and brine (1x). The organic layer was 
dried over Na2SO4, filtered, and concentrated. The product was purified by flash 
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column chromatography (hexane/EtOAc, 6:1 towards 3:1) to afford compound 2-
65 as a yellow oil (2.42 g, 78%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.59 (dd, 
J = 6.6, 2.9 Hz, 2H), 7.48 (dd, J = 7.5, 1.7 Hz, 2H), 7.36 – 7.25 (m, 6H), 5.67 (d, J 
= 5.4 Hz, 1H), 5.45 (d, J = 2.8 Hz, 1H), 5.32 (d, J = 3.0 Hz, 1H), 5.15 (dd, J = 
11.1, 3.2 Hz, 1H), 4.85 (dd, J = 10.3, 3.2 Hz, 1H), 4.72 (d, J = 6.5 Hz, 1H), 4.51 
(d, J = 10.1 Hz, 1H), 4.29 (dd, J = 11.1, 5.5 Hz, 1H), 4.18 – 4.11 (m, 1H), 4.11 – 
4.02 (m, 3H), 3.87 (d, J = 6.6 Hz, 1H), 3.62 (t, J = 10.2 Hz, 1H), 2.12 (s, 3H), 
2.04 (d, J = 10.5 Hz, 6H), 2.00 (d, J = 5.4 Hz, 6H), 1.95 (s, 3H).
 13
C NMR (500 
MHz, CDCl3) δ 170.2, 170.2, 169.8, 169.8, 169.5, 169.4, 133.4, 132.4, 132.3, 
130.9, 129.0, 128.8, 128.4, 127.9, 86.7, 86.2, 74.2, 72.8, 70.0, 67.4, 67.3, 66.4, 
61.5, 61.4, 59.2, 57.9, 20.5, 20.4, 20.4. HRMS (ESI): m/z: calcd for 
C18H21N3NaO7S [M + Na]: 446.0992; found: 446.0999. 
 
 
Compound 2-66: To a solution of compound 2-65 (5.28 g, 12.28 mmol) in 
methanol (80 mL) and CH2Cl2 (8 mL) was added NaOMe (265.3 mg, 4.91 mmol) 
and the mixture was stirred at room temperature for 1 h. When TLC analysis 
(hexane/EtOAc, 2:1 v/v) showed completion of reaction, the reaction mixture was 
quenched with Amberlyst-15 and stirred for another 15 min. When the pH was 
about 3 – 4, the mixture was filtered and concentrated to form a pale brown oil, 
which was redissolved in MeCN (100 mL), followed by the addition of 
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PhCH(OMe)2 (3.69 mL, 24.56 mmol) and camphorsulfonic acid (934 mg, 4.91 
mmol). The reaction mixture was stirred for 16 h at 55°C. When TLC analysis 
(hexane/EtOAc, 3:1 v/v) showed completion of reaction, the mixture was 
quenched with TEA (1.5 mL), followed by evaporation of solvent. The product 
was purified by flash column chromatography (hexane/EtOAc, 6:1 towards 3:1 
towards 1:1) to afford compound 2-66 as a yellow oil (3.5 g, 74%, 2 steps). 
1
H 
NMR (500 MHz, CDCl3) δ 7.53 – 7.45 (m, 4H), 7.42 – 7.38 (m, 3H), 7.32 – 7.24 
(m, 3H), 5.75 (d, J = 5.2 Hz, 1H), 5.58 (s, 1H), 4.27 (d, J = 3.6 Hz, 1H), 4.19 (dd, 
J = 11.2, 5.9 Hz, 3H), 4.08 (dd, J = 12.9, 1.8 Hz, 1H), 4.00 (dd, J = 10.1, 2.4 Hz, 
1H).
 13
C NMR (500 MHz, CDCl3) δ 137.1, 133.5, 131.0, 129.3, 129.0, 128.2, 
127.3, 126.1, 101.2, 87.1, 75.0, 69.4, 69.0, 63.5, 61.1. HRMS (ESI): m/z: calcd for 
C19H19N3NaO4S [M + Na]: 408.0988; found: 408.0996. 
 
 
Compound 2-67: Compound 2-66 (2.44 g, 6.32 mmol) and NapBr (1.68 g, 7.59 
mmol) were dissolved in DMF (24 ml) before NaH (304 mg, 7.59 mmol) was 
added in 3 portions to the reaction mixture. Reaction mixture was stirred for 3 h at 
room temperature. When TLC analysis (hexane/EtOAc, 3:1 v/v) showed 
completion of reaction, the mixture was diluted in diethyl ether and washed with 
H2O (3x) and brine (1x). The organic layer was dried over Na2SO4, filtered, and 
concentrated. The product was purified by flash column chromatography 
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(hexane/CH2Cl2, 3:1 towards 1:1 towards 100% CH2Cl2) to afford compound 2-
67 as a white solid (2.69 g, 81%). 
1
H NMR (500 MHz, CDCl3) δ 7.85 (ddd, J = 
10.6, 9.4, 7.8 Hz, 4H), 7.62 – 7.45 (m, 7H), 7.40 (q, J = 5.5 Hz, 3H), 7.32 – 7.25 
(m, 3H), 5.80 (d, J = 5.3 Hz, 1H), 5.50 (s, 1H), 4.95 (dd, J = 31.0, 12.2 Hz, 2H), 
4.55 (dd, J = 10.6, 5.4 Hz, 1H), 4.27 (d, J = 3.1 Hz, 1H), 4.19 (dd, J = 12.6, 1.0 
Hz, 1H), 4.11 (s, 1H), 4.02 (dd, J = 12.6, 1.4 Hz, 1H), 3.92 (dd, J = 10.6, 3.4 Hz, 
1H).
 13
C NMR (500 MHz, CDCl3) δ 137.5, 135.1, 133.6, 133.2, 133.1, 131.0, 
129.0, 128.2, 128.2, 127.9, 127.7, 127.3, 126.4, 126.2, 126.0, 125.6, 100.9, 87.5, 
76.5, 72.9, 71.5, 69.2, 63.7, 59.3. HRMS (ESI): m/z: calcd for C30H27N3NaO4S [M 
+ Na]: 548.1614; found: 548.1615. 
 
 
Compound 2-68: To a solution of compound 2-67 (2 g, 3.8 mmol) in CH2Cl2 (40 
mL) was added 4Å molecular sieves (1 g). The mixture was stirred at room 
temperature for 30 mins, before cooling to -78°C. Triethylsilane (1.97 mL, 12.35 
mmol) and TfOH (962 µL, 10.9 mmol) were then added dropwise into the 
reaction mixture, and the solution was stirred for another 2 h at -78°C. When TLC 
analysis (hexane/EtOAc, 3:1 v/v) showed completion of reaction, the mixture was 
quenched with TEA (2 mL) and MeOH (3 mL), followed by evaporation of 
solvent. The product was purified by flash column chromatography 





H NMR (500 MHz, CDCl3) δ 7.88 (dd, J = 9.7, 6.7 Hz, 4H), 7.59 – 7.44 
(m, 5H), 7.39 – 7.28 (m, 5H), 7.26 (dd, J = 5.0, 2.0 Hz, 3H), 5.64 (d, J = 5.5 Hz, 
1H), 4.91 (d, J = 4.1 Hz, 2H), 4.56 – 4.50 (m, 3H), 4.36 (dd, J = 10.4, 5.5 Hz, 1H), 
4.21 (d, J = 2.3 Hz, 1H), 3.84 – 3.76 (m, 2H), 3.73 (dd, J = 10.3, 5.9 Hz, 1H). 13C 
NMR (500 MHz, CDCl3) δ 137.7, 134.4, 133.2, 133.2, 133.2, 133.1, 132.4, 129.0, 
128.5, 128.4, 127.9, 127.7, 127.6, 127.6, 126.9, 126.3, 126.2, 125.6, 87.4, 77.8, 
73.5, 72.1, 69.7, 69.5, 66.7, 59.6. HRMS (ESI): m/z: calcd for C30H29N3NaO4S [M 
+ Na]: 550.1771; found: 550.1777. 
 
 
Compound 2-69: To a solution of compound 2-68 (3 g, 5.69 mmol) in CH2Cl2 
(40 mL) was added DMAP (1.04 g, 8.54 mmol) and Ac2O (643 µL, 6.82 mmol) 
and reaction mixture was stirred at room temperature for 2 h. When TLC analysis 
(hexane/EtOAc, 3:1 v/v) showed completion of reaction, the reaction mixture was 
diluted with CH2Cl2 and washed with 5M HCl (3x), followed by saturated 
NaHCO3 (3x) and brine (1x). The organic layer was dried over Na2SO4, filtered 
and concentrated to form compound 2-69 as a yellow oil which was immediately 





Compound 2-70: Compound 2-68 (2.6 g, 4.95 mmol) was treated as described 
for the preparation of compound 2-69 except that triethylsilane (2.57 mL, 16.1 
mmol) and PhBCl2 (1.84 mL, 14.2 mmol) were used, to afford compound 2-70 as 
a yellow oil (1.78 g, 68%). 
1
H NMR (500 MHz, CDCl3) δ 7.94 – 7.83 (m, 4H), 
7.58 (dd, J = 8.5, 1.3 Hz, 1H), 7.57 – 7.49 (m, 4H), 7.36 – 7.25 (m, 8H), 5.70 (d, J 
= 5.4 Hz, 1H), 5.02 – 4.89 (m, 3H), 4.63 (d, J = 11.5 Hz, 1H), 4.51 (dd, J = 10.6, 
5.5 Hz, 1H), 4.29 (t, J = 6.0 Hz, 1H), 4.00 (s, 1H), 3.88 (dd, J = 10.5, 2.7 Hz, 1H), 
3.75 (dd, J = 11.4, 6.8 Hz, 1H), 3.55 (dd, J = 11.4, 5.2 Hz, 1H).
 13
C NMR (500 
MHz, CDCl3) δ 137.7, 134.7, 133.2, 133.1, 132.4, 129.0, 128.5, 128.4, 128.2, 
128.0, 127.9, 127.7, 127.7, 126.7, 126.2, 126.1, 125.6, 87.3, 79.2, 74.6, 73.3, 72.8, 
71.9, 62.0, 60.4. HRMS (ESI): m/z: calcd for C30H29N3NaO4S [M + Na]: 
550.1771; found: 550.1780. 
 
 
Compound 2-71: Compound 2-70 (1.78 g, 3.37 mmol) was treated as described 
for the preparation of 2-69 to form compound 2-76 as a yellow oil which was 




Compound 2-72: Compound 2-67 (1.5 g, 2.86 mmol) was dissolved in 
AcOH/H2O (16 mL/3 mL) and stirred at 100°C for 2 h. When TLC analysis 
(hexane/EtOAc, 1:1 v/v) showed completion of reaction, the mixture was diluted 
with EtOAc and washed with saturated NaHCO3 (3x) and brine (1x). The organic 
layer was dried over Na2SO4, filtered, and concentrated. The product was purified 
by flash column chromatography (hexane/EtOAc, 3:1 towards 1:1) to afford 
compound 2-72 as a white solid (1.13 g, 90%). 
1
H NMR (500 MHz, CDCl3) δ 
7.96 – 7.77 (m, 4H), 7.62 – 7.41 (m, 5H), 7.38 – 7.22 (m, 3H), 5.64 (d, J = 5.4 Hz, 
1H), 4.89 (dd, J = 31.2, 11.5 Hz, 2H), 4.31 (dd, J = 10.0, 5.6 Hz, 2H), 4.16 (s, 1H), 
3.89 (dd, J = 11.8, 5.6 Hz, 1H), 3.87 – 3.68 (m, 2H). 13C NMR (500 MHz, CDCl3) 
δ 134.3, 133.2, 132.4, 129.1, 128.6, 127.9, 127.8, 127.7, 127.0, 126.4, 126.3, 
125.6, 87.2, 77.6, 72.3, 70.5, 67.6, 62.8, 59.6. HRMS (ESI): m/z: calcd for 
C23H23N3NaO4S [M + Na]: 460.1301; found: 460.1300. 
 
 
Compound 2-73: To a solution of compound 2-72 (2.2 g, 5.02 mmol) in DMF 
(30 mL) was added BnBr (1.44 mL, 12 mmol) and NaH (480 mg, 12 mmol). The 
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reaction was stirred at room temperature for 3 h. When TLC analysis 
(hexane/EtOAc, 6:1 v/v) showed completion of reaction, the mixture was diluted 
with diethyl ether and washed with water (3x) and brine (1x). The organic layer 
was dried over Na2SO4, filtered, and concentrated. The product was purified by 
flash column chromatography (hexane/EtOAc, 12:1 towards 8:1) to afford 
compound 2-73 as a yellow oil (2.33 g, 75%). 
1
H NMR (500 MHz, CDCl3) δ 7.93 
– 7.85 (m, 4H), 7.59 – 7.48 (m, 5H), 7.39 – 7.24 (m, 13H), 5.67 (d, J = 5.5 Hz, 
1H), 5.00 – 4.92 (m, 3H), 4.62 (d, J = 11.3 Hz, 1H), 4.56 – 4.50 (m, 2H), 4.50 – 
4.42 (m, 2H), 4.12 (d, J = 1.7 Hz, 1H), 3.88 (dd, J = 10.6, 2.7 Hz, 1H), 3.68 (dd, J 
= 9.4, 7.0 Hz, 1H), 3.59 (dd, J = 9.4, 6.1 Hz, 1H).
 13
C NMR (500 MHz, CDCl3) δ 
138.2, 137.8, 134.8, 133.4, 133.2, 133.0, 132.2, 128.9, 128.4, 128.3, 128.3, 127.9, 
127.7, 127.7, 127.5, 126.5, 126.2, 126.0, 125.6, 87.6, 79.2, 74.9, 73.5, 73.4, 72.5, 
70.5, 68.6, 60.4. HRMS (ESI): m/z: calcd for C37H35N3NaO4S [M + Na]: 
640.2240; found: 640.2245. 
 
 
Compound 2-74: Compound 2-72 (2 g, 4.57 mmol) was treated as described for 
the preparation of 2-69 except that 2.4 equivalents of Ac2O and DMAP were used, 
to afford compound 2-74 as a yellow oil which was immediately used for the next 





Compound 2-75: To a solution of crude compound 2-69 in EtOH/H2O (40 mL/13 
mL) was added Zn (492 mg, 7.57 mmol) and NH4Cl (703 mg, 13.26 mmol) and 
the mixture stirred was at 80°C for 2 h. When TLC analysis (hexane/EtOAc, 6:1 
v/v) showed completion of reaction, the reaction was diluted with EtOAc, 
quenched with diluted saturated NaHCO3 and the solid precipitates were filtered 
off. The filtrate was washed with saturated NaHCO3 (3x) and brine (1x), and the 
organic layer was dried over Na2SO4, filtered, and concentrated. The yellow oil 
was redissolved in THF (40 mL) and cooled to 0°C, before TEA (2.5 mL, 17.1 
mmol) and CCl3COCl (1.9 ml, 17.1 mmol) were added. The mixture was stirred 
for 30 min at 0°C. When TLC analysis (hexane/EtOAc, 4:1 v/v) showed 
completion of reaction, water was added and THF was evaporated. The 
compound was extracted using EtOAc, washed with saturated NaHCO3 (3x) and 
brine (1x), dried over Na2SO4, filtered and concentrated. The product was purified 
by flash column chromatography (hexane/EtOAc, 6:1 towards 4:1) to afford 
compound 2-75 as a yellow oil (2.09 g, 48%, 3 steps). 
1
H NMR (500 MHz, CDCl3) 
δ 7.84 (dd, J = 7.8, 3.9 Hz, 3H), 7.79 (s, 1H), 7.55 – 7.47 (m, 2H), 7.47 – 7.29 (m, 
8H), 7.26 – 7.20 (m, 3H), 6.75 (d, J = 7.0 Hz, 1H), 5.83 (d, J = 5.3 Hz, 1H), 5.79 
(d, J = 2.1 Hz, 1H), 4.94 (d, J = 12.1 Hz, 1H), 4.67 (d, J = 6.4 Hz, 1H), 4.64 – 
4.55 (m, 3H), 4.49 (d, J = 11.7 Hz, 1H), 3.73 (dd, J = 11.3, 3.0 Hz, 1H), 3.60 (d, J 
= 6.4 Hz, 2H), 2.13 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.3, 161.7, 137.6, 
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134.3, 133.2, 133.2, 132.8, 132.6, 129.1, 128.7, 128.5, 128.1, 128.0, 127.9, 127.7, 
127.2, 126.4, 126.2, 125.7, 92.2, 88.4, 73.7, 73.6, 71.0, 69.3, 68.1, 65.8, 51.6, 20.8. 




Compound 2-76: Crude compound 2-71 was treated as described for the 
preparation of compound 2-75 to afford compound 2-76 as a yellow oil (1.21 g, 
52%, 3 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.94 – 7.82 (m, 4H), 7.58 – 7.48 (m, 
3H), 7.45 (dd, J = 6.7, 2.9 Hz, 2H), δ 7.38 – 7.26 (m, 8H), 6.86 (d, J = 7.4 Hz, 
1H), 5.86 (d, J = 5.1 Hz, 1H), 5.00 (d, J = 11.5 Hz, 1H), 4.96 – 4.88 (m, 2H), 4.75 
(d, J = 12.0 Hz, 1H), 4.67 (d, J = 11.6 Hz, 1H), 4.52 – 4.46 (m, 1H), 4.29 (dd, J = 
11.3, 7.4 Hz, 1H), 4.22 (dd, J = 11.4, 5.0 Hz, 1H), 4.10 (s, 1H), 3.80 (dd, J = 11.1, 
2.3 Hz, 1H), 2.00 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.5, 161.5, 137.6, 
134.2, 133.2, 133.1, 132.8, 132.3, 129.0, 128.7, 128.4, 128.2, 127.9, 127.9, 127.7, 
126.7, 126.4, 126.3, 125.4, 92.3, 88.2, 77.1, 74.4, 71.8, 71.7, 70.1, 63.2, 51.4, 20.7. 






Compound 2-77: Compound 2-73 (2.51g, 4.07 mmol) was treated as described 
for the preparation of compound 2-75 to afford compound 2-77 as a yellow oil 
(1.65 g, 55%, 2 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.90 – 7.80 (m, 4H), 7.54 – 
7.44 (m, 5H), 7.40 – 7.21 (m, 13H), 6.87 (d, J = 7.3 Hz, 1H), 5.85 (d, J = 5.1 Hz, 
1H), 4.99 (d, J = 11.4 Hz, 1H), 4.96 – 4.85 (m, 2H), 4.68 (t, J = 11.3 Hz, 2H), 
4.57 – 4.47 (m, 3H), 4.22 (s, 1H), 3.81 – 3.71 (m, 2H), 3.66 (dd, J = 9.3, 5.9 Hz, 
1H).
 13
C NMR (500 MHz, CDCl3) δ 161.5, 138.1, 137.8, 134.5, 133.3, 133.2, 
133.1, 132.3, 129.1, 128.6, 128.4, 128.3, 128.0, 127.9, 127.8, 127.8, 127.7, 126.6, 
126.4, 126.2, 125.40, 92.4, 88.7, 77.1, 74.7, 73.5, 72.1, 71.3, 71.0, 68.5, 51.6. 




Compound 2-78: Crude compound 2-74 was treated as described for the 
preparation of compound 2-75 to afford compound 2-78 as a yellow oil (1.49 g, 
51%, 3 steps). 
1
H NMR (500 MHz, CDCl3) δ 7.78 – 7.71 (m, 4H), 7.44 – 7.34 (m, 
5H), 7.21 (dd, J = 4.9, 1.6 Hz, 3H), 5.83 (d, J = 5.2 Hz, 1H), 5.65 (d, J = 2.4 Hz, 
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1H), 4.83 (d, J = 11.4 Hz, 1H), 4.71 – 4.63 (m, 1H), 4.60 – 4.49 (m, 2H), 4.17 (dd, 
J = 11.4, 5.2 Hz, 1H), 4.08 (dd, J = 11.4, 7.5 Hz, 1H), 3.87 (dd, J = 11.3, 3.0 Hz, 
1H), 3.22 (dq, J = 14.3, 7.2 Hz, 1H), 2.07 (s, 3H), 1.97 (s, 3H).
 13
C NMR (500 
MHz, CDCl3) δ 170.1, 169.9, 161.5, 134.2, 132.8, 132.7, 132.4, 132.1, 128.8, 
128.1, 127.7, 127.5, 127.3, 126.7, 125.9, 125.8, 125.5, 87.5, 84.2, 73.2, 70.8, 67.7, 
65.4, 62.0, 51.3, 20.4, 20.4. HRMS (ESI): m/z: calcd for C29H27Cl3NO7S [M + 
Na]: 638.0579; found: 638.0584. 
 
 
Compound 2-79: Compound 2-75 (3.8 g, 5.51 mmol) was dissolved in CH2Cl2 
(70 mL) and cooled to -20°C. NIS (2.48g, 11 mmol) pre-dissolved in 10 mL 
MeOH was added, followed by TMSOTf (1.99 mL, 11 mmol). The reaction was 
stirred for 2 h at -10°C. When TLC analysis (hexane/EtOAc, 3:1 v/v) showed 
completion of reaction, the reaction was quenched with TEA (2.5 mL), diluted 
with CH2Cl2 and washed with saturated Na2S2O3 (3x), followed by brine (1x). 
The organic layer was dried over Na2SO4, filtered, and concentrated. The product 
was purified by flash column chromatography (hexane/EtOAc, 5:1 towards 3:1) 
to afford compound 2-79 as a yellow oil (2.52 g, 75%). 
1
H NMR (500 MHz, 
CDCl3) δ 7.80 (dd, J = 12.3, 4.3 Hz, 3H), 7.76 (s, 1H), 7.53 – 7.40 (m, 3H), 7.42 – 
7.29 (m, 5H), 6.94 (d, J = 7.5 Hz, 1H), 5.73 (d, J = 3.0 Hz, 1H), 4.91 (dd, J = 10.9, 
4.8 Hz, 1H), 4.80 (dd, J = 8.3, 5.3 Hz, 1H), 4.66 – 4.54 (m, 2H), 4.50 (dd, J = 
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11.9, 5.0 Hz, 1H), 4.24 (dd, J = 10.9, 3.2 Hz, 1H), 3.86 (t, J = 6.2 Hz, 1H), 3.72 
(dd, J = 8.0, 2.7 Hz, 1H), 3.64 (dd, J = 9.4, 5.6 Hz, 1H), 3.58 (dd, J = 9.3, 7.1 Hz, 
1H), 3.53 (s, 3H), 2.07 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.1, 161.9, 137.4, 
134.4, 133.0, 133.0, 128.3, 128.2, 127.9, 127.8, 127.8, 127.5, 127.3, 126.1, 126.0, 
125.9, 100.5, 92.3, 74.4, 73.5, 72.1, 71.7, 67.7, 65.7, 57.1, 55.5, 20.6. HRMS 
(ESI): m/z: calcd for C29H30Cl3NNaO7 [M + Na]: 632.0980; found: 632.0988. 
 
 
Compound 2-80: Compound 2-76 (3.28 g, 4.76 mmol) was treated as described 
for the preparation of compound 2-79 to afford compound 2-80 as a yellow oil 
(2.04 g, 70%). 
1
H NMR (500 MHz, CDCl3) δ 7.96 – 7.73 (m, 4H), 7.56 – 7.40 (m, 
3H), 7.34 – 7.19 (m, 5H), 7.03 (d, J = 7.1 Hz, 1H), 4.95 (d, J = 11.5 Hz, 1H), 4.86 
(dd, J = 9.9, 3.4 Hz, 2H), 4.77 (d, J = 11.4 Hz, 1H), 4.65 (d, J = 11.7 Hz, 1H), 
4.39 (dd, J = 10.9, 2.6 Hz, 1H), 4.27 (dd, J = 11.1, 6.6 Hz, 1H), 4.11 (dd, J = 11.2, 
6.3 Hz, 1H), 3.91 – 3.88 (m, 1H), 3.89 – 3.82 (m, 1H), 3.67 (t, J = 6.4 Hz, 1H), 
3.51 (s, 3H), 1.97 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.4, 162.1, 137.8, 
134.7, 133.2, 133.0, 128.4, 128.3, 128.2, 127.8, 127.8, 127.6, 126.8, 126.2, 126.1, 
125.8, 100.0, 92.5, 77.3, 74.4, 72.8, 72.2, 71.9, 62.8, 57.0, 56.0, 20.6. HRMS 





Compound 2-81: Compound 2-77 (2.5 g, 3.4 mmol) was treated as described for 
the preparation of compound 2-79 to afford compound 2-81 as a yellow oil (1.66 
g, 74%). 
1
H NMR (500 MHz, CDCl3) δ 7.93 – 7.75 (m, 4H), 7.59 – 7.43 (m, 3H), 
7.42 – 7.24 (m, 10H), 7.02 (d, J = 7.3 Hz, 1H), 4.94 (d, J = 11.5 Hz, 1H), 4.85 (dd, 
J = 20.0, 9.9 Hz, 2H), 4.69 (dd, J = 26.7, 11.5 Hz, 2H), 4.51 (q, J = 11.8 Hz, 2H), 
4.34 (dd, J = 11.0, 2.7 Hz, 1H), 4.09 (d, J = 2.6 Hz, 1H), 3.92 (dt, J = 10.8, 7.9 Hz, 
1H), 3.78 – 3.62 (m, 3H), 3.53 (s, 3H). 13C NMR (500 MHz, CDCl3) δ 162.0, 
138.2, 137.7, 134.8, 133.1, 133.0, 128.4, 128.3, 128.1, 128.1, 127.8, 127.8, 127.6, 
127.5, 126.7, 126.1, 126.0, 125.8, 100.2, 92.5, 77.3, 74.5, 73.5, 73.4, 72.3, 72.2, 
68.4, 56.9, 56.0. HRMS (ESI): m/z: calcd for C34H34Cl3NNaO6 [M + Na]: 
680.1344; found: 680.1346.  
 
 
Compound 2-82: Compound 2-78 (1.8 g, 2.81 mmol) was treated as described 
for the preparation of compound 2-79 to afford compound 2-82 as a yellow oil 
(1.07 g, 68%). 
1
H NMR (500 MHz, CDCl3) δ 7.83 – 7.76 (m, 3H), 7.73 (s, 1H), 
7.50 – 7.43 (m, 2H), 7.40 (dd, J = 8.5, 1.2 Hz, 1H), 6.93 (d, J = 7.2 Hz, 1H), 5.62 
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(d, J = 2.9 Hz, 1H), 4.88 (d, J = 8.9 Hz, 2H), 4.56 (d, J = 10.8 Hz, 1H), 4.34 (dd, J 
= 10.9, 3.3 Hz, 1H), 4.20 (d, J = 6.6 Hz, 2H), 3.90 (t, J = 6.6 Hz, 1H), 3.62 (dt, J 
= 10.9, 7.9 Hz, 1H), 3.52 (s, 3H), 2.15 (s, 3H), 2.09 (s, 3H).
 13
C NMR (500 MHz, 
CDCl3) δ 170.5, 170.3, 162.0, 134.3, 133.2, 133.1, 128.4, 127.9, 127.6, 127.6, 
126.2, 126.1, 126.1, 100.2, 92.4, 74.0, 72.1, 70.9, 65.6, 61.9, 57.2, 55.8, 20.8, 20.7. 
HRMS (ESI): m/z: calcd for C24H25Cl3NO8 [M – H]: 560.0651; found: 560.0655. 
 
 
Acceptor A1: To a solution of compound 2-82 (1.51 g, 2.3 mmol) dissolved in 
CH2Cl2 (50 mL) was added DDQ (626 mg, 2.76 mmol) and 3 mL H2O, and the 
reaction was stirred for 14 h at room temperature. When TLC analysis 
(hexane/EtOAc, 2:1 v/v) showed completion of reaction, the reaction was diluted 
with CH2Cl2 and washed with saturated NaHCO3 (3x) and brine (1x). The organic 
layer was dried over Na2SO4, filtered and concentrated. The product was purified 
by flash column chromatography (hexane/EtOAc, 4:1 towards 2:1) to afford 
compound A1 as a white foam (920 mg, 77%). 
1
H NMR (500 MHz, CDCl3) δ 
7.22 (d, J = 7.8 Hz, 1H), 5.31 (d, J = 3.1 Hz, 1H), 4.62 (d, J = 8.3 Hz, 1H), 4.37 – 
4.19 (m, 1H), 4.13 (d, J = 6.4 Hz, 2H), 3.87 (t, J = 6.3 Hz, 1H), 3.83 – 3.72 (m, 
1H), 3.70 (d, J = 6.2 Hz, 1H), 3.49 (s, 3H), 2.14 (s, 3H), 2.04 (s, 3H). 
13
C NMR 
(500 MHz, CDCl3) δ 171.3, 170.6, 162.8, 101.0, 92.3, 70.9, 69.4, 68.7, 62.0, 57.1, 
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Acceptor A2: Compound 2-79 (2 g, 3.27 mmol) was treated as described for the 
preparation of A1 to afford A2 as a white foam (1.14 g, 74%). 
1
H NMR (500 
MHz, MeOD) δ 7.33 (d, J = 4.2 Hz, 4H), 7.29 – 7.25 (m, 1H), 5.35 (d, J = 2.8 Hz, 
1H), 4.54 (d, J = 11.8 Hz, 1H), 4.48 (dd, J = 9.7, 7.9 Hz, 2H), 4.00 (dd, J = 10.8, 
3.2 Hz, 1H), 3.95 – 3.88 (m, 1H), 3.85 (t, J = 6.0 Hz, 1H), 3.58 – 3.52 (m, 2H), 
3.49 (d, J = 14.5 Hz, 3H), 2.09 (s, 3H).
 13C NMR (500 MHz, MeOD) δ 172.3, 
164.5, 139.2, 129.3, 129.0, 128.8, 103.5, 94.1, 74.5, 73.6, 71.4, 70.3, 69.6, 57.4, 




Acceptor A3: Compound 2-80 (1.1 g, 1.8 mmol) was treated as described for the 
preparation of A1 to afford A3 as a white foam (610 mg, 72%). 
1
H NMR (500 
MHz, CDCl3) δ 7.41 – 7.21 (m, 5H), 6.98 (d, J = 7.2 Hz, 1H), 4.73 (dd, J = 26.3, 
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11.6 Hz, 2H), 4.51 (d, J = 8.3 Hz, 1H), 4.30 (dd, J = 11.2, 6.6 Hz, 1H), 4.07 (ddd, 
J = 10.9, 7.9, 4.8 Hz, 2H), 3.85 – 3.74 (m, 2H), 3.67 (t, J = 6.5 Hz, 1H), 3.46 (s, 
3H), 2.00 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.5, 162.8, 137.5, 128.5, 
128.2, 128.0, 100.8, 92.4, 75.4, 72.3, 71.1, 62.6, 56.9, 56.8, 20.7. HRMS (ESI): 
m/z: calcd for C18H22Cl3NNaO7 [M + Na]: 492.0354; found: 492.0362. 
 
 
Acceptor A4: Compound 2-81 (1 g, 1.78 mmol) was treated as described for the 
preparation of A1 to afford A4 as a white foam (563 mg, 75%). 
1
H NMR (500 
MHz, CDCl3) δ 7.39 – 7.25 (m, 10H), 6.90 (d, J = 7.3 Hz, 1H), 4.71 (d, J = 1.4 
Hz, 2H), 4.61 – 4.43 (m, 3H), 4.02 (dd, J = 10.8, 3.3 Hz, 1H), 3.91 (d, J = 3.2 Hz, 
1H), 3.76 (dd, J = 7.8, 2.8 Hz, 1H), 3.72 – 3.66 (m, 3H), 3.49 (s, 3H). 13C NMR 
(500 MHz, CDCl3) δ 162.6, 137.9, 137.6, 128.5, 128.4, 128.0, 127.9, 127.8, 127.8, 
100.9, 92.5, 75.7, 75.3, 73.5, 73.5, 70.9, 68.1, 57.1, 56.8. HRMS (ESI): m/z: calcd 
for C23H26Cl3NNaO6 [M + Na]: 540.0718; found: 540.0710. 
 
General procedure for the synthesis of protected dimers 
Glycosyl donor (0.385 mmol) and glycosyl acceptor (0.321 mmol) was dissolved 
in CH2Cl2 (8 mL) and 4Å molecular sieves (400 mg) was added. The mixture was 
stirred at room temperature for 30 min, before cooling to -20°C. TMSOTf (0.064 
mmol) was added and the reaction stirred for 2 h at -10°C. When TLC analysis 
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showed completion of reaction, TEA (0.1 mmol) was added and the reaction 
filtered, followed by evaporation of solvent. The product was purified by flash 
column chromatography to afford the expected dimers. 
 
 
Protected dimer D1-A1: 
1
H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 15.8, 7.6 
Hz, 4H), 7.49 (q, J = 7.3 Hz, 2H), 7.34 (q, J = 7.8 Hz, 4H), 6.77 (d, J = 6.7 Hz, 
1H), 5.63 (t, J = 9.5 Hz, 1H), 5.56 – 5.46 (m, 2H), 5.39 (dd, J = 9.4, 7.7 Hz, 1H), 
4.88 (dd, J = 22.1, 7.9 Hz, 2H), 4.81 (dd, J = 10.9, 3.4 Hz, 1H), 4.22 (d, J = 10.0 
Hz, 1H), 4.13 (ddd, J = 18.5, 11.5, 6.4 Hz, 2H), 3.92 (dd, J = 15.9, 6.7 Hz, 3H), 
3.81 (s, 3H), 3.48 (s, 3H), 3.43 (dd, J = 7.3, 2.8 Hz, 1H), 2.15 (s, 3H), 2.07 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 170.5, 169.8, 166.5, 165.9, 165.5, 164.7, 162.3, 
133.6, 133.5, 129.8, 129.8, 128.7, 128.4, 128.4, 100.5, 99.3, 91.9, 73.1, 72.1, 71.9, 
71.5, 71.2, 70.7, 68.8, 62.2, 57.4, 56.4, 53.0, 40.2, 20.7, 20.6. HRMS (ESI): m/z: 





H NMR (500 MHz, CDCl3) δ 7.86 (dd, J = 15.0, 7.6 
Hz, 4H), 7.49 (dd, J = 14.1, 7.3 Hz, 2H), 7.38 – 7.27 (m, 9H), 6.76 (d, J = 6.7 Hz, 
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1H), 5.66 – 5.56 (m, 2H), 5.52 (t, J = 9.6 Hz, 1H), 5.40 (dd, J = 9.4, 7.7 Hz, 1H), 
4.88 (dd, J = 24.4, 8.0 Hz, 2H), 4.78 (dd, J = 10.9, 3.3 Hz, 1H), 4.52 (dd, J = 26.6, 
11.7 Hz, 2H), 4.20 (d, J = 9.9 Hz, 1H), 3.94 (q, J = 14.9 Hz, 2H), 3.86 (t, J = 5.9 
Hz, 1H), 3.75 (s, 3H), 3.56 (d, J = 5.9 Hz, 2H), 3.49 (s, 3H), 3.46 – 3.38 (m, 1H), 
2.13 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 169.9, 166.5, 165.9, 165.5, 164.7, 
162.2, 137.7, 133.5, 133.5, 129.8, 129.8, 128.7, 128.4, 128.4, 127.8, 127.7, 100.4, 
99.3, 91.9, 73.6, 73.4, 72.8, 72.1, 72.0, 71.5, 70.7, 69.2, 68.7, 57.4, 56.5, 53.0, 




Protected dimer D1-A3: 
1
H NMR (500 MHz, CDCl3) δ 7.87 (dd, J = 20.2, 7.3 
Hz, 4H), 7.51 – 7.44 (m, 4H), 7.39 – 7.30 (m, 7H), 6.84 (d, J = 6.5 Hz, 1H), 5.71 
(t, J = 9.6 Hz, 1H), 5.55 – 5.44 (m, 2H), 5.03 (d, J = 11.4 Hz, 1H), 4.95 (d, J = 7.8 
Hz, 1H), 4.82 – 4.76 (m, 2H), 4.73 (d, J = 11.4 Hz, 1H), 4.28 (d, J = 9.9 Hz, 1H), 
4.22 (dd, J = 11.1, 6.6 Hz, 1H), 4.11 (d, J = 2.6 Hz, 1H), 4.04 (dd, J = 11.2, 6.3 
Hz, 1H), 3.96 (q, J = 14.9 Hz, 2H), 3.80 (s, 3H), 3.71 (t, J = 6.4 Hz, 1H), 3.59 – 
3.50 (m, 1H), 3.43 (s, 3H), 2.00 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 170.5, 
166.6, 166.2, 165.5, 164.8, 162.5, 138.1, 133.6, 133.5, 129.9, 129.8, 129.0, 128.7, 
128.5, 128.4, 128.3, 128.3, 127.7, 101.2, 99.1, 91.9, 76.6, 74.9, 74.9, 71.9, 71.8, 
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71.4, 70.9, 62.6, 57.2, 56.3, 53.0, 40.2, 20.7. HRMS (ESI): m/z: calcd for 
C41H41Cl4NNaO16 [M + Na]: 966.1072; found: 966.1068. 
 
 
Protected dimer D1-A4: 
1
H NMR (500 MHz, CDCl3) δ 7.88 (dd, J = 20.3, 7.6 
Hz, 4H), 7.46 (dd, J = 29.2, 7.3 Hz, 4H), 7.39 – 7.27 (m, 12H), 6.80 (d, J = 6.5 Hz, 
1H), 5.68 (d, J = 9.7 Hz, 1H), 5.49 (dd, J = 5.7, 4.1 Hz, 2H), 5.01 (d, J = 11.5 Hz, 
1H), 4.95 (d, J = 7.9 Hz, 1H), 4.81 (d, J = 8.3 Hz, 2H), 4.68 (d, J = 11.4 Hz, 1H), 
4.56 – 4.50 (m, 1H), 4.43 (dd, J = 34.7, 11.6 Hz, 2H), 4.25 (d, J = 10.0 Hz, 1H), 
4.19 (d, J = 1.9 Hz, 1H), 4.00 – 3.91 (m, 2H), 3.74 – 3.66 (m, 4H), 3.62 – 3.53 (m, 
2H), 3.43 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 166.6, 166.1, 165.5, 164.8, 
162.4, 138.5, 137.9, 133.6, 133.4, 129.9, 129.7, 128.8, 128.5, 128.4, 128.4, 128.4, 
128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 101.2, 99.2, 92.0, 75.7, 75.5, 75.0, 
73.5, 73.3, 71.9, 71.8, 71.4, 70.8, 68.6, 57.2, 56.5, 52.9, 40.2. HRMS (ESI): m/z: 
calcd for C46H45Cl4NNaO15 [M + Na]: 1014.1436; found: 1014.1441. 
 
 
Protected dimer D2-A1: 
1
H NMR (500 MHz, CDCl3) δ 7.99 – 7.88 (m, 2H), 
7.59 (t, J = 7.5 Hz, 1H), 7.44 (t, J = 7.8 Hz, 2H), 7.17 (dd, J = 5.0, 1.7 Hz, 3H), 
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7.08 (dd, J = 6.4, 3.0 Hz, 2H), 6.80 (s, 1H), 5.50 (d, J = 3.4 Hz, 1H), 5.36 – 5.19 
(m, 2H), 4.83 (d, J = 8.4 Hz, 1H), 4.80 – 4.71 (m, 2H), 4.55 (dd, J = 32.2, 11.7 Hz, 
2H), 4.20 – 4.06 (m, 2H), 4.00 (d, J = 9.9 Hz, 1H), 3.85 (ddd, J = 31.9, 11.8, 6.3 
Hz, 4H), 3.76 (s, 3H), 3.48 – 3.41 (m, 4H), 2.12 (s, 3H), 2.06 (s, 3H). 13C NMR 
(500 MHz, CDCl3) δ 170.5, 169.8, 167.0, 165.8, 164.6, 162.2, 137.1, 133.5, 129.8, 
129.2, 128.5, 128.3, 127.9, 127.9, 100.3, 99.3, 92.0, 78.9, 74.1, 72.9, 72.8, 72.2, 
72.0, 71.3, 68.7, 62.3, 57.3, 56.3, 52.9, 40.3, 20.7, 20.6. HRMS (ESI): m/z: calcd 
for C36H38Cl4NO16 [M – H]: 880.0950; found: 880.0946. 
 
 
Protected dimer D2-A2: 
1
H NMR (500 MHz, CDCl3) δ 7.97 (dd, J = 8.0, 0.9 Hz, 
2H), 7.58 (dd, J = 10.8, 4.2 Hz, 1H), 7.44 (t, J = 7.8 Hz, 2H), 7.36 – 7.25 (m, 5H), 
7.21 – 7.14 (m, 3H), 7.08 (dd, J = 6.3, 3.0 Hz, 2H), 6.81 (d, J = 6.8 Hz, 1H), 5.54 
(d, J = 3.3 Hz, 1H), 5.38 – 5.24 (m, 2H), 4.80 (dd, J = 20.7, 7.9 Hz, 2H), 4.73 – 
4.66 (m, 1H), 4.59 – 4.42 (m, 4H), 4.00 (d, J = 9.9 Hz, 1H), 3.89 (d, J = 14.8 Hz, 
1H), 3.85 – 3.77 (m, 3H), 3.71 (s, 3H), 3.55 (dd, J = 5.8, 3.1 Hz, 2H), 3.47 (d, J = 
4.0 Hz, 4H), 2.10 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 169.8, 167.0, 165.7, 
164.6, 162.1, 137.8, 137.1, 133.5, 129.8, 129.2, 128.5, 128.3, 128.3, 127.9, 127.8, 
127.8, 127.7, 100.2, 99.4, 92.0, 78.9, 74.1, 73.6, 73.2, 72.9, 72.8, 72.2, 72.0, 69.1, 
68.8, 57.3, 56.4, 52.8, 40.3, 20.6. HRMS (ESI): m/z: calcd for C41H43Cl4NNaO15 




Protected dimer D2-A3: 
1
H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.6 Hz, 2H), 
7.59 (t, J = 7.4 Hz, 1H), 7.44 (t, J = 7.1 Hz, 4H), 7.35 (t, J = 7.4 Hz, 2H), 7.28 (dd, 
J = 13.5, 6.4 Hz, 1H), 7.21 – 7.15 (m, 3H), 7.09 (dd, J = 6.2, 2.4 Hz, 2H), 6.87 (d, 
J = 6.5 Hz, 1H), 5.41 (dd, J = 8.9, 8.2 Hz, 1H), 5.30 (t, J = 9.5 Hz, 1H), 5.01 (d, J 
= 11.5 Hz, 1H), 4.82 – 4.68 (m, 4H), 4.59 (dd, J = 32.3, 11.7 Hz, 2H), 4.20 (dd, J 
= 11.1, 6.6 Hz, 1H), 4.08 (d, J = 10.1 Hz, 2H), 4.02 (dd, J = 11.1, 6.4 Hz, 1H), 
3.95 – 3.79 (m, 3H), 3.75 (s, 3H), 3.69 (dd, J = 11.5, 5.0 Hz, 1H), 3.58 – 3.48 (m, 
1H), 3.42 (d, J = 5.5 Hz, 3H), 1.99 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.5, 
167.0, 166.0, 164.6, 162.3, 138.1, 137.1, 133.5, 129.9, 129.1, 128.9, 128.5, 128.3, 
128.2, 127.9, 127.9, 127.6, 101.1, 99.2, 92.0, 79.1, 76.2, 74.9, 74.8, 74.6, 72.9, 
72.4, 71.9, 62.6, 57.1, 56.3, 52.8, 40.3, 20.6. HRMS (ESI): m/z: calcd for 
C41H43Cl4NNaO15 [M + Na]: 952.1279; found: 952.1276. 
 
 
Protected dimer D2-A4: 
1
H NMR (500 MHz, CDCl3) δ 8.02 – 7.95 (m, 2H), 
7.63 – 7.56 (m, 1H), 7.48 – 7.39 (m, 4H), 7.37 – 7.26 (m, 8H), 7.23 – 7.14 (m, 
3H), 7.10 – 7.04 (m, 2H), 6.79 (d, J = 6.5 Hz, 1H), 5.39 (dd, J = 9.2, 7.9 Hz, 1H), 
5.33 – 5.23 (m, 1H), 4.99 (d, J = 11.5 Hz, 1H), 4.79 (dd, J = 14.1, 8.0 Hz, 2H), 
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4.71 (dd, J = 11.0, 2.9 Hz, 1H), 4.67 – 4.60 (m, 2H), 4.55 (d, J = 11.6 Hz, 1H), 
4.41 (dd, J = 34.8, 11.7 Hz, 2H), 4.16 (d, J = 2.6 Hz, 1H), 4.04 (d, J = 10.0 Hz, 
1H), 3.96 – 3.74 (m, 3H), 3.68 (t, J = 6.3 Hz, 1H), 3.65 (s, 3H), 3.54 (dddd, J = 
14.5, 10.7, 8.7, 6.0 Hz, 3H), 3.43 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 167.1, 
166.0, 164.6, 162.3, 138.5, 137.9, 137.2, 133.5, 130.0, 129.2, 128.8, 128.5, 128.47, 
128.1, 127.9, 127.8, 127.7, 127.5, 101.1, 99.2, 92.1, 79.1, 76.4, 75.5, 74.9, 74.5, 
73.5, 73.5, 72.9, 72.4, 71.9, 68.7, 57.2, 56.6, 52.8, 40.3. HRMS (ESI): m/z: calcd 
for C48H46Cl4NO14 [M + Na]: 1000.1667; found: 1000.1660. 
 
 
Protected dimer D3-A1: 
1
H NMR (500 MHz, CDCl3) δ 7.94 – 7.82 (m, 4H), 
7.48 (td, J = 7.2, 1.2 Hz, 2H), 7.34 (t, J = 7.6 Hz, 4H), 7.18 – 7.10 (m, 3H), 7.10 – 
7.02 (m, 2H), 6.77 (d, J = 6.8 Hz, 1H), 5.61 (t, J = 9.1 Hz, 1H), 5.50 (d, J = 3.4 
Hz, 1H), 5.31 (dd, J = 9.3, 7.5 Hz, 1H), 4.87 (d, J = 7.9 Hz, 2H), 4.73 (dd, J = 
10.8, 3.5 Hz, 1H), 4.53 (dd, J = 33.5, 11.1 Hz, 2H), 4.13 (ddt, J = 18.7, 11.6, 8.2 
Hz, 4H), 3.90 (t, J = 6.3 Hz, 1H), 3.79 (s, 3H), 3.49 – 3.40 (m, 4H), 2.14 (s, 3H), 
2.07 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.5, 169.8, 168.0, 165.3, 165.0, 
162.2, 136.9, 133.3, 133.3, 129.8, 129.6, 129.0, 128.9, 128.4, 128.3, 128.2, 128.0, 
127.9, 100.6, 99.3, 91.8, 74.7, 74.4, 74.0, 73.0, 71.8, 71.2, 68.8, 62.3, 57.3, 56.3, 
52.7, 20.7, 20.6. HRMS (ESI): m/z: calcd for C41H42Cl3NNaO16 [M + Na]: 




Protected dimer D3-A2: 
1
H NMR (500 MHz, CDCl3) δ 7.95 – 7.81 (m, 4H), 
7.48 (ddd, J = 7.3, 3.5, 1.4 Hz, 2H), 7.37 – 7.31 (m, 8H), 7.30 – 7.25 (m, 1H), 
7.16 – 7.12 (m, 3H), 7.09 (dd, J = 6.7, 2.9 Hz, 2H), 6.77 (d, J = 7.0 Hz, 1H), 5.63 
(t, J = 9.1 Hz, 1H), 5.57 (d, J = 3.4 Hz, 1H), 5.33 (dd, J = 9.1, 7.4 Hz, 1H), 4.89 
(dd, J = 30.2, 7.8 Hz, 2H), 4.71 (dd, J = 10.8, 3.5 Hz, 1H), 4.55 (dt, J = 23.4, 11.4 
Hz, 4H), 4.22 (t, J = 9.3 Hz, 1H), 4.13 (d, J = 9.5 Hz, 1H), 3.86 (t, J = 6.0 Hz, 1H), 
3.75 (s, 3H), 3.58 (dd, J = 5.9, 2.3 Hz, 2H), 3.53 – 3.44 (m, 4H), 2.12 (s, 3H). 13C 
NMR (500 MHz, CDCl3) δ 169.8, 168.0, 165.3, 164.9, 162.0, 137.8, 137.0, 133.2, 
133.1, 129.8, 129.6, 129.1, 129.0, 128.3, 128.3, 128.2, 127.9, 127.7, 127.7, 127.6, 
100.5, 99.5, 91.9, 77.0, 74.6, 74.4, 74.1, 73.5, 73.3, 72.8, 72.0, 69.3, 68.7, 57.2, 
56.3, 52.5, 20.6. HRMS (ESI): m/z: calcd for C46H46Cl3NNaO15 [M + Na]: 
980.1825; found: 980.1820. 
 
 
Protected dimer D3-A3: 
1
H NMR (500 MHz, CDCl3) δ 7.90 (dd, J = 12.5, 4.4 
Hz, 4H), 7.55 – 7.42 (m, 4H), 7.40 – 7.28 (m, 7H), 7.20 – 7.14 (m, 3H), 7.10 (dd, 
J = 6.5, 2.9 Hz, 2H), 6.81 (d, J = 6.5 Hz, 1H), 5.70 (dd, J = 9.3, 8.6 Hz, 1H), 5.48 
(dd, J = 9.6, 8.0 Hz, 1H), 5.02 (d, J = 11.4 Hz, 1H), 4.92 (d, J = 7.8 Hz, 1H), 4.82 
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(d, J = 8.3 Hz, 1H), 4.74 (dd, J = 10.9, 2.9 Hz, 1H), 4.69 (d, J = 11.4 Hz, 1H), 
4.56 (dd, J = 29.3, 11.1 Hz, 2H), 4.19 (dt, J = 11.3, 8.5 Hz, 3H), 4.00 (dd, J = 11.3, 
5.9 Hz, 2H), 3.79 (s, 3H), 3.69 (t, J = 6.4 Hz, 1H), 3.56 – 3.47 (m, 1H), 3.43 (s, 
3H), 1.98 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 170.4, 168.3, 165.3, 165.1, 
162.4, 138.0, 136.8, 133.3, 133.3, 129.9, 129.6, 129.0, 128.9, 128.4, 128.3, 128.3, 
128.2, 128.0, 127.9, 127.7, 101.5, 99.1, 91.9, 77.4, 76.3, 74.7, 74.6, 74.3, 73.8, 
71.9, 71.8, 62.7, 57.1, 56.4, 52.6, 20.6. HRMS (ESI): m/z: calcd for 
C46H45Cl3NO15 [M – H]: 956.1860; found: 956.1867. 
 
 
Protected dimer D3-A4: 
1
H NMR (500 MHz, CDCl3) δ 7.94 – 7.84 (m, 4H), 
7.54 – 7.43 (m, 2H), 7.44 – 7.37 (m, 2H), 7.40 – 7.23 (m, 12H), 7.18 – 7.13 (m, 
3H), 7.09 (dd, J = 6.5, 2.9 Hz, 2H), 6.73 (d, J = 6.6 Hz, 1H), 5.72 – 5.60 (m, 1H), 
5.44 (dd, J = 9.6, 7.8 Hz, 1H), 5.00 (d, J = 11.4 Hz, 1H), 4.91 (d, J = 7.7 Hz, 1H), 
4.82 (d, J = 8.3 Hz, 1H), 4.71 (dd, J = 11.0, 2.8 Hz, 1H), 4.66 – 4.47 (m, 3H), 
4.45 – 4.34 (m, 2H), 4.21 – 4.13 (m, 2H), 4.07 (d, J = 2.6 Hz, 1H), 3.78 – 3.67 (m, 
4H), 3.59 – 3.44 (m, 3H), 3.43 (s, 3H). 13C NMR (500 MHz, CDCl3) δ 168.3, 
165.4, 165.1, 162.3, 138.5, 136.9, 133.3, 129.9, 129.7, 129.0, 128.9, 128.4, 128.4, 
128.3, 128.2, 128.0, 127.9, 127.8, 127.7, 127.6, 101.5, 99.2, 92.0, 77.4, 76.5, 75.3, 
74.8, 74.7, 74.3, 73.9, 73.4, 73.3, 71.8, 68.7, 57.2, 56.6, 52.6. HRMS (ESI): m/z: 




Protected dimer D4-A1: 
1
H NMR (500 MHz, CDCl3) δ 7.94 (dd, J = 8.1, 0.9 Hz, 
2H), 7.56 (t, J = 7.5 Hz, 1H), 7.42 (t, J = 7.8 Hz, 2H), 7.33 – 7.21 (m, 5H), 7.14 – 
7.05 (m, 5H), 6.84 (d, J = 7.0 Hz, 1H), 5.47 (d, J = 3.3 Hz, 1H), 5.22 (dd, J = 8.3, 
7.4 Hz, 1H), 4.84 (d, J = 8.4 Hz, 1H), 4.78 – 4.59 (m, 6H), 4.16 (dd, J = 11.6, 5.4 
Hz, 1H), 4.07 (dd, J = 11.6, 7.2 Hz, 1H), 4.02 – 3.98 (m, 2H), 3.87 (t, J = 6.3 Hz, 
1H), 3.76 (d, J = 6.0 Hz, 3H), 3.74 – 3.70 (m, 1H), 3.52 – 3.40 (m, 4H), 2.08 (s, 
3H), 2.06 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.5, 169.8, 168.4, 164.8, 
162.0, 137.5, 137.3, 133.3, 129.8, 129.3, 128.4, 128.3, 128.2, 127.9, 127.9, 127.7, 
100.4, 99.4, 91.9, 81.4, 78.8, 74.9, 74.6, 74.2, 73.1, 72.6, 71.2, 68.7, 62.3, 57.2, 
56.2, 52.5, 20.6, 20.5. HRMS (ESI): m/z: calcd for C41H44Cl3NNaO15 [M + Na]: 
918.1669; found: 918.1673. 
 
 
Protected dimer D4-A2: 
1
H NMR (500 MHz, CDCl3) δ 7.58 (dd, J = 5.9, 1.9 Hz, 
2H), 7.35 – 7.26 (m, 16H), 7.16 – 7.12 (m, 2H), 6.71 (d, J = 7.4 Hz, 1H), 6.05 (d, 
J = 4.8 Hz, 1H), 5.63 (d, J = 3.1 Hz, 1H), 4.86 (d, J = 8.3 Hz, 1H), 4.69 (d, J = 
11.7 Hz, 1H), 4.53 (dt, J = 20.2, 11.4 Hz, 5H), 4.44 (d, J = 11.4 Hz, 1H), 4.38 (dd, 
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J = 10.9, 3.3 Hz, 1H), 3.95 (d, J = 7.9 Hz, 1H), 3.83 – 3.71 (m, 3H), 3.65 (s, 3H), 
3.59 – 3.53 (m, 3H), 3.51 (d, J = 5.2 Hz, 3H), 2.05 (s, 3H). 13C NMR (500 MHz, 
CDCl3) δ 169.9, 169.8, 162.2, 137.6, 137.6, 137.5, 137.4, 129.8, 129.4, 128.4, 
128.3, 128.2, 127.9, 127.9, 127.8, 127.8, 127.7, 126.0, 122.4, 100.2, 97.7, 92.3, 
78.0, 77.7, 75.7, 73.7, 73.2, 72.7, 72.5, 71.8, 69.5, 68.9, 68.4, 57.3, 55.2, 52.3, 




Protected dimer D4-A3: 
1
H NMR (500 MHz, CDCl3) δ 8.03 – 7.94 (m, 2H), 
7.61 – 7.54 (m, 1H), 7.47 – 7.38 (m, 4H), 7.36 – 7.23 (m, 8H), 7.18 – 7.06 (m, 
5H), 6.83 (d, J = 6.7 Hz, 1H), 5.41 (dd, J = 9.0, 7.9 Hz, 1H), 5.00 (d, J = 11.4 Hz, 
1H), 4.83 – 4.72 (m, 4H), 4.67 (ddd, J = 14.4, 11.9, 5.3 Hz, 4H), 4.19 (dd, J = 
11.2, 6.7 Hz, 1H), 4.10 – 3.94 (m, 4H), 3.87 – 3.80 (m, 1H), 3.77 (s, 3H), 3.68 (t, 
J = 6.4 Hz, 1H), 3.54 (ddd, J = 10.9, 8.2, 6.8 Hz, 1H), 3.43 (s, 3H), 1.98 (s, 3H).
 
13
C NMR (500 MHz, CDCl3) δ 170.4, 168.5, 164.9, 162.2, 138.0, 137.4, 137.2, 
133.3, 129.9, 129.3, 128.9, 128.4, 128.4, 128.2, 128.1, 127.9, 127.9, 127.7, 127.6, 
101.3, 99.1, 92.0, 81.4, 79.4, 75.8, 75.1, 75.0, 74.55, 74.5, 74.2, 73.2, 71.9, 62.7, 
57.0, 56.3, 52.5, 20.6. HRMS (ESI): m/z: calcd for C46H48Cl3NNaO14 [M + Na]: 





Protected dimer D4-A4: 
1
H NMR (500 MHz, CDCl3) δ 8.03 (d, J = 7.3 Hz, 2H), 
7.60 (t, J = 7.5 Hz, 1H), 7.51 – 7.40 (m, 4H), 7.40 – 7.26 (m, 13H), 7.21 – 7.10 
(m, 5H), 6.90 (d, J = 6.7 Hz, 1H), 5.48 – 5.37 (m, 1H), 5.02 (d, J = 11.4 Hz, 1H), 
4.90 – 4.75 (m, 4H), 4.69 (ddd, J = 23.2, 12.9, 7.2 Hz, 4H), 4.43 (dd, J = 39.1, 
11.7 Hz, 2H), 4.14 – 4.07 (m, 2H), 4.09 – 4.02 (m, 1H), 3.85 (t, J = 8.8 Hz, 1H), 
3.74 – 3.67 (m, 4H), 3.64 – 3.52 (m, 3H), 3.45 (s, 3H). 13C NMR (500 MHz, 
CDCl3) δ 168.4, 164.9, 162.1, 138.4, 137.8, 137.4, 137.2, 133.2, 129.8, 129.3, 
128.7, 128.4, 128.3, 128.2, 128.1, 128.0, 127.9, 127.8, 127.7, 127.6, 127.6, 127.4, 
101.2, 99.2, 92.0, 81.4, 79.3, 76.0, 75.2, 75.0, 74.9, 74.7, 74.1, 73.3, 73.2, 68.6, 
57.0, 56.3, 52.4. HRMS (ESI): m/z: calcd for C51H52Cl3NNaO13 [M + Na]: 
1014.2396; found: 1014.2401. 
 
General procedure for the synthesis of compounds 2-83a – 2-83h 
The protected dimer (0.25 mmol) was dissolved in toluene (8 mL) and Bu3SnH (2 
mmol) and ABCN (145 mg) was added. The reaction was heated to 100°C for 4 h. 
When TLC analysis showed completion of reaction, the solvent was evaporated 








H NMR (500 MHz, CDCl3) δ 7.99 – 7.80 (m, 4H), 7.57 – 
7.42 (m, 2H), 7.40 – 7.29 (m, 4H), 5.65 (t, J = 9.6 Hz, 1H), 5.50 – 5.34 (m, 4H), 
4.93 (d, J = 8.3 Hz, 1H), 4.85 (d, J = 7.6 Hz, 1H), 4.80 (dd, J = 10.8, 3.4 Hz, 1H), 
4.20 – 4.12 (m, 2H), 4.04 (dd, J = 11.6, 7.3 Hz, 1H), 3.89 – 3.84 (m, 1H), 3.79 (s, 
3H), 3.44 (s, 3H), 3.12 (dt, J = 10.7, 7.8 Hz, 1H), 2.12 (s, 3H), 2.05 (s, 3H), 1.93 
(s, 3H), 1.44 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 171.2, 170.5, 169.9, 169.2, 
166.8, 165.5, 164.7, 133.5, 133.4, 129.8, 129.7, 129.0, 128.6, 128.6, 128.4, 101.0, 
99.7, 75.1, 72.6, 72.2, 71.6, 71.2, 69.2, 68.7, 62.6, 57.0, 55.5, 52.8, 23.0, 20.7, 






H NMR (500 MHz, CDCl3) δ 7.90 (dd, J = 24.9, 7.5 Hz, 4H), 
7.59 – 7.47 (m, 2H), 7.40 – 7.22 (m, 9H), 5.64 (t, J = 9.6 Hz, 1H), 5.53 – 5.34 (m, 
4H), 4.93 (d, J = 8.2 Hz, 1H), 4.85 (d, J = 7.6 Hz, 1H), 4.78 (dd, J = 10.8, 3.3 Hz, 
1H), 4.51 (q, J = 11.7 Hz, 2H), 4.15 (d, J = 9.9 Hz, 1H), 3.84 (t, J = 5.8 Hz, 1H), 
3.76 (s, 3H), 3.55 (ddd, J = 17.0, 10.2, 5.9 Hz, 2H), 3.45 (s, 3H), 3.13 (dt, J = 10.5, 
7.8 Hz, 1H), 2.10 (s, 3H), 1.93 (s, 3H), 1.43 (s, 3H). 
13
C NMR (500 MHz, CDCl3) 
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δ 171.1, 170.0, 169.2, 166.8, 165.5, 164.7, 137.9, 133.5, 133.4, 129.8, 129.7, 
129.0, 128.6, 128.6, 128.4, 128.4, 127.7, 127.6, 100.9, 99.7, 75.3, 73.5, 72.9, 72.6, 
72.3, 71.6, 69.2, 57.1, 55.6, 52.8, 34.0, 23.0, 20.8, 20.4. HRMS (ESI): m/z: calcd 





H NMR (500 MHz, CDCl3) δ 7.93 (dd, J = 23.4, 7.5 Hz, 4H), 
7.57 – 7.26 (m, 11H), 5.74 (t, J = 9.7 Hz, 1H), 5.52 – 5.39 (m, 2H), 5.30 (d, J = 
6.6 Hz, 1H), 5.01 (d, J = 11.6 Hz, 1H), 4.90 (d, J = 7.9 Hz, 1H), 4.81 (dd, J = 13.0, 
5.2 Hz, 2H), 4.71 (d, J = 11.6 Hz, 1H), 4.23 (d, J = 10.0 Hz, 1H), 4.16 (dd, J = 
11.1, 6.7 Hz, 1H), 4.02 (d, J = 1.6 Hz, 1H), 3.97 (dd, J = 11.2, 6.1 Hz, 1H), 3.78 
(s, 3H), 3.67 (t, J = 6.3 Hz, 1H), 3.40 (s, 3H), 3.19 (dt, J = 10.7, 7.8 Hz, 1H), 1.96 
(d, J = 3.1 Hz, 6H), 1.49 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 171.4, 170.5, 
169.4, 167.0, 165.6, 164.6, 138.4, 133.5, 129.8, 129.6, 129.2, 129.0, 128.6, 128.5, 
128.2, 127.6, 102.0, 99.6, 78.2, 74.9, 74.6, 72.3, 72.0, 71.8, 70.6, 69.4, 62.9, 56.8, 
55.6, 52.8, 23.3, 20.7, 20.4. HRMS (ESI): m/z: calcd for C41H45NNaO16 [M + Na]: 








H NMR (500 MHz, CDCl3) δ 7.92 (dd, J = 24.8, 7.5 Hz, 4H), 
7.55 – 7.46 (m, 2H), 7.43 – 7.25 (m, 14H), 5.72 (t, J = 9.7 Hz, 1H), 5.46 (dd, J = 
13.6, 6.1 Hz, 2H), 5.28 (d, J = 6.5 Hz, 1H), 5.00 (d, J = 11.7 Hz, 1H), 4.90 (d, J = 
7.8 Hz, 1H), 4.84 (d, J = 8.2 Hz, 1H), 4.78 (d, J = 2.7 Hz, 1H), 4.66 (d, J = 11.7 
Hz, 1H), 4.39 (dd, J = 36.8, 11.7 Hz, 2H), 4.20 (d, J = 10.0 Hz, 1H), 4.10 (s, 1H), 
3.68 (d, J = 5.8 Hz, 4H), 3.56 (dd, J = 9.5, 5.7 Hz, 1H), 3.49 (dd, J = 9.4, 6.8 Hz, 
1H), 3.40 (s, 3H), 3.19 (dd, J = 7.2, 2.8 Hz, 1H), 1.96 (s, 3H), 1.47 (s, 3H). 
13
C 
NMR (500 MHz, CDCl3) δ 171.3, 169.4, 167.0, 165.6, 164.7, 138.8, 138.1, 133.5, 
129.8, 129.7, 129.3, 128.8, 128.7, 128.6, 128.5, 128.3, 128.1, 127.8, 127.6, 127.4, 
102.0, 99.6, 78.4, 75.6, 74.7, 73.4, 73.3, 72.3, 72.1, 71.8, 69.4, 69.0, 56.8, 55.7, 






H NMR (500 MHz, CDCl3) δ 7.97 (d, J = 7.6 Hz, 2H), 7.59 
(t, J = 7.4 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.19 – 7.11 (m, 3H), 7.08 (dd, J = 6.4, 
2.5 Hz, 2H), 5.53 (d, J = 6.7 Hz, 1H), 5.38 (d, J = 3.2 Hz, 1H), 5.31 – 5.21 (m, 
2H), 4.91 (d, J = 8.2 Hz, 1H), 4.71 (dd, J = 14.3, 5.5 Hz, 2H), 4.56 (s, 2H), 4.15 
146 
 
(dd, J = 11.6, 4.9 Hz, 1H), 4.01 (dd, J = 11.6, 7.4 Hz, 1H), 3.95 (d, J = 9.8 Hz, 
1H), 3.84 (dd, J = 11.4, 6.9 Hz, 2H), 3.75 (s, 3H), 3.42 (s, 3H), 3.14 (dt, J = 10.4, 
7.8 Hz, 1H), 2.08 (s, 3H), 2.04 (s, 3H), 1.97 (s, 3H), 1.38 (s, 3H).
 13
C NMR (500 
MHz, CDCl3) δ 171.1, 170.5, 170.0, 169.2, 167.2, 164.7, 137.2, 133.5, 129.7, 
128.6, 128.3, 127.8, 127.8, 100.7, 99.7, 79.0, 75.1, 73.9, 72.8, 71.3, 70.7, 68.4, 
62.7, 57.0, 55.3, 52.7, 23.0, 20.7, 20.6. HRMS (ESI): m/z: calcd for C36H42NO16 





H NMR (500 MHz, CDCl3) δ 7.98 (d, J = 7.9 Hz, 2H), 7.59 (t, 
J = 7.5 Hz, 1H), 7.45 (t, J = 7.7 Hz, 2H), 7.32 (dd, J = 7.2, 6.3 Hz, 4H), 7.26 (dd, 
J = 8.4, 4.9 Hz, 1H), 7.18 – 7.03 (m, 5H), 5.52 (d, J = 6.7 Hz, 1H), 5.41 (d, J = 
3.2 Hz, 1H), 5.28 (dd, J = 18.3, 9.0 Hz, 2H), 4.93 (d, J = 8.2 Hz, 1H), 4.78 – 4.65 
(m, 2H), 4.57 (d, J = 12.2 Hz, 2H), 4.54 – 4.44 (m, 2H), 3.95 (d, J = 9.7 Hz, 1H), 
3.88 – 3.79 (m, 2H), 3.73 (s, 3H), 3.57 (dd, J = 10.2, 4.8 Hz, 1H), 3.50 (dd, J = 
10.3, 6.9 Hz, 1H), 3.44 (s, 3H), 3.15 (dt, J = 10.5, 7.7 Hz, 1H), 2.07 (s, 3H), 1.98 
(s, 3H), 1.38 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 171.0, 170.1, 169.2, 167.2, 
164.6, 137.9, 137.2, 133.5, 129.7, 129.3, 128.5, 128.3, 128.2, 127.8, 127.7, 127.7, 
127.6, 100.6, 99.7, 79.0, 75.4, 73.8, 73.5, 72.9, 72.8, 72.7, 70.7, 69.3, 68.8, 57.1, 
55.4, 52.6, 22.9, 20.7, 20.6. HRMS (ESI): m/z: calcd for C41H47NNaO15 [M + Na]: 






H NMR (500 MHz, CDCl3) δ 8.02 – 7.92 (m, 2H), 7.60 (t, J 
= 7.5 Hz, 1H), 7.48 – 7.38 (m, 4H), 7.34 (t, J = 7.4 Hz, 2H), 7.30 – 7.24 (m, 1H), 
7.19 – 7.09 (m, 5H), 5.42 – 5.31 (m, 2H), 5.27 (t, J = 9.5 Hz, 1H), 4.99 (d, J = 
11.6 Hz, 1H), 4.78 (dd, J = 13.2, 8.1 Hz, 2H), 4.74 – 4.65 (m, 2H), 4.62 (s, 2H), 
4.15 (dd, J = 11.2, 6.7 Hz, 1H), 4.01 (t, J = 13.3 Hz, 2H), 3.95 (dt, J = 18.5, 7.7 
Hz, 2H), 3.73 (d, J = 8.0 Hz, 3H), 3.65 (t, J = 6.3 Hz, 1H), 3.39 (d, J = 5.6 Hz, 
3H), 3.19 (dt, J = 10.9, 7.9 Hz, 1H), 2.01 (s, 3H), 1.95 (s, 3H), 1.48 (s, 3H).
 13
C 
NMR (500 MHz, CDCl3) δ 171.3, 170.5, 169.5, 167.4, 164.5, 138.4, 137.3, 133.5, 
129.7, 129.5, 128.9, 128.6, 128.3, 128.2, 127.8, 127.5, 101.9, 99.6, 79.0, 77.9, 
75.0, 74.6, 74.2, 73.2, 72.3, 71.7, 71.1, 62.9, 56.7, 55.4, 52.7, 23.4, 20.7, 20.6. 





H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.3 Hz, 2H), 7.60 
(t, J = 7.4 Hz, 1H), 7.50 – 7.36 (m, 4H), 7.33 (dd, J = 11.0, 5.2 Hz, 4H), 7.26 (dd, 
J = 7.0, 5.2 Hz, 4H), 7.20 – 7.06 (m, 5H), 5.35 (dd, J = 16.2, 7.9 Hz, 2H), 5.27 (t, 
J = 9.6 Hz, 1H), 4.99 (d, J = 11.7 Hz, 1H), 4.82 (d, J = 8.3 Hz, 1H), 4.77 (d, J = 
7.8 Hz, 1H), 4.71 (dd, J = 11.0, 2.6 Hz, 1H), 4.68 – 4.55 (m, 3H), 4.38 (dd, J = 
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36.7, 11.7 Hz, 2H), 4.10 (d, J = 2.1 Hz, 1H), 4.01 (d, J = 9.9 Hz, 1H), 3.92 (t, J = 
9.2 Hz, 1H), 3.72 – 3.58 (m, 4H), 3.55 (dd, J = 9.4, 5.7 Hz, 1H), 3.50 – 3.45 (m, 
1H), 3.39 (s, 3H), 3.19 (dt, J = 10.8, 7.8 Hz, 1H), 2.01 (s, 3H), 1.46 (s, 3H).
 13
C 
NMR (500 MHz, CDCl3) δ 171.3, 169.5, 167.4, 164.5, 138.9, 138.1, 137.3, 133.5, 
129.7, 129.6, 128.8, 128.6, 128.3, 128.1, 127.8, 127.8, 127.7, 127.6, 127.4, 101.9, 
99.6, 79.0, 78.2, 75.6, 74.7, 74.2, 73.3, 73.3, 73.2, 72.3, 71.0, 69.0, 56.8, 55.6, 
52.6, 23.3, 20.6. HRMS (ESI): m/z: calcd for C46H51NNaO14 [M + Na]: 864.3202; 
found: 864.3206. 
 
General procedure for the synthesis of compounds 2-84b – 2-84h 
Precursor 2-83b – 2-83h (0.2 mmol) was dissolved in CH2Cl2/methanol (2 mL/2 
mL) and 10% Pd on carbon (50 mg) was added. The reaction was placed under H2 
atmosphere and stirred for 16 h at room temperature. When TLC analysis showed 
completion of reaction, the mixture was filtered through Celite and 2-84b – 2-84h 
was afforded as a white solid which was immediately used for the next reaction to 
obtain analogues 2-85b – 2-85h.  
 
General procedure for the synthesis of compounds 2-85b – 2-85h 
Precursor 2-84b – 2-84h (0.08 mmol) was dissolved in DMF (1 mL) and 
SO3
.
TEA (5 equivalent per –OH present in precursor) was added. The reaction 
was stirred at 50°C for 36 h. When TLC analysis showed completion of reaction, 
the reaction was quenched with methanol (0.5 mL) and concentrated. The crude 
product was first purified using Sephadex LH-20 (CH2Cl2/methanol, 1:1) before 
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purification by flash column chromatography. Purified product was next passed 
through Sephadex C-25 Na
+
 resin (methanol/H2O, 1:1) to afford 2-85b – 2-85h. 




1H NMR (500 MHz, DMSO) δ 7.78 (d, J = 8.1 Hz, 4H), 7.63 
– 7.55 (m, 2H), 7.45 (dd, J = 16.3, 8.0 Hz, 4H), 5.77 – 5.68 (m, 1H), 5.31 – 5.22 
(m, 3H), 4.58 – 4.49 (m, 2H), 4.29 (dd, J = 12.1, 2.9 Hz, 1H), 4.22 – 4.15 (m, 2H), 
3.85 (m, 3H), 3.70 (s, 3H), 3.11 (s, 3H), 1.98 (s, 3H), 1.90 (s, 3H), 1.59 (s, 3H). 
13C NMR (500 MHz, DMSO) δ 170.0, 169.1, 168.8, 167.4, 165.0, 164.5, 133.7, 
133.2, 129.3, 129.2, 129.1, 128.7, 128.5, 128.3, 101.2, 99.5, 76.0, 73.0, 72.6, 72.2, 
71.8, 71.1, 69.1, 64.6, 54.9, 52.6, 50.1, 22.6, 20.7, 20.2. HRMS (ESI): m/z: calcd 




1H NMR (500 MHz, DMSO) δ 7.78 (d, J = 6.9 Hz, 4H), 7.66 
– 7.53 (m, 2H), 7.44 (dt, J = 15.7, 7.7 Hz, 4H), 5.73 (t, J = 8.9 Hz, 1H), 5.34 – 
5.18 (m, 3H), 4.61 – 4.48 (m, 2H), 4.29 (dd, J = 12.0, 2.7 Hz, 1H), 4.23 – 4.09 (m, 
2H), 3.85 (dd, J = 24.3, 7.7 Hz, 3H), 3.70 (s, 3H), 3.11 (s, 3H), 1.98 (s, 3H), 1.90 
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(s, 3H), 1.57 (s, 3H). 
13C NMR (500 MHz, DMSO) δ 170.0, 169.1, 168.8, 167.5, 
164.9, 164.5, 133.7, 133.2, 129.3, 129.2, 129.1, 128.7, 128.5, 128.3, 101.1, 99.6, 
76.2, 73.0, 72.2, 71.7, 71.1, 69.1, 64.5, 54.9, 52.6, 50.1, 22.5, 20.7, 20.1. HRMS 





H NMR (500 MHz, CDCl3) δ 7.81 – 7.71 (m, 4H), 7.58 (ddd, 
J = 20.9, 13.8, 8.1 Hz, 2H), 7.49 – 7.36 (m, 4H), 5.70 (t, J = 9.4 Hz, 1H), 5.36 – 
5.24 (m, 2H), 5.20 (d, J = 7.8 Hz, 1H), 4.58 – 4.50 (m, 2H), 4.16 (d, J = 7.6 Hz, 
1H), 4.09 (dd, J = 12.0, 2.0 Hz, 1H), 3.90 – 3.75 (m, 3H), 3.71 (s, 3H), 3.66 (d, J 
= 8.0 Hz, 1H), 3.25 (s, 3H), 1.90 (s, 3H), 1.44 (s, 3H). 
13
C NMR (500 MHz, 
DMSO) δ 169.1, 168.7, 167.8, 165.0, 164.5, 133.7, 133.2, 129.3, 129.2, 129.1, 
128.7, 128.5, 128.3, 101.6, 100.6, 77.4, 74.1, 73.5, 73.2, 71.8, 71.0, 69.0, 66.9, 
55.1, 52.8, 52.7, 22.5, 20.1. HRMS (ESI): m/z: calcd for C32H36NO21S2 [M – H]: 




1H NMR (500 MHz, DMSO) δ 7.95 (d, J = 7.3 Hz, 2H), 7.59 
(t, J = 7.4 Hz, 1H), 7.46 (t, J = 7.6 Hz, 2H), 5.22 (d, J = 3.2 Hz, 1H), 4.99 (d, J = 
151 
 
8.1 Hz, 1H), 4.89 – 4.78 (m, 2H), 4.58 (t, J = 9.4 Hz, 1H), 4.29 – 4.19 (m, 2H), 
4.05 (dd, J = 11.4, 3.4 Hz, 1H), 3.95 – 3.87 (m, 1H), 3.80 (ddd, J = 11.3, 9.6, 5.7 
Hz, 2H), 3.71 (d, J = 9.5 Hz, 1H), 3.64 (s, 3H), 3.24 (s, 3H), 1.99 (d, J = 2.5 Hz, 
6H), 1.92 (s, 3H), 1.18 (s, 3H).
 13C NMR (500 MHz, DMSO) δ 170.1, 169.9, 
169.2, 168.8, 167.5, 164.5, 132.7, 130.1, 130.0, 128.0, 101.6, 99.7, 77.4, 75.6, 
71.8, 71.7, 70.8, 70.0, 68.4, 62.9, 55.7, 52.2, 22.2, 20.7, 20.6. HRMS (ESI): m/z: 




1H NMR (500 MHz, MeOD) δ 8.09 (d, J = 7.2 Hz, 2H), 7.54 
(dd, J = 10.5, 4.1 Hz, 1H), 7.41 (t, J = 7.8 Hz, 2H), 5.30 (dd, J = 18.1, 9.0 Hz, 2H), 
5.00 – 4.89 (m, 2H), 4.38 (dd, J = 11.8, 4.4 Hz, 1H), 4.35 – 4.20 (m, 3H), 3.96 (dd, 
J = 10.5, 8.2 Hz, 1H), 3.84 (d, J = 10.7 Hz, 1H), 3.78 (dd, J = 8.0, 5.1 Hz, 1H), 
3.73 (s, 3H), 3.27 (dd, J = 3.1, 1.7 Hz, 3H), 2.03 (d, J = 4.7 Hz, 3H), 2.01 (s, 3H), 
1.32 (s, 3H).
 13C NMR (500 MHz, MeOD) δ 173.7, 172.6, 171.8, 170.0, 167.8, 
134.3, 131.8, 131.2, 129.2, 103.3, 103.1, 79.8, 78.9, 76.6, 73.7, 73.5, 73.3, 71.0, 
65.3, 56.7, 53.4, 52.2, 22.4, 21.0, 20.8. HRMS (ESI): m/z: calcd for 






1H NMR (500 MHz, MeOD) δ 8.09 (d, J = 8.1 Hz, 2H), 7.55 
(t, J = 7.4 Hz, 1H), 7.41 (t, J = 7.6 Hz, 2H), 5.29 (t, J = 8.9 Hz, 2H), 4.99 – 4.92 
(m, 2H), 4.88 – 4.81 (m, 1H), 4.38 (dd, J = 11.8, 4.1 Hz, 1H), 4.28 (ddd, J = 17.6, 
12.6, 7.9 Hz, 3H), 3.95 (d, J = 8.2 Hz, 1H), 3.84 (d, J = 10.9 Hz, 1H), 3.78 (dd, J 
= 7.2, 4.5 Hz, 1H), 3.73 (s, 3H), 3.27 (s, 3H), 2.04 (s, 3H), 2.01 (s, 3H), 1.32 (s, 
3H).
 13C NMR (500 MHz, MeOD) δ 173.7, 172.7, 171.9, 170.0, 167.8, 134.3, 
131.8, 131.1, 129.2, 103.4, 103.1, 79.8, 78.9, 76.7, 73.7, 73.4, 73.3, 71.1, 65.2, 
56.7, 53.5, 52.2, 22.4, 21.0, 20.8. HRMS (ESI): m/z: calcd for C27H33NNa3O21S2 




1H NMR (500 MHz, DMSO) δ 7.95 (d, J = 7.6 Hz, 2H), 7.56 
(s, 1H), 7.43 (t, J = 7.5 Hz, 2H), 5.15 – 5.01 (m, 2H), 4.92 (d, J = 8.0 Hz, 1H), 
4.59 (t, J = 9.2 Hz, 1H), 4.53 (s, 1H), 4.28 (d, J = 10.1 Hz, 1H), 4.11 – 4.02 (m, 
2H), 3.88 – 3.80 (m, 1H), 3.78 – 3.67 (m, 5H), 3.62 (d, J = 8.3 Hz, 1H), 3.23 (s, 
3H), 1.94 (s, 3H), 1.16 (s, 3H).
 13C NMR (500 MHz, DMSO) δ 169.2, 168.8, 
168.7, 164.9, 132.3, 130.6, 130.0, 127.7, 101.8, 101.7, 78.6, 76.1, 74.6, 73.4, 71.8, 
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71.6, 69.7, 66.8, 55.0, 52.6, 49.9, 22.1, 20.7. HRMS (ESI): m/z: calcd for 
C25H30NNa4O23S3 [M + Na]: 899.9956; found: 899.9953. 
 
 
Compound P1: Precursor 2-83a (22.6 mg, 0.03 mmol) was dissolved in 
THF/H2O (0.9 mL/0.3mL) and cooled to 0°C, before addition of H2O2 (151 µL) 
and LiOH (303 µL, 1 M). The reaction was stirred for 16 h at room temperature, 
after which, methanol (0.5 mL) was added and the reaction was cooled to 0°C 
before addition of NaOH (365 µL). The reaction was stirred at room temperature 
for 6 h. When the reaction was complete, it was quenched with Amberlyst-15 and 
stirred for another 15 min. At pH 3 – 4, the mixture was filtered and solvent was 
evaporated off. The product was purified using Sephadex G-10 (100% H2O). 
Purified product was passed through Sephadex C-25 Na resin (100% H2O) to 
afford P1 (11.9 mg, 92%). 
1
H NMR (500 MHz, D2O) δ 4.43 (d, J = 7.9 Hz, 1H), 
4.36 (d, J = 8.5 Hz, 1H), 4.11 (d, J = 3.0 Hz, 1H), 3.95 (dd, J = 10.8, 8.7 Hz, 1H), 
3.78 – 3.70 (m, 3H), 3.62 (dd, J = 8.3, 4.1 Hz, 2H), 3.45 (s, 3H), 3.41 (dd, J = 5.7, 
3.3 Hz, 2H), 3.29 – 3.22 (m, 1H), 1.95 (s, 3H). 13C NMR (500 MHz, D2O) δ 175.9, 
174.9, 104.1, 102.2, 80.3, 76.2, 75.3, 74.9, 72.7, 71.8, 67.8, 61.1, 57.0, 51.0, 22.2. 





General procedure for the synthesis of compounds P2 – P8 
Precursor 2-85b – 2-85h was treated as described for the preparation of P1 to 





H NMR (500 MHz, D2O) δ 4.46 (d, J = 7.9 Hz, 1H), 4.40 (d, J = 
8.6 Hz, 1H), 4.22 – 4.13 (m, 3H), 3.99 (dd, J = 10.8, 8.7 Hz, 1H), 3.89 (dd, J = 
7.6, 4.4 Hz, 1H), 3.81 (dd, J = 10.9, 3.2 Hz, 1H), 3.68 – 3.63 (m, 1H), 3.47 (d, J = 
3.7 Hz, 3H), 3.46 – 3.41 (m, 2H), 3.32 – 3.25 (m, 1H), 1.97 (s, 3H). 13C NMR 
(500 MHz, D2O) δ 175.95, 174.91, 104.09, 102.13, 80.08, 76.16, 75.40, 72.75, 
72.68, 71.82, 67.70, 67.63, 57.10, 50.95, 22.27. HRMS (ESI): m/z: calcd for 





H NMR (500 MHz, D2O) δ 4.43 (dd, J = 7.7, 3.7 Hz, 2H), 4.05 
– 3.96 (m, 2H), 3.83 – 3.71 (m, 3H), 3.62 (d, J = 9.6 Hz, 1H), 3.54 – 3.46 (m, 4H), 
3.42 (t, J = 9.1 Hz, 1H), 3.36 – 3.29 (m, 1H), 1.98 (s, 3H). 13C NMR (500 MHz, 
D2O) δ 175.9, 174.9, 103.3, 102.1, 76.5, 76.4, 75.2, 74.9, 74.5, 72.5, 71.8, 61.1, 
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57.2, 51.7, 22.3. HRMS (ESI): m/z: calcd for C15H23NNa3O15S [M + Na]: 




H NMR (500 MHz, D2O) δ 4.45 (dd, J = 7.8, 1.5 Hz, 2H), 4.29 
(dd, J = 11.4, 3.0 Hz, 1H), 4.19 (dd, J = 11.4, 8.7 Hz, 1H), 4.05 (qd, J = 10.6, 8.1 
Hz, 3H), 3.64 (d, J = 9.8 Hz, 1H), 3.54 – 3.48 (m, 4H), 3.43 (d, J = 9.0 Hz, 1H), 
3.36 – 3.30 (m, 1H), 2.00 (s, 3H). 13C NMR (500 MHz, D2O) δ 175.9, 174.9, 
103.3, 102.0, 76.4, 76.3, 75.2, 74.7, 72.5, 72.4, 71.9, 68.0, 57.3, 51.6, 22.3. 






H NMR (500 MHz, D2O) δ 4.52 (d, J = 7.9 Hz, 1H), 4.36 (d, J = 
8.6 Hz, 1H), 4.21 (t, J = 9.0 Hz, 1H), 4.11 (d, J = 3.0 Hz, 1H), 3.95 (dd, J = 10.8, 
8.6 Hz, 1H), 3.78 – 3.67 (m, 5H), 3.64 – 3.57 (m, 2H), 3.46 – 3.40 (m, 4H), 1.94 
(s, 3H).
 13
C NMR (500 MHz, D2O) δ 175.5, 174.9, 103.7, 102.2, 83.9, 80.7, 76.1, 
74.9, 71.6, 70.5, 67.6, 61.1, 57.0, 50.9, 22.3. HRMS (ESI): m/z: calcd for 







H NMR (500 MHz, D2O) δ 4.51 (d, J = 7.9 Hz, 1H), 4.42 (d, J = 
7.8 Hz, 1H), 4.22 (t, J = 9.0 Hz, 1H), 4.03 – 3.95 (m, 2H), 3.80 – 3.72 (m, 4H), 
3.68 (t, J = 9.4 Hz, 1H), 3.50 – 3.41 (m, 4H), 1.96 (s, 3H). 13C NMR (500 MHz, 
D2O) δ 175.0, 174.6, 103.3, 102.0, 83.6, 76.4, 75.9, 75.7, 74.5, 71.3, 70.4, 61.0, 
57.2, 51.6, 22.3. HRMS (ESI): m/z: calcd for C15H22NNa4O18S2 [M + Na]: 





H NMR (500 MHz, D2O) δ 4.52 (d, J = 7.8 Hz, 1H), 4.44 (d, J = 
7.9 Hz, 1H), 4.24 (t, J = 8.6 Hz, 1H), 4.06 – 3.95 (m, 2H), 3.81 – 3.74 (m, 3H), 
3.69 (q, J = 10.1 Hz, 2H), 3.50 – 3.47 (m, 4H), 1.98 (s, 3H). 13C NMR (500 MHz, 
D2O) δ 175.2, 175.0, 103.2, 102.1, 83.7, 76.5, 76.3, 75.5, 74.5, 71.3, 70.5, 61.1, 
57.2, 51.6, 22.3. HRMS (ESI): m/z: calcd for C15H22NNa4O18S2 [M + Na]: 









H NMR (500 MHz, D2O) δ 4.50 (d, J = 7.9 Hz, 1H), 4.43 (d, J = 
7.7 Hz, 1H), 4.29 – 4.20 (m, 2H), 4.18 – 4.11 (m, 1H), 4.06 – 3.96 (m, 3H), 3.67 
(q, J = 10.1 Hz, 2H), 3.53 – 3.42 (m, 4H), 1.96 (s, 3H). 13C NMR (500 MHz, D2O) 
δ 175.4, 175.0, 103.1, 102.0, 83.8, 76.4, 76.2, 75.2, 72.4, 71.3, 70.5, 68.0, 57.2, 
51.5, 22.3. HRMS (ESI): m/z: calcd for C15H21NNa5O21S3 [M + Na]: 761.9251; 
found: 761.9258. 
 
General procedure for the synthesis of compounds 2-86a – 2-86h 
The protected dimer (0.25 mmol) was dissolved in toluene (8 mL) and Bu3SnH 
(1.5 mmol) and ABCN (109 mg) was added. The reaction was heated to 100°C 
for 4 h. When TLC analysis showed completion of reaction, the solvent was 
evaporated off and the product was purified by flash column chromatography to 





H NMR (500 MHz, CDCl3) δ 7.90 (dd, J = 19.5, 7.9 Hz, 4H), 
7.55 – 7.45 (m, 2H), 7.43 – 7.31 (m, 4H), 7.18 – 7.10 (m, 3H), 7.10 – 7.04 (m, 
2H), 5.65 (t, J = 9.2 Hz, 1H), 5.41 (dd, J = 20.3, 5.1 Hz, 2H), 5.33 (dd, J = 9.3, 
158 
 
7.7 Hz, 1H), 4.95 (d, J = 8.2 Hz, 1H), 4.81 (d, J = 7.5 Hz, 1H), 4.80 – 4.72 (m, 
1H), 4.53 (dd, J = 33.4, 11.1 Hz, 2H), 4.21 – 4.13 (m, 2H), 4.10 (d, J = 9.5 Hz, 
1H), 4.04 (dd, J = 11.5, 7.4 Hz, 1H), 3.90 – 3.83 (m, 1H), 3.79 (s, 3H), 3.44 (s, 
3H), 3.10 (dt, J = 10.5, 7.7 Hz, 1H), 2.10 (s, 3H), 2.05 (s, 3H), 1.39 (s, 3H).
 13
C 
NMR (500 MHz, CDCl3) δ 171.1, 170.5, 169.9, 168.0, 165.4, 164.9, 137.0, 133.5, 
133.3, 129.7, 129.1, 128.6, 128.4, 128.2, 128.0, 127.9, 101.2, 99.6, 75.0, 74.7, 
74.3, 74.1, 71.9, 71.2, 68.9, 62.7, 57.0, 55.5, 52.7, 22.9, 20.7, 20.7. HRMS (ESI): 





H NMR (500 MHz, CDCl3) δ 8.02 – 7.83 (m, 4H), 7.51 (dd, 
J = 13.7, 7.1 Hz, 2H), 7.41 – 7.22 (m, 9H), 7.18 – 7.12 (m, 3H), 7.08 (dt, J = 5.9, 
3.1 Hz, 2H), 5.65 (t, J = 9.2 Hz, 1H), 5.46 (d, J = 3.4 Hz, 1H), 5.40 – 5.21 (m, 
2H), 4.95 (d, J = 8.3 Hz, 1H), 4.80 (d, J = 7.5 Hz, 1H), 4.73 (dd, J = 10.7, 3.4 Hz, 
1H), 4.60 – 4.45 (m, 4H), 4.18 (t, J = 9.3 Hz, 1H), 4.09 (d, J = 9.6 Hz, 1H), 3.90 – 
3.80 (m, 1H), 3.77 (d, J = 7.8 Hz, 3H), 3.55 (ddd, J = 17.0, 10.3, 5.9 Hz, 2H), 
3.46 (d, J = 7.8 Hz, 3H), 3.11 (dt, J = 10.6, 7.8 Hz, 1H), 2.09 (s, 3H), 1.41 (s, 3H).
 
13
C NMR (500 MHz, CDCl3) δ 171.0, 170.1, 168.1, 165.4, 165.0, 138.0, 137.1, 
133.5, 133.3, 129.7, 129.3, 128.6, 128.4, 128.3, 128.0, 127.9, 127.7, 127.7, 101.2, 
99.8, 77.1, 75.2, 74.7, 74.3, 74.2, 73.6, 72.9, 72.0, 69.4, 69.3, 57.2, 55.7, 52.7, 
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1H NMR (500 MHz, CDCl3) δ 7.93 (dd, J = 16.6, 7.8 Hz, 4H), 
7.51 (dt, J = 11.0, 7.5 Hz, 2H), 7.37 (tdd, J = 25.2, 21.1, 7.2 Hz, 9H), 7.16 (dd, J = 
4.9, 1.7 Hz, 3H), 7.12 – 7.08 (m, 2H), 5.81 – 5.69 (m, 1H), 5.44 (dd, J = 9.4, 8.2 
Hz, 1H), 5.27 (d, J = 6.6 Hz, 1H), 4.98 (d, J = 11.6 Hz, 1H), 4.86 (dd, J = 14.3, 
8.0 Hz, 2H), 4.77 (dd, J = 11.0, 2.6 Hz, 1H), 4.68 (d, J = 11.6 Hz, 1H), 4.57 (dd, J 
= 28.7, 11.1 Hz, 2H), 4.19 (d, J = 3.9 Hz, 2H), 4.15 – 4.10 (m, 1H), 3.94 (dd, J = 
9.9, 4.3 Hz, 2H), 3.78 (s, 3H), 3.65 (t, J = 6.2 Hz, 1H), 3.39 (s, 3H), 3.18 (dt, J = 
10.7, 7.7 Hz, 1H), 1.94 (s, 3H), 1.48 (s, 3H). 
 13
C NMR (500 MHz, CDCl3) δ 
171.4, 170.5, 168.4, 165.5, 164.9, 138.4, 137.0, 133.5, 133.4, 129.8, 129.7, 129.4, 
129.2, 128.6, 128.4, 128.3, 128.3, 128.0, 128.0, 127.7, 102.5, 99.6, 78.3, 77.5, 
74.8, 74.7, 74.4, 74.3, 74.00, 72.1, 71.8, 63.1, 56.8, 55.7, 52.7, 23.3, 20.7. HRMS 










H NMR (500 MHz, CDCl3) δ 8.04 – 7.85 (m, 4H), 7.59 – 
7.45 (m, 2H), 7.43 – 7.24 (m, 14H), 7.20 – 7.14 (m, 3H), 7.15 – 7.07 (m, 2H), 
5.74 (dt, J = 9.2, 4.4 Hz, 1H), 5.43 (dd, J = 9.7, 7.9 Hz, 1H), 5.26 (d, J = 6.7 Hz, 
1H), 4.97 (d, J = 11.5 Hz, 1H), 4.87 (dd, J = 8.0, 2.3 Hz, 2H), 4.76 (dd, J = 10.9, 
2.8 Hz, 1H), 4.67 – 4.49 (m, 3H), 4.39 (dd, J = 40.2, 11.7 Hz, 2H), 4.17 (t, J = 5.2 
Hz, 2H), 4.02 (d, J = 2.5 Hz, 1H), 3.77 – 3.62 (m, 4H), 3.55 (dd, J = 9.5, 5.7 Hz, 
1H), 3.46 (dd, J = 9.5, 6.5 Hz, 1H), 3.40 (s, 3H), 3.21 – 3.14 (m, 1H), 1.47 (s, 3H). 
13
C NMR (500 MHz, CDCl3) δ 171.3, 168.3, 165.4, 164.9, 138.8, 138.1, 137.0, 
133.4, 133.3, 129.7, 129.6, 129.4, 129.1, 128.9, 128.6, 128.4, 128.3, 128.3, 128.1, 
128.0, 127.9, 127.7, 127.6, 127.5, 102.4, 99.6, 78.4, 77.4, 75.3, 74.7, 74.5, 74.2, 
74.00, 73.3, 73.2, 72.1, 69.0, 56.8, 55.8, 52.6, 23.3. HRMS (ESI): m/z: calcd for 





H NMR (500 MHz, CDCl3) δ 8.03 – 7.93 (m, 2H), 7.60 (t, J 
= 7.5 Hz, 1H), 7.46 (t, J = 7.8 Hz, 2H), 7.35 – 7.21 (m, 5H), 7.17 – 7.06 (m, 5H), 
5.58 (d, J = 6.8 Hz, 1H), 5.40 (d, J = 3.4 Hz, 1H), 5.26 (dd, J = 8.7, 7.7 Hz, 1H), 
4.97 (d, J = 8.3 Hz, 1H), 4.73 (ddd, J = 14.7, 12.3, 7.3 Hz, 4H), 4.64 (dd, J = 11.1, 
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3.8 Hz, 2H), 4.19 (dd, J = 11.6, 4.8 Hz, 1H), 4.06 – 3.95 (m, 3H), 3.86 (dd, J = 
7.2, 5.1 Hz, 1H), 3.82 – 3.74 (m, 4H), 3.45 (s, 3H), 3.15 (dt, J = 10.6, 7.9 Hz, 1H), 
2.07 (s, 3H), 2.06 (s, 3H), 1.36 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 171.0, 
170.5, 170.0, 168.3, 164.8, 137.5, 137.4, 133.4, 129.7, 129.4, 128.5, 128.3, 128.2, 
127.9, 127.9, 127.6, 101.0, 99.6, 81.4, 79.0, 74.9, 74.8, 74.2, 73.2, 71.2, 68.6, 62.8, 
56.9, 55.3, 52.5, 22.8, 20.7, 20.6. HRMS (ESI): m/z: calcd for C41H47NNaO15 [M 





H NMR (500 MHz, CDCl3) δ 7.60 (dd, J = 7.4, 1.9 Hz, 2H), 
7.41 – 7.21 (m, 16H), 7.19 – 7.09 (m, 2H), 6.10 (d, J = 4.8 Hz, 1H), 5.59 (d, J = 
3.0 Hz, 1H), 4.95 (d, J = 7.9 Hz, 1H), 4.68 (dd, J = 23.7, 10.1 Hz, 2H), 4.52 (tdd, 
J = 14.4, 10.2, 4.5 Hz, 5H), 4.42 (d, J = 11.5 Hz, 1H), 4.19 (dd, J = 10.9, 3.2 Hz, 
1H), 3.93 (d, J = 8.4 Hz, 1H), 3.85 – 3.72 (m, 3H), 3.67 (s, 3H), 3.58 – 3.47 (m, 
3H), 3.45 (d, J = 4.8 Hz, 3H), 2.05 (s, 3H), 1.78 (s, 3H).
 13
C NMR (500 MHz, 
CDCl3) δ 170.6, 170.3, 169.7, 137.7, 137.6, 137.4, 137.2, 129.4, 128.4, 128.4, 
128.2, 128.0, 127.9, 127.9, 127.8, 127.7, 127.7, 126.1, 121.8, 101.3, 98.0, 76.6, 
76.0, 73.6, 72.9, 72.4, 72.2, 71.1, 69.8, 68.4, 56.9, 53.3, 52.4, 23.8, 20.9. HRMS 







H NMR (500 MHz, CDCl3) δ 7.99 (d, J = 7.5 Hz, 2H), 7.60 
(t, J = 7.5 Hz, 1H), 7.48 – 7.38 (m, 4H), 7.38 – 7.21 (m, 8H), 7.19 – 7.06 (m, 5H), 
5.36 (dd, J = 9.0, 8.2 Hz, 1H), 5.30 (d, J = 6.6 Hz, 1H), 4.96 (d, J = 11.6 Hz, 1H), 
4.86 – 4.60 (m, 8H), 4.14 (dd, J = 11.2, 6.8 Hz, 1H), 4.07 – 3.98 (m, 2H), 3.94 (dd, 
J = 11.1, 6.0 Hz, 2H), 3.87 (d, J = 8.6 Hz, 1H), 3.75 (s, 3H), 3.64 (t, J = 6.3 Hz, 
1H), 3.40 (s, 3H), 3.18 (dd, J = 7.1, 3.0 Hz, 1H), 1.93 (d, J = 6.5 Hz, 3H), 1.50 (s, 
3H).
 13
C NMR (500 MHz, CDCl3) δ 171.2, 170.4, 168.6, 164.7, 138.4, 137.6, 
137.5, 133.4, 129.6, 129.0, 128.6, 128.4, 128.3, 128.2, 127.9, 127.9, 127.7, 127.6, 
102.4, 99.5, 81.6, 79.5, 77.9, 75.1, 75.1, 74.6, 74.3, 74.1, 73.6, 71.7, 63.0, 56.7, 
55.6, 52.5, 23.4, 20.7. HRMS (ESI): m/z: calcd for C46H51NNaO14 [M + Na]: 





H NMR (500 MHz, CDCl3) δ 8.00 (d, J = 7.2 Hz, 2H), 7.59 
(t, J = 7.3 Hz, 1H), 7.53 – 7.19 (m, 17H), 7.21 – 7.08 (m, 5H), 5.36 (dd, J = 14.8, 
6.6 Hz, 2H), 4.97 (d, J = 11.7 Hz, 1H), 4.86 (d, J = 8.3 Hz, 1H), 4.83 – 4.74 (m, 
3H), 4.74 – 4.58 (m, 4H), 4.38 (dd, J = 41.6, 11.7 Hz, 2H), 4.15 – 3.95 (m, 3H), 
3.88 (t, J = 8.9 Hz, 1H), 3.74 – 3.60 (m, 4H), 3.55 (dd, J = 9.5, 5.8 Hz, 1H), 3.46 
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(dd, J = 9.6, 6.6 Hz, 1H), 3.40 (d, J = 4.6 Hz, 3H), 3.19 (dt, J = 10.8, 7.8 Hz, 1H), 
1.48 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 171.1, 168.5, 164.7, 138.8, 138.0, 
137.5, 137.5, 133.5, 129.6, 128.8, 128.5, 128.4, 128.3, 128. 2, 128.0, 127.9, 
127.84, 127.6, 127.5, 127.3, 102.38, 99.5, 81.6, 79.4, 78.1, 75.3, 75.0, 75.0, 74.4, 
74.0, 73.6, 73.2, 73.2, 69.0, 56.7, 55.6, 52.3, 23.3. HRMS (ESI): m/z: calcd for 
C51H55NNaO13 [M + Na]: 912.3566; found: 912.3572. 
 
General procedure for the synthesis of compounds 2-87a – 2-87h 
Precursor 2-86a – 2-86h (0.2 mmol) was dissolved in THF (3.5 mL) and cooled to 
0°C, before addition of H2O2 (0.4 mL) and LiOH (0.8 mL, 1 M). The reaction was 
stirred for 16 h at room temperature, after which, methanol (2.26 mL) was added 
and the reaction was cooled to 0°C before addition of NaOH (0.9 mL). The 
reaction was stirred at room temperature for 6 h. When TLC analysis showed 
completion of reaction, the reaction was quenched with Amberlyst-15 and stirred 
for another 15 min. At pH 3 – 4, the mixture was filtered and solvent was 
evaporated off. The product was purified by flash column chromatography to 




1H NMR (500 MHz, DMSO) δ 7.69 (d, J = 8.9 Hz, 1H), 7.36 
– 7.22 (m, 5H), 4.72 (d, J = 11.2 Hz, 1H), 4.57 (d, J = 11.2 Hz, 1H), 4.34 (d, J = 
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7.6 Hz, 1H), 4.25 (d, J = 8.4 Hz, 1H), 3.90 – 3.78 (m, 2H), 3.62 – 3.52 (m, 3H), 
3.52 – 3.39 (m, 2H), 3.33 (dd, J = 9.9, 4.0 Hz, 2H), 3.31 (d, J = 6.1 Hz, 3H), 3.14 
(dd, J = 16.2, 8.1 Hz, 1H), 1.78 (s, 3H).
 13C NMR (500 MHz, DMSO) δ 171.7, 
170.0, 139.1, 127.9, 127.6, 127.6, 127.1, 104.5, 101.8, 80.5, 80.5, 76.3, 75.5, 75.0, 
73.3, 73.2, 66.7, 60.1, 55.3, 50.6, 23.1. HRMS (ESI): m/z: calcd for 




1H NMR (500 MHz, DMSO) δ 7.75 (d, J = 8.7 Hz, 1H), 7.38 
– 7.15 (m, 10H), 4.65 (s, 2H), 4.49 (d, J = 13.5 Hz, 3H), 4.34 (d, J = 7.3 Hz, 1H), 
4.28 (d, J = 8.4 Hz, 1H), 3.89 – 3.78 (m, 2H), 3.67 – 3.43 (m, 6H), 3.30 (s, 3H), 
3.14 (t, J = 7.1 Hz, 1H), 1.79 (s, 3H). 
13C NMR (500 MHz, DMSO) δ 173.7, 
170.1, 139.5, 138.5, 128.2, 128.2, 127.8, 127.7, 127.7, 127.5, 127.4, 126.9, 104.3, 
101.6, 80.9, 79.6, 75.4, 73.3, 73.1, 72.7, 72.3, 69.5, 67.6, 56.0, 55.4, 50.6, 23.1. 




1H NMR (500 MHz, DMSO) δ 7.71 (d, J = 7.8 Hz, 1H), 7.42 
– 7.12 (m, 10H), 4.86 (d, J = 11.5 Hz, 1H), 4.79 (d, J = 11.2 Hz, 1H), 4.58 (d, J = 
165 
 
11.2 Hz, 1H), 4.52 (d, J = 11.5 Hz, 1H), 4.38 (d, J = 7.7 Hz, 1H), 4.28 (d, J = 4.2 
Hz, 1H), 3.86 (s, 1H), 3.81 (d, J = 7.4 Hz, 2H), 3.70 (d, J = 9.5 Hz, 2H), 3.49 – 
3.34 (m, 4H), 3.29 (s, 3H), 3.11 (t, J = 8.3 Hz, 1H), 1.79 (s, 3H).
 13
C NMR (500 
MHz, DMSO) δ 170.9, 170.1, 139.2, 139.0, 128.1, 128.0, 127.6, 127.3, 127.2, 
105.0, 101.7, 80.5, 80.0, 75.8, 75.4, 75.3, 74.7, 73.9, 73.6, 60.1, 55.5, 51.4, 23.2. 




1H NMR (500 MHz, DMSO) δ 7.72 (d, J = 7.1 Hz, 1H), 7.37 
– 7.21 (m, 14H), 4.82 (dd, J = 23.6, 11.4 Hz, 2H), 4.60 (d, J = 11.2 Hz, 1H), 4.47 
(d, J = 11.6 Hz, 1H), 4.42 – 4.33 (m, 3H), 4.30 (d, J = 7.2 Hz, 1H), 3.87 – 3.76 (m, 
3H), 3.71 (d, J = 9.5 Hz, 1H), 3.61 (t, J = 5.9 Hz, 1H), 3.51 (t, J = 9.3 Hz, 1H), 
3.45 – 3.34 (m, 3H), 3.33 – 3.30 (m, 1H), 3.28 (s, 3H), 3.12 (t, J = 8.3 Hz, 1H), 
1.80 (s, 3H).
 13C NMR (500 MHz, DMSO) δ 170.8, 170.0, 139.0, 138.9, 138.2, 
128.3, 128.2, 128.1, 127.9, 127.6, 127.4, 127.3, 127.1, 104.9, 101.6, 80.3, 80.1, 
75.8, 75.3, 73.9, 73.7, 73.5, 72.6, 72.2, 68.8, 60.00, 55.5, 51.3, 23.1. HRMS (ESI): 








1H NMR (500 MHz, DMSO) δ 7.75 (d, J = 8.7 Hz, 1H), 7.34 
– 7.21 (m, 9H), 5.45 (s, 1H), 5.13 (s, 1H), 4.81 (d, J = 11.7 Hz, 1H), 4.69 (dd, J = 
11.1, 6.3 Hz, 2H), 4.61 (s, 1H), 4.53 (d, J = 10.9 Hz, 1H), 4.38 (d, J = 6.3 Hz, 1H), 
4.28 (d, J = 8.4 Hz, 1H), 3.96 (s, 1H), 3.81 (d, J = 9.7 Hz, 1H), 3.74 (t, J = 7.4 Hz, 
1H), 3.60 (dd, J = 18.8, 10.8 Hz, 3H), 3.46 – 3.42 (m, 2H), 3.30 (s, 3H), 1.80 (s, 
3H).
 13C NMR (500 MHz, DMSO) δ 172.9, 170.0, 139.2, 138.9, 127.9, 127.9, 
127.4, 127.1, 127.1, 104.5, 101.8, 83.7, 80.7, 80.4, 77.6, 74.9, 73.5, 73.0, 72.8, 
66.5, 59.9, 55.3, 50.7, 23.1. HRMS (ESI): m/z: calcd for C29H36NO12 [M – Na]: 




1H NMR (500 MHz, DMSO) δ 7.69 (d, J = 8.9 Hz, 1H), 7.38 
– 7.18 (m, 14H), 4.87 (d, J = 11.5 Hz, 1H), 4.82 (s, 1H), 4.68 (dd, J = 18.3, 11.2 
Hz, 2H), 4.58 (d, J = 10.9 Hz, 1H), 4.51 (s, 2H), 4.46 (d, J = 7.6 Hz, 1H), 4.30 (d, 
J = 8.5 Hz, 1H), 3.86 (dd, J = 20.1, 10.9 Hz, 2H), 3.77 (d, J = 9.2 Hz, 1H), 3.69 – 
3.58 (m, 4H), 3.54 (dd, J = 11.3, 8.4 Hz, 1H), 3.48 – 3.43 (m, 1H), 3.40 – 3.33 (m, 
2H), 3.32 (s, 3H), 1.82 (s, 3H).
 13
C NMR (500 MHz, CDCl3) δ 170.5, 169.9, 138.9, 
138.5, 138.3, 128.2, 128.0, 127.6, 127.6, 127.4, 127.4, 127.3, 127.2, 104.2, 101.6, 
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83.7, 79.7, 79.3, 73.7, 73.6, 73.3, 73.2, 72.2, 69.4, 67.6, 59.9, 55.3, 50.5, 23.1. 




1H NMR (500 MHz, DMSO) δ 7.71 (d, J = 7.5 Hz, 1H), 7.41 
– 7.19 (m, 14H), 4.93 – 4.82 (m, 2H), 4.71 (d, J = 11.5 Hz, 1H), 4.68 – 4.56 (m, 
2H), 4.54 (d, J = 11.5 Hz, 1H), 4.48 (d, J = 7.5 Hz, 1H), 4.31 (d, J = 7.4 Hz, 1H), 
3.90 (s, 1H), 3.83 (dd, J = 12.5, 8.8 Hz, 3H), 3.64 (t, J = 9.3 Hz, 1H), 3.53 – 3.46 
(m, 2H), 3.44 – 3.32 (m, 3H), 3.31 (s, 3H), 1.83 (s, 3H). 13C NMR (500 MHz, 
DMSO) δ 170.5, 170.0, 139.2, 139.0, 138.4, 128.0, 127.9, 127.7, 127.5, 127.4, 
127.2, 104.7, 101.7, 83.8, 80.5, 79.2, 75.3, 74.7, 73.9, 73.9, 73.8, 73.8, 60.0, 55.5, 





1H NMR (500 MHz, DMSO) δ 7.74 (d, J = 7.3 Hz, 1H), 7.43 
– 7.19 (m, 19H), 4.90 (dd, J = 21.2, 11.5 Hz, 2H), 4.77 – 4.67 (m, 2H), 4.61 (d, J 
= 10.8 Hz, 1H), 4.52 (dd, J = 16.7, 9.6 Hz, 2H), 4.38 (dt, J = 17.4, 8.7 Hz, 3H), 
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3.97 – 3.79 (m, 4H), 3.66 (dt, J = 12.2, 7.6 Hz, 2H), 3.55 (t, J = 8.9 Hz, 1H), 3.45 
(dd, J = 9.6, 6.3 Hz, 1H), 3.40 – 3.33 (m, 2H), 3.31 (s, 3H), 1.85 (s, 3H). 13C 
NMR (500 MHz, DMSO) δ 170.4, 170.1, 139.0, 138.9, 138.3, 138.2, 128.3, 128.1, 
128.1, 127.7, 127.6, 127.5, 127.4, 127.3, 127.3, 104.8, 101.7, 83.8, 80.6, 79.1, 
75.4, 74.4, 73.9, 73.9, 73.8, 72.6, 72.3, 68.8, 55.5, 51.3, 48.6, 23.2. HRMS (ESI): 
m/z: calcd for C43H49NNaO12 [M + Na]: 794.3147; found: 794.3140. 
 
General procedure for the synthesis of compounds 2-88b – 2-88h 
Precursor 2-87b – 2-87h was treated as described for the preparation of 2-85b – 




1H NMR (500 MHz, DMSO) δ 7.69 (d, J = 7.9 Hz, 1H), 7.41 
(d, J = 7.2 Hz, 2H), 7.36 – 7.19 (m, 8H), 4.86 (s, 2H), 4.74 (d, J = 11.2 Hz, 1H), 
4.59 (s, 1H), 4.53 (d, J = 4.7 Hz, 1H), 4.49 (s, 2H), 4.44 (d, J = 11.2 Hz, 1H), 4.38 
(d, J = 8.0 Hz, 1H), 4.11 (s, 1H), 3.92 (d, J = 3.4 Hz, 1H), 3.81 (d, J = 10.6 Hz, 
1H), 3.77 – 3.61 (m, 3H), 3.58 (dd, J = 10.5, 7.8 Hz, 1H), 3.32 (s, 3H), 1.89 (s, 
3H).
 13C NMR (500 MHz, DMSO) δ 173.5, 170.9, 138.8, 138.6, 128.2, 127.9, 
127.9, 127.4, 127.3, 127.2, 101.8, 101.6, 79.0, 77.4, 76.7, 75.9, 73.4, 73.2, 72.1, 
70.5, 70.3, 55.5, 51.1, 23.1. HRMS (ESI): m/z: calcd for C29H33NNa5O21S3 [M + 





1H NMR (500 MHz, DMSO) δ 7.77 (d, J = 8.6 Hz, 1H), 7.46 
(d, J = 7.4 Hz, 2H), 7.34 – 7.25 (m, 4H), 7.24 – 7.14 (m, 4H), 5.16 (d, J = 11.5 Hz, 
1H), 5.05 (d, J = 2.2 Hz, 1H), 4.82 (d, J = 11.1 Hz, 1H), 4.63 – 4.51 (m, 2H), 4.47 
(d, J = 11.2 Hz, 2H), 4.35 (d, J = 8.3 Hz, 1H), 4.30 (dd, J = 8.9, 5.9 Hz, 1H), 4.17 
(s, 1H), 4.04 – 3.97 (m, 1H), 3.93 (dd, J = 10.4, 5.7 Hz, 1H), 3.87 (dd, J = 10.4, 
6.3 Hz, 1H), 3.78 (d, J = 8.9 Hz, 1H), 3.73 – 3.67 (m, 1H), 3.63 (t, J = 6.0 Hz, 
1H), 3.28 (s, 3H), 1.83 (s, 3H).
 13C NMR (500 MHz, DMSO) δ 172.9, 170.2, 
139.8, 139.1, 127.9, 127.9, 127.9, 127.8, 127.0, 126.9, 101.8, 100.1, 78.3, 77.2, 
76.7, 76.3, 76.1, 74.1, 73.0, 71.6, 65.2, 55.6, 51.5, 23.1. HRMS (ESI): m/z: calcd 




1H NMR (500 MHz, DMSO) δ 7.78 (d, J = 8.3 Hz, 1H), 7.44 
– 7.14 (m, 15H), 5.11 (d, J = 11.8 Hz, 1H), 5.00 (d, J = 2.9 Hz, 1H), 4.79 (d, J = 
11.1 Hz, 1H), 4.61 – 4.53 (m, 2H), 4.52 – 4.42 (m, 4H), 4.34 (d, J = 8.3 Hz, 1H), 
4.29 – 4.22 (m, 1H), 4.14 (s, 1H), 4.03 (d, J = 11.5 Hz, 1H), 3.78 – 3.70 (m, 2H), 
3.63 (t, J = 5.5 Hz, 1H), 3.54 (t, J = 8.4 Hz, 1H), 3.48 (dd, J = 10.0, 4.4 Hz, 1H), 
3.27 (s, 3H), 1.83 (s, 3H).
 13C NMR (500 MHz, DMSO) δ 173.2, 170.1, 139.7, 
170 
 
139.3, 138.3, 128.2, 128.0, 127.8, 127.8, 127.7, 127.6, 127.4, 126.8, 102.0, 100.4, 
77.8, 77.6, 76.8, 76.7, 76.5, 76.0, 74.0, 73.6, 72.2, 71.4, 69.6, 55.4, 51.4, 23.1. 





1H NMR (500 MHz, DMSO) δ 7.91 (d, J = 7.4 Hz, 1H), 7.35 
(d, J = 6.8 Hz, 2H), 7.28 – 7.16 (m, 8H), 4.91 (d, J = 11.4 Hz, 1H), 4.74 (d, J = 
8.2 Hz, 1H), 4.55 (dd, J = 18.5, 9.2 Hz, 3H), 4.48 (s, 2H), 4.44 (t, J = 6.2 Hz, 1H), 
4.04 (d, J = 9.9 Hz, 1H), 3.88 (d, J = 10.8 Hz, 1H), 3.81 – 3.66 (m, 5H), 3.33 (s, 
3H), 1.90 (s, 3H).
 13C NMR (500 MHz, DMSO) δ 172.6, 171.1, 138.9, 138.7, 
128.0, 127.8, 127.7, 127.5, 127.1, 103.2, 100.5, 79.9, 78.6, 78.3, 78.2, 77.7, 74.8, 
72.9, 72.2, 71.7, 66.6, 55.5, 52.3, 23.1. HRMS (ESI): m/z: calcd for 




1H NMR (500 MHz, DMSO) δ 7.95 (d, J = 7.2 Hz, 1H), 7.37 
– 7.20 (m, 14H), 4.91 (d, J = 11.4 Hz, 1H), 4.79 (d, J = 8.2 Hz, 1H), 4.63 – 4.37 
171 
 
(m, 9H), 3.95 (d, J = 10.9 Hz, 1H), 3.74 (d, J = 11.4 Hz, 3H), 3.68 (d, J = 7.9 Hz, 
1H), 3.61 (t, J = 8.5 Hz, 2H), 3.38 (s, 3H), 1.89 (s, 3H).
 13
C NMR (500 MHz, 
DMSO) δ 172.1, 170.9, 138.9, 138.8, 138.8, 128.1, 127.9, 127.8, 127.8, 127.6, 
127.3, 127.0, 102.8, 100.7, 80.2, 78.6, 77.8, 74.2, 73.3, 72.2, 72.0, 71.9, 70.3, 55.5, 
52.8, 48.6, 23.2. HRMS (ESI): m/z: calcd for C36H40NNa2O18S [M - Na]: 




1H NMR (500 MHz, DMSO) δ 7.93 (d, J = 8.0 Hz, 1H), 7.35 
(dd, J = 6.5, 2.7 Hz, 2H), 7.32 – 7.28 (m, 2H), 7.24 – 7.17 (m, 10H), 5.09 (d, J = 
11.1 Hz, 1H), 4.93 (d, J = 11.3 Hz, 1H), 4.77 (d, J = 4.9 Hz, 1H), 4.66 (d, J = 11.3 
Hz, 1H), 4.57 – 4.51 (m, 3H), 4.48 (d, J = 11.1 Hz, 1H), 4.29 (t, J = 5.0 Hz, 1H), 
4.18 (s, 1H), 4.04 – 3.93 (m, 2H), 3.91 (dd, J = 10.3, 6.5 Hz, 1H), 3.82 (dd, J = 
10.3, 5.9 Hz, 1H), 3.70 – 3.57 (m, 4H), 3.29 (s, 3H), 1.87 (s, 3H). 13C NMR (500 
MHz, DMSO) δ 173.0, 170.2, 139.5, 139.3, 139.1, 128.0, 127. 9, 127.8, 127.8, 
127.5, 127.0, 126.9, 101.6, 100.9, 82.9, 79.0, 77.8, 77.4, 76.7, 75.4, 73.9, 72.9, 
72.7, 71.9, 64.7, 55.6, 52.1, 23.1. HRMS (ESI): m/z: calcd for C36H40NNa2O18S2 







1H NMR (500 MHz, DMSO) δ 7.94 (d, J = 8.0 Hz, 1H), 7.47 
– 7.17 (m, 19H), 4.99 (d, J = 11.3 Hz, 1H), 4.95 – 4.80 (m, 2H), 4.61 – 4.51 (m, 
3H), 4.44 (dt, J = 18.0, 11.7 Hz, 4H), 4.37 – 4.29 (m, 1H), 4.11 – 3.94 (m, 3H), 
3.89 – 3.74 (m, 3H), 3.62 (s, 1H), 3.43 – 3.58 (m, 2H), 3.27 (s, 3H), 1.87 (s, 3H). 
13C NMR (500 MHz, DMSO) δ 172.2, 170.3, 139.2, 138.8, 138.8, 138.3, 128.2, 
128.2, 128.0, 127.9, 127.6, 127.5, 127.4, 127.1, 127.0, 101.7, 100.5, 82.4, 78.5, 
77.7, 77.4, 75.3, 73.9, 73.1, 73.0, 72.3, 71.8, 69.1, 55.6, 51.8, 23.1. HRMS (ESI): 
m/z: calcd for C43H48NNa2O15S [M + Na]: 896.2535; found: 896.2539. 
 
General procedure for the synthesis of compounds P10 – P16 
Precursor 2-88b – 2-88h (0.03 mmol) was dissolved in H2O/MeOH (1 mL/1 mL) 
and 10% Pd on carbon (100 mg) was added. The reaction was placed under H2 
atmosphere and stirred for 16 h at room temperature. When the reaction was 
complete, the mixture was filtered through Celite and purified using Sephadex G-
10 (100% H2O). Purified product was passed through Sephadex C-25 Na resin 








H NMR (500 MHz, D2O) δ 4.84 (d, J = 2.7 Hz, 1H), 4.38 (dd, 
J = 13.3, 5.5 Hz, 1H), 4.27 (t, J = 7.2 Hz, 1H), 4.20 – 4.12 (m, 1H), 3.92 (t, J = 
9.0 Hz, 1H), 3.85 – 3.73 (m, 5H), 3.69 (dd, J = 11.1, 8.8 Hz, 1H), 3.46 (s, 3H), 
2.00 (s, 3H). 
13
C NMR (500 MHz, D2O) δ 175.4, 175.0, 101.9, 101.8, 81.7, 77.4, 
76.5, 76.4, 76.1, 74.7, 70.3, 61.1, 57.1, 52.6, 22.6. HRMS (ESI): m/z: calcd for 





H NMR (500 MHz, D2O) δ 4.84 (d, J = 6.4 Hz, 1H), 4.45 (d, J 
= 8.4 Hz, 1H), 4.39 – 4.34 (m, 1H), 4.25 (t, J = 6.8 Hz, 1H), 4.21 – 4.14 (m, 3H), 
3.93 – 3.76 (m, 5H), 3.44 (s, 3H), 1.98 (s, 3H). 13C NMR (500 MHz, D2O) δ 175.6, 
175.0, 102.4, 100.7, 81.2, 79.6, 77.2, 76.1, 72.6, 70.4, 67.8, 67.1, 57.1, 51.1, 22.5. 









H NMR (500 MHz, D2O) δ 4.83 (d, J = 6.5 Hz, 1H), 4.44 (d, J 
= 8.4 Hz, 1H), 4.39 – 4.32 (m, 1H), 4.24 (t, J = 6.8 Hz, 1H), 4.14 (d, J = 2.8 Hz, 
1H), 3.81 (dddd, J = 24.4, 9.7, 7.6, 2.6 Hz, 6H), 3.63 (dd, J = 7.4, 4.7 Hz, 1H), 
3.43 (s, 3H), 1.98 (s, 3H).
 13
C NMR (500 MHz, D2O) δ 175.6, 174.9, 102.4, 100.7, 
81.1, 79.7, 77.2, 76.1, 74.8, 70.4, 67.2, 61.1, 57.0, 51.2, 22.5. HRMS (ESI): m/z: 





H NMR (500 MHz, D2O) δ 4.87 (d, J = 2.6 Hz, 1H), 4.62 (d, J 
= 8.0 Hz, 2H), 4.28 (dd, J = 11.4, 2.7 Hz, 1H), 4.20 – 4.09 (m, 3H), 4.03 (dd, J = 
8.9, 2.7 Hz, 1H), 3.80 (dd, J = 10.8, 8.9 Hz, 1H), 3.70 – 3.57 (m, 3H), 3.49 (s, 3H), 
2.00 (s, 3H).
 13
C NMR (500 MHz, D2O) δ 175.7, 174.9, 101.9, 101.8, 80.1, 76.3, 
76.2, 76.1, 75.1, 72.5, 71.4, 68.1, 57.2, 52.3, 22.4. HRMS (ESI): m/z: calcd for 







H NMR (500 MHz, D2O) δ 4.83 (d, J = 2.8 Hz, 1H), 4.62 (dd, 
J = 8.0, 4.1 Hz, 2H), 4.13 (dt, J = 15.1, 5.2 Hz, 2H), 3.76 (dt, J = 8.2, 5.8 Hz, 4H), 
3.72 – 3.61 (m, 4H), 3.47 (s, 3H), 2.00 (s, 3H). 13C NMR (500 MHz, D2O) δ 175.7, 
174.9, 101.9, 101.8, 80.2, 76.4, 76.3, 76.2, 75.1, 74.7, 71.3, 61.1, 57.1, 52.5, 22.4. 






H NMR (500 MHz, D2O) δ 4.48 (d, J = 8.2 Hz, 1H), 4.25 – 
4.14 (m, 3H), 4.09 – 4.03 (m, 1H), 3.91 (tdd, J = 16.7, 11.2, 5.6 Hz, 3H), 3.73 – 
3.66 (m, 3H), 3.56 (t, J = 9.5 Hz, 1H), 3.47 (s, 3H), 2.01 (s, 3H).
 13
C NMR (500 
MHz, D2O) δ 175.7, 174.9, 102.4, 101.2, 79.9, 79.7, 76.0, 74.6, 72.6, 71.5, 67.8, 
67.2, 57.1, 51.1, 22.5. HRMS (ESI): m/z: calcd for C15H22NNa2O18S2 [M – Na]: 







H NMR (500 MHz, D2O) δ 4.44 (d, J = 8.3 Hz, 1H), 4.14 (d, J 
= 2.7 Hz, 1H), 4.03 (dd, J = 8.8, 7.8 Hz, 1H), 3.87 (ddd, J = 19.2, 11.0, 5.7 Hz, 
2H), 3.76 – 3.70 (m, 2H), 3.70 – 3.65 (m, 2H), 3.63 (dd, J = 7.3, 4.6 Hz, 1H), 3.53 
(t, J = 9.5 Hz, 1H), 3.44 (s, 3H), 1.98 (s, 3H). 
13
C NMR (500 MHz, D2O) δ 175.7, 
174.9, 102.4, 101.2, 79.9, 79.8, 76.0, 74.8, 74.6, 71.5, 67.4, 61.1, 57.0, 51.2, 22.5. 




Compound 2-87a’: To a solution of 2-87a (37 mg, 0.071 mmol) in DMF (0.5 mL) 
was added BnBr (12.7µL, 0.107 mmol) and NaHCO3 (30 mg, 0.355 mmol) and 
the reaction stirred at 50°C for 2 h. When the reaction was complete, the solvent 
was evaporated off. The product was purified by Sephadex LH-20 
(CH2Cl2/methanol, 1:1) to afford 2-87a’ (37.7 mg, 90%). 
1
H NMR (500 MHz, 
MeOD) δ 7.42 – 7.16 (m, 10H), 5.15 (d, J = 2.1 Hz, 1H), 4.60 (s, 1H), 4.46 (dd, J 
= 21.7, 9.4 Hz, 2H), 4.36 (d, J = 8.3 Hz, 1H), 4.03 (dd, J = 10.7, 8.6 Hz, 1H), 3.99 
– 3.93 (m, 2H), 3.82 – 3.67 (m, 3H), 3.64 – 3.53 (m, 3H), 3.51 – 3.48 (m, 1H), 
3.47 (s, 3H), 3.28 – 3.21 (m, 2H), 1.94 (s, 3H). 13C NMR (500 MHz, MeOD) δ 
177 
 
174.4, 170.4, 139.6, 136.8, 129.6, 129.5, 129.2, 129.0, 128.6, 106.4, 103.6, 82.0, 
80.8, 77.4, 76.4, 75.7, 74.7, 69.7, 68.3, 62.5, 59.5, 56.9, 52.8, 23.2. HRMS (ESI): 
m/z: calcd for C29H37NNaO12 [M + Na]: 614.2208; found: 614.2214. 
 
 
Compound 2-88a: Precursor 2-87a’  (37.7 mg, 0.064 mmol) was treated as 
described for the preparation of 2-85b – 2-85h with a longer reaction period of 48 
h to afford 2-88a (43.5 mg, 68%). 
1H NMR (500 MHz, MeOD) δ 7.45 – 7.27 (m, 
7H), 7.23 (dd, J = 8.1, 4.2 Hz, 3H), 5.22 (dd, J = 35.0, 12.1 Hz, 2H), 5.12 (t, J = 
4.9 Hz, 2H), 4.95 (s, 1H), 4.70 (d, J = 5.6 Hz, 1H), 4.62 – 4.56 (m, 2H), 4.54 – 
4.46 (m, 2H), 4.39 (dd, J = 11.7, 3.7 Hz, 1H), 4.25 (dd, J = 11.6, 7.8 Hz, 1H), 
3.97 (d, J = 3.3 Hz, 2H), 3.93 (dd, J = 7.6, 3.7 Hz, 1H), 3.46 (s, 3H), 2.01 (s, 3H).
 
13C NMR (500 MHz, MeOD) δ 174.9, 172.2, 139.0, 136.6, 129.7, 129.6, 129.5, 
129.2, 128.7, 103.0, 102.3, 79.4, 78.5, 77.9, 76.6, 76.5, 76.5, 74.1, 73.4, 69.0, 68.9, 
57.1, 53.1, 23.3. HRMS (ESI): m/z: calcd for C29H33NNa3O24S4 [M – Na]: 







Compound P9: Compound 2-88a  (43.5 mg, 0.044 mmol) was treated as 
described for the preparation of P10 – P16 to afford P9 (33 mg, 90%). 1H NMR 
(500 MHz, D2O) δ 4.88 (d, J = 2.6 Hz, 1H), 4.66 (d, J = 8.6 Hz, 1H), 4.38 (t, J = 
7.9 Hz, 1H), 4.30 – 4.24 (m, 2H), 4.20 – 4.11 (m, 2H), 4.02 (dd, J = 8.8, 2.5 Hz, 
1H), 3.92 (t, J = 8.9 Hz, 1H), 3.75 (dt, J = 11.0, 6.1 Hz, 2H), 3.47 (s, 3H), 2.01 (s, 
3H).
 13
C NMR (500 MHz, D2O) δ 175.4, 175.0, 101.9, 101.7, 81.6, 77.3, 76.5, 
76.4, 75.9, 72.5, 70.4, 68.1, 57.2, 52.4, 22.5. HRMS (ESI): m/z: calcd for 
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CHAPTER 3: BIOLOGICAL EVALUATION OF 
CHONDROITIN SULFATE IN BREAST CANCER 
 
3.1 Introduction to Breast Cancer 
Breast cancer is the top diagnosed cancer for women worldwide, accounting for 
29% of the new cancer cases, and is ranked second for the number of female 
cancer-related deaths after lung cancer in 2013.
[1]
 It is estimated that 1 in 8 
women will develop breast cancer in her lifetime in the United States.
[2]
 In 
Singapore, breast cancer is the most common cancer in the female population and 
has the highest mortality rate across all ethnic groups, accounting for up to 18.1% 




Breast cancer arises from the uncontrolled division of cells in the breast tissue, 
which can either occur in the lobules (glands involved in milk production), or the 
ducts (which connect the lobules to the nipple). In the in situ stage of breast 
cancer, the abnormal cells are localized to form lobular carcinoma in situ (LCIS) 
or the ductal carcinoma in situ (DCIS).
[1]
 This could progress to the invasive 
forms of breast cancer, which is classified into various stages, depending on the 
primary tumor size (T), extend of tumor spread to nearby lymph nodes (N), and 
whether distant metastasis (M) to other organs has occurred. The TNM staging 
system
[4]
 was established by the Union for International Cancer Control (UICC) 
to categorize the degree of cancer spread (Table 3-1), and is currently recognized 
as the global standard.  
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Table 3-1. TNM staging system 
Stage Characteristics 
0 in situ carcinoma: cancer cells localized at original site 
I Tumor size ≤ 2 cm; negative lymph node involvement 
II Tumor size between 2-5cm; metastasis to nearby axillary lymph nodes 
Tumor size ≥ 5 cm; negative lymph node involvement 
IIIA Tumor ≥ 5 cm; metastasis to nearby axillary lymph nodes 
IIIB Tumor of any size; spread to chest wall, breast skin and axillary lymph 
nodes 
IV Tumor of any size; metastasis to distant organs 
 
The common risk factors of breast cancer include an increase in age, family 
history of breast cancer, use of menopausal hormone therapy, physical inactivity 
and alcohol intake.
[5]
 Detection of breast cancer in early stages via mammography 
is often recommended to improve survival outcomes, reducing the risk of death 
by more than 30%.
[6, 7]
 In addition, early detection provides more treatment 
options such as less extensive surgery, radiotherapy and the use of milder 
chemotherapeutic drugs with less severe side effects.
[1]
 For instance, the patient 
may opt for lumpectomy instead of mastectomy to conserve the breast tissue if the 
detected tumor is small and has yet to spread. To reduce the risk of a relapse, a 
combination of chemotherapeutic drugs is commonly prescribed, which is more 
effective than single drug treatment.
[8]
 Examples include taxotere with 
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cyclophosphamide (TC chemotherapy), adriamycin with cyclophosphamide (AC 




Breast cancer is a complicated disease with a heterogeneous molecular profile. 
Thus, this may lead to unpredictable clinical responses when treated with the 
same therapeutic approach, making it difficult to predict survival outcome.
[10-12]
 
Many unique molecular subtypes of breast cancer have been identified through 
gene expression profiling, and these subtypes may be characterized based on the 
tumor grade, histological type, lymph node involvement and expression of distinct 
biological markers such as estrogen receptors (ER), progesterone receptors (PR) 
and human epidermal growth factor receptor 2 (HER2).
[13, 14]
 The five molecular 





For each molecular subtype, the therapy indicated primarily depends on the 
therapeutic targets available.
[15]
 For example, the expression of ER enables 
treatment via hormone/endocrine therapy. This approach targets breast cancer 
cells which require estrogen to multiply, through the use of estrogen receptor 
antagonists such as tamoxifen.
[16]
 This drug binds competitively to the estrogen 
receptor but does not activate it, thereby arresting the development of the cancer 
cells. In addition, tumor subtypes which over-express HER2 can be targeted using 
trasuszumab, a monoclonal antibody which binds to the HER2 receptor; this drug 





 However, some breast cancer subtypes (such as basal tumors) do 
not express any known therapeutic targets such as ER, PR, and HER2, and are 
otherwise known as triple negative breast cancer (TNBC).
[18]
 These tumor 
subtypes are more challenging to treat as they are endocrine non-responsive and 
show low response to chemotherapy. TNBC subtypes are biologically more 
aggressive, and usually results in higher patient mortality. Thus, new treatment 
options are required to diagnose and treat TBNC molecular subtypes, so as to 
improve survival outcomes. 
 
3.2 Chondroitin Sulfate in Breast Cancer 
Glycosaminoglycans (GAGs) have gained interest as potential therapeutic agents 
in cancer treatment, with studies showing their involvement in various 
pathobiological cancer stages, including the modification of cellular 
characteristics such as proliferation, invasion, migration and angiogenesis.
[19, 20]
 
GAGs have also been shown to interact with various effective molecules such as 





Recently, a correlation was established between chondroitin sulfate proteoglycan 
(CSPG) expression and various cancer phenotypes, with the overexpression of 
CSPGs versican and decorin in prostate, testicular, gastric, pancreatic and breast 
cancer.
[22-26]
 For instance, compositional analysis of proteoglycan side chains 





, and these sequences have been shown to regulate many 
important cellular signaling processes affecting cell proliferation, adhesion and 
migration.
[29]
 The increased expression of specific CS sulfation patterns such as 
CS-E on the surface of breast cancer cells has also been associated with their 
metastatic spread. These CS GAGs were reported to act as P-selectin ligands
[30-32]
, 
which can cause blood borne metastasis.
[33, 34]
 Specifically, there is a down 
regulation of CHST3 gene which codes for biosynthesis of CS-C and CS-D 
sulfation sequences and an increase in expression of CHST11 which encodes for 




The dysregulation of CS expression has the potential to serve as prognostic and 
diagnostic markers for targeted cancer therapy.
[38]
 In addition, structural changes 
to the CS proteoglycans of malignant breast tissues indicate that sulfate groups 
present on CS might play an important role in the cellular processes involved in 




With our complete library of CS disaccharides (Table 3-2), we proceeded to 
evaluate their biological effects in breast cancer by systematic structural activity 
relationship studies to investigate the CS “sulfation code”. The aim is to 
determine if position specific sulfate groups encode important functional 

























P5 C-3  
P3 C-4’  CS-A 











P14 C-2, C-4’  
P15 C-2, C-6’ CS-D 
P7 C-3, C-4’ CS-K 
P6 C-3, C-6’ CS-L 







C-2, C-3, C-4’ 
 
P10 C-2, C-3, C-6’  
P13 C-2, C-4’, C-6’ CS-T 











3.3 Biological Evaluation of Chondroitin Sulfate Disaccharide Library  
 
3.3.1 Cell Viability Assay 
The effect of CS sulfation patterns on breast cancer cell viability was first 
assessed via the MTS assay; this colorimetric method determined the number of 
viable cells present after drug treatment. The MTS solution contained a 
tetrazolium compound (Owen’s reagent), which was reduced by dehydrogenase 
enzymes in metabolically active cells to form a colored formazan product.
[42]
 The 
number of viable cells was thus proportional to the absorbance readings measured.  
 
In the preliminary MTS assays conducted, the synthesized CS disaccharides were 
tested on 4 different human breast cell lines. This included the non-tumorigenic 
breast epithelial cell line MCF-12A, to evaluate compound cytotoxicity, and 3 
breast cancer cell lines: MCF-7, T47D and MDA-MB-231. MCF-7 and T47D are 
low grade breast cancer cells which express the estrogen receptor; while MDA-
MB-231 cells are high grade triple negative breast cancer cells (TNBC) which do 




The biological effect of each CS disaccharide was investigated by incubating the 
cells with the CS disaccharide for 72 hours, prior to the addition of MTS reagent 
to determine the number of viable cells after treatment period. Absorbance 
readings were measured after 3 hours; 4 different CS disaccharide concentrations 
were tested (0.1µg/mL, 1µg/mL, 10µg/mL and 100µg/mL).   
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We first screened the 16 CS disaccharides on normal breast cells (MCF-12A), and 
there was no significant change in cell viability even at the highest tested 
concentration of 100µg/mL (Figure 3-1). Hence these 16 CS disaccharides did not 
































































Figure 3-1. MTS assay results for MCF-12A breast cell line. Data represents the 
mean ± SD (n=6) with reference to non-treatment group (control), analyzed using 
one-way ANOVA with post-hoc Dunnett's test. 
 
Interestingly, when the 16 CS disaccharides were tested on the more aggressive 
MDA-MB-231 cell line, a statistically significant decrease in cell viability was 
observed for CS disaccharides P2, P13 and P14 (Figure 3-2). This effect was only 
observed at the highest drug concentration of 100µg/mL, but not at the other 






































































Figure 3-2. MTS assay results for MDA-MB-231 breast cancer cell line. Data 
represents the mean ± SD (n=6) with reference to non-treatment group (control), 











































Figure 3-3. MDA-MB-231 MTS assay results for CS disaccharides P2, P13, P14. 
Data represents the mean ± SD (n=6) with reference to non-treatment group 





We next proceeded to screen the CS disaccharides on low grade breast cancer 
cells. The results showed no change in the number of viable cells after treatment 
with the CS disaccharides, indicating that all 16 CS disaccharides had no 
significant effect on both (a) MCF-7 cells and (b) T47D cells (Figure 3-4). This 
suggested differences in the pathological and biological features of MCF-7 and 
T47D cell types when compared to the MDA-MB-231 MTS assay results.  
 
Figure 3-4. MTS assay results for (a) MCF-7 and (b) T47D breast cancer cell line. 
Data represents the mean ± SD (n=6) with reference to non-treatment group 
(control), analyzed using one-way ANOVA with post-hoc Dunnett's test 
 
Based on the cell viability assay results obtained for CS disaccharides P2, P13 
and P14  (Figure 3-5), both the number of sulfate groups present in the CS 
disaccharide and the position of these negative charges appeared to have an effect 



















































































































































































































































Figure 3-5. Cell viability assay results for MCF-12A, MCF-7, T47D and MDA-
MB-231 cells at 100µg/mL CS disaccharide concentration; (a): P2, (b): P14, 
(c): P13. Data represents the mean ± SD (n=6) with reference to non-treatment 




Disaccharide P2 was the only monosulfated CS analogue which elicited a 20% 
decrease in cell viability when treated on MDA-MB-231 cells (at 200µM drug 
concentration). P2 has the sulfation pattern of CS-C, where the C-6’ position is 
sulfated (Figure 3-5a). This sulfation sequence has previously been shown to be 
down regulated in breast cancer tumours.[35] Since our results indicate that CS-C 
could decrease cancer cell viability, malignant cells could thus have escaped the 
regulatory control exerted of CS by decreasing the expression of CS-C. 
 
In the case of the disulfated CS analogues, a 50% decrease in cell viability was 
observed when MDA-MB-231 cells were treated with P14 (at 150µM drug 
concentration). Disaccharide P14 has sulfate groups attached on both the C-2 and 
C-4’ positions (Figure 3-5b). This sulfation sequence is not commonly occurring 
and thus has not been extensively studied. Access to this CS sulfation motif 
through chemical synthesis enabled us identify the inhibitory effects of P14 on 
MDA-MB-231. 
 
For the trisulfated CS analogues, there was a 45% decrease in cell viability when 
CS disaccharide P13 was tested (at 175µM drug concentration). Disaccharide P13 
has the sulfation pattern of CS-T, where the C-2, C-4’ and C-6’ positions are 
sulfated (Figure 3-5c). Again, this is a rarely occurring CS sulfation sequence 
which has not been previously evaluated in breast cancer. Our results indicate that 
non-commonly occurring CS sulfate motifs might also be important in regulating 
the progression of breast cancer. 
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The non-sulfated and fully sulfated CS disaccharides, P1 and P9, had no effect on 
cell viability suggesting that the presence of some sulfate groups was required for 
CS to elicit an inhibitory effect on MDA-MB-231 cells but saturating all the 
possible sulfation sites would lead to a loss of activity.   
 
3.3.2 Apoptosis Assay 
To further evaluate the active CS disaccharides P2, P13 and P14, apoptosis assays 
were subsequently conducted with the Caspase-Glo 3/7 kit which monitored the 
amount of caspase-3 and -7 activities present in the MDA-MB-231 cells after 
treatment with the respective CS disaccharides. Caspase (cysteine aspartic acid-
specific protease) enzymes have been shown to play key effector roles in 
apoptosis in mammalian cells.[43, 44] Addition of the Caspase-Glo reagent first 
induced cell lysis, which released the caspase 3/7 enzymes for reaction with the 
proluminescent substrate. This generated the free aminoluciferin product, which 
was subsequently cleaved by luciferase to generated a “glow-type” luminescent 
signal[44]; the luminescent intensity was proportional to the degree of caspase 
activity 3/7 present.  
 
Results from the caspase assay showed an increase in luminescence when MDA-
MB-231 cells were treated with CS disaccharides P2, P13 and P14 (Figure 3-6), 
indicating an increase in caspase-3 and -7 activities. This suggested that the CS 
disaccharides could induce death of breast cancer cells via apoptosis, which 
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corroborated with the drop in cell viability observed in the previously conducted 


















































Figure 3-6. Caspase-Glo 3/7 assay results for MDA-MB-231. Data represents the 
mean ± SD (n=6) with reference to non-treatment group (control), ***p < 0.001. 
 
Interestingly, the largest decrease in cancer cell viability and highest amount of 
caspase activity were seen in the CS disaccharide P14–treated group. On the other 
hand, P13 elicited similar assay readings as P2, this indicates that P13 could 
induce the death of breast cancer cells by other non-apoptotic pathways such as 
the inhibition of cancer cell proliferation. Preliminary biological evaluation thus 
indicates that sulfate groups present on CS could encode important regulatory 









Biological evaluation of all 16 CS disaccharides was conducted on 4 different 
breast cell types, and results indicated that CS sulfation patterns had differential 
effects on different types of breast cancer cells. High grade breast tumor cells 
(MDA-MB-231) showed significant reduction in cell viability upon treatment 
with CS disaccharides P2, P13 and P14 while low grade breast tumor cells (MCF-
7, T47D) and normal breast cells (MCF-12A) were unaffected. Apoptosis assays 





Cell culture medium RPMI 1640 containing 2.05mM L-Glutamine, Dulbecco's 
Modified Eagle Medium (DMEM), Dulbecco's Modified Eagle Medium: Nutrient 
Mixture F-12 (DMEM-F12) and Fetal Bovine Serum (FBS) were purchased from 
GE Healthcare Life Sciences (Buckinghamshire, United Kingdom). Human 
mammary and breast cancer cell lines MCF-12A, MCF-7, MDA-MB-231 and 
T47D were obtained from American Type Culture Collection (ATCC, USA), and 
cultured at 37
o
C with 5% CO2. The growth medium used was DMEM 
supplemented with 10% fetal bovine serum for MCF-7, RPMI-1640 
supplemented with 10% fetal bovine serum for T47D and MDA-MB-231; and 
DMEM-F12 supplemented with 5% FBS, 0.5µg/mL hydrocortisone, 20ng/mL 
EGF, 10µg/mL insulin, 40µg/mL gentamicin and 100ng/mL cholera toxin for 
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MCF-12A. CellTiter 96® AQueous One Solution Cell Proliferation Assay (MTS 
assay) kit and Caspase-Glo® 3/7 Assay System were purchased from Promega 
(Wisconsin, USA). Absorbance readings were taken using the Tecan Infinite F200 
Pro plate reader with the Tecan i-control software, while the luminescence 
readings were taken using the SpectraMax M5 plate reader using the SpectraMax 
software (integration time= 1 sec). The readings obtained were normalized with 
respect to the control data and statistical analysis calculated using GraphPad 
Prism software; level of statistical significance was set at p <0.05. 
 
Cell viability assay (MTS) 
The cells were plated onto a 96-well plate and cultured for 24 hours at 37
o
C (5% 
CO2) with 100µL complete medium/well. The seeding density used was 2500 
cells/well for MCF-12A; 4000 cells/well for MCF-7; 5000 cells/well for MDA-
MB-231 and 6000 cells/well for T47D. After 24h growth period, the cells were 
treated with the desired CS disaccharide at 4 different concentrations: 0.1µg/mL, 
1µg/mL, 10µg/mL and 100µg/mL. A control group was included where only the 
drug vehicle was used. Six biological replicates were set up for each group. Upon 
addition of the drug, the cells were incubated at 37
o
C (5% CO2) for 72 hours. 
After removal of the medium and washing of the cells with phosphate-buffered 
saline (PBS), the CellTiter 96® AQueous One Solution (MTS reagent) was next 
added to each well (100µL complete medium + 20µL MTS reagent per well) and 
the cells were incubated at 37
o
C (5% CO2) in the absence of light. Absorbance 
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readings (λ=490nm) taken at the 3rd hour were analyzed using one-way Analysis 
of Variance (ANOVA) with post-hoc Dunnett's test.  
 
Apoptosis assay 
MDA-MB-231 cells were plated on a 6-well plate with a seeding density of 
200,000 cells/well and cultured for 24 hours at 37
o
C (5% CO2) with 2mL 
complete medium/well. After 24h, the cells were treated with the desired CS 
disaccharide at 100µg/mL drug concentration and incubated for a further 48 hours. 
A control set was included where only the drug vehicle was used. To facilitate 
luminescence measurements, the cells were then reseeded into a white opaque 96-
well plate at a seeding density of 20,000 cells/well and incubated for an additional 
24 hours. Thereafter, 100µL of Caspase-Glo® 3/7 reagent was added to each well 
(n=6). The contents in the wells were gently mixed and were incubated at room 
temperature in the dark. Luminescence readings taken at after 1 hr were analyzed 
using one-way Analysis of Variance (ANOVA) with post-hoc Dunnett's test. 
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CHAPTER 4: CONCLUSION AND PERSPECTIVES 
 
4.1 Conclusion 
In this project we devised a synthetic strategy to obtain 16 differently sulfated 
chondroitin sulfate (CS) disaccharides; these isomers encompass all the sulfation 
patterns theoretically plausible in the CS repeating unit. The strategy incorporated 
orthogonal protecting groups in glucuronic acid and N-acetyl galactosamine 
precursor units obtained through a divergent approach, prior to modular 
glycosylation and selective final transformations to prepare the library of 16 CS 
disaccharides (Figure 4-1). The CS disaccharides were then biologically evaluated 
on breast cancer cells. Cell viability assays indicated that high grade breast tumor 
MDA-MB-231 could be inhibited by disaccharides P2, P13 and P14, while low 
grade breast tumor (MCF-7, T47D) and normal breast cells (MCF-12A) were 
unaffected. Apoptosis assays further suggested that disaccharides P2, P13 and 
P14 could induce apoptosis in MDA-MB-231 cells.  
 
Figure 4-1. Chemical synthesis and biological evaluation of CS disaccharides 
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4.2 Future Perspectives 
With the potent CS sulfate motifs identified, the mechanism of inhibition of 
MDA-MB-231 cells can next be elucidated by conducting additional phenotypic 
assays which include adhesion, migration and invasion assays to determine how 
disaccharides P2, P13 and P14 may affect cellular characteristics. 
 
In addition, a relatively high concentration of 100µg/mL was required to elicit a 
decrease in MDA-MB-231 cell viability. Since longer CS sequences could 
provide stronger activities than disaccharides, further studies may include the 
synthesis and evaluation of CS tetra-/hexa- saccharides with the active sulfation 
profiles to determine if inhibition can be enhanced, using a lower concentration of 
CS compounds. 
 
To extend the scope of study, the CS “sulfation code” may also be probed on 
other cancer cell lines which have dysregulated GAG expression, these include 
gastric and prostate cells. This enables us to investigate the molecular effects of 
CS sulfation in different forms of cancer biology. 
 
 
